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A B S T R A C T
Background
Active management of the third stage of labour reduces the risk of postpartum blood loss (postpartum haemorrhage (PPH)), and is
defined as administration of a prophylactic uterotonic, early umbilical cord clamping and controlled cord traction to facilitate placental
delivery. The choice of uterotonic varies across the globe and may have an impact on maternal outcomes. This is an update of a review
first published in 2001 and last updated in 2013.
Objectives
To determine the effectiveness of prophylactic oxytocin to prevent PPH and other adverse maternal outcomes in the third stage of
labour.
Search methods
For this update, we searched Cochrane Pregnancy and Childbirth’s Trials Register, ClinicalTrials.gov, WHO International Clinical
Trials Registry Platform (ICTRP) (6 March 2019) and reference lists of retrieved studies.
Selection criteria
Randomised, quasi- or cluster-randomised trials including women undergoing vaginal delivery who received prophylactic oxytocin
during management of the third stage of labour. Primary outcomes were blood loss 500 mL or more after delivery, need for additional
uterotonics, and maternal all-cause mortality.
Data collection and analysis
Two review authors independently assessed trials for inclusion, extracted data, and assessed trial quality. Data were checked for accuracy.
We assessed the quality of the evidence using the GRADE approach.
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Main results
This review includes 24 trials, with 23 trials involving 10,018 women contributing data. Due to many trials assessed at high risk of
bias, evidence grade ranged from very low to moderate quality.
Prophylactic oxytocin versus no uterotonics or placebo (nine trials)
Prophylactic oxytocin compared with no uterotonics or placebo may reduce the risk of blood loss of 500 mL after delivery (average
risk ratio (RR) 0.51, 95% confidence interval (C) 0.37 to 0.72; 4162 women; 6 studies; Tau² = 0.10, I² = 75%; low-quality evidence),
and blood loss 1000 mL after delivery (RR 0.59, 95% CI 0.42 to 0.83; 4123 women; 5 studies; low-quality evidence). Prophylactic
oxytocin probably reduces the need for additional uterotonics (average RR 0.54, 95% CI 0.36 to 0.80; 3135 women; 4 studies; Tau² =
0.07, I² = 44%; moderate-quality evidence). There may be no difference in the risk of needing a blood transfusion in women receiving
oxytocin compared to no uterotonics or placebo (RR 0.88, 95% CI 0.44 to 1.78; 3081 women; 3 studies; low-quality evidence).
Oxytocin may be associated with an increased risk of a third stage greater than 30 minutes (RR 2.55, 95% CI 0.88 to 7.44; 1947
women; 1 study; moderate-quality evidence), however the confidence interval is wide and includes 1.0, indicating that there may be
little or no difference.
Prophylactic oxytocin versus ergot alkaloids (15 trials)
It is uncertain whether oxytocin reduces the likelihood of blood loss 500 mL (average RR 0.84, 95% CI 0.56 to 1.25; 3082 women; 10
studies; Tau² = 0.14, I² = 49%; very low-quality evidence) or the need for additional uterotonics compared to ergot alkaloids (average
RR 0.89, 95% CI 0.43 to 1.81; 2178 women; 8 studies; Tau² = 0.76, I² = 79%; very low-quality evidence), because the quality of
this evidence is very low. The quality of evidence was very low for blood loss of 1000 mL (RR 1.13, 95% CI 0.63 to 2.01; 1577
women; 3 studies; very low-quality evidence), and need for blood transfusion (average RR 1.37, 95% CI 0.34 to 5.51; 1578 women;
7 studies; Tau² = 1.34, I² = 45%; very low-quality evidence), making benefit of oxytocin over ergot alkaloids uncertain. Oxytocin
probably increases the risk of a prolonged third stage greater than 30 minutes (RR 4.69, 95% CI 1.63 to 13.45; 450 women; 2 studies;
moderate-quality evidence), although it is uncertain if this translates into increased risk of manual placental removal (average RR 1.10,
95% CI 0.39 to 3.10; 3127 women; 8 studies; Tau² = 1.07, I² = 76%; very low-quality evidence). Oxytocin may make little or no
difference to risk of diastolic blood pressure > 100 mm Hg (average RR 0.28, 95% CI 0.04 to 2.05; 960 women; 3 studies; Tau² =
1.23, I² = 50%; low-quality evidence), and is probably associated with a lower risk of vomiting (RR 0.09, 95% CI 0.05 to 0.14; 1991
women; 7 studies; moderate-quality evidence), although the impact of oxytocin on headaches is uncertain (average RR 0.19, 95% CI
0.03 to 1.02; 1543 women; 5 studies; Tau² = 2.54, I² = 72%; very low-quality evidence).
Prophylactic oxytocin-ergometrine versus ergot alkaloids (four trials)
Oxytocin-ergometrine may slightly reduce the risk of blood loss greater than 500 mL after delivery compared to ergot alkaloids (RR
0.44, 95% CI 0.20 to 0.94; 1168 women; 3 studies; low-quality evidence), based on outcomes from quasi-randomised trials with a
high risk of bias. There were no maternal deaths reported in either treatment group in the one trial that reported this outcome (RR
not estimable; 1 trial, 807 women; moderate-quality evidence). Need for additional uterotonics was not reported.
No subgroup differences were observed between active or expectant management, or different routes or doses of oxytocin for any of
our comparisons.
Authors’ conclusions
Prophylactic oxytocin compared with no uterotonics may reduce blood loss and the need for additional uterotonics. The effect of
oxytocin compared to ergot alkaloids is uncertain with regards to blood loss, need for additional uterotonics, and blood transfusion.
Oxytocin may increase the risk of a prolonged third stage compared to ergot alkaloids, although whether this translates into increased
risk of manual placental removal is uncertain. This potential risk must be weighed against the possible increased risk of side effects
associated with ergot alkaloids. Oxytocin-ergometrine may reduce blood loss compared to ergot alkaloids, however the certainty of this
conclusion is low. More high-quality trials are needed to assess optimal dosing and route of oxytocin administration, with inclusion of
important outcomes such as maternal mortality, shock, and transfer to a higher level of care. A network meta-analysis of uterotonics
for PPH prevention plans to address issues around optimal dosing and routes of oxytocin and other uterotonics.
P L A I N L A N G U A G E S U M M A R Y
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Oxytocin to prevent excessive blood loss for women during the third stage of labour
What is the issue?
Active management of the third stage of labour (AMTSL) has been shown to decrease the risk of excessive blood loss after delivery.
This management strategy has been defined as administration of a medication to increase uterine tone and contractions, early umbilical
cord clamping and gentle cord traction to facilitate placental delivery. While AMTSL has become standard practice in many countries
and institutions, execution of the individual components varies. Oxytocin is a uterotonic medication that promotes increased uterine
tone and contractions, and is commonly administered immediately following delivery of the infant’s shoulder as part of AMTSL. This
review considers the efficacy and safety of oxytocin prophylaxis in the third stage of labour compared with no uterotonics, a placebo,
ergot alkaloids, and in combination with ergometrine compared with ergot alkaloids.
Why is this important?
Postpartum haemorrhage is one of the most prevalent causes of maternal morbidity and mortality worldwide, therefore, determining
the most effective preventative strategies is crucial.
What evidence did we find?
We searched for evidence in March 2019 and identified six trials that met the inclusion criteria for the review. Outcomes from an
additional 1100 women from these six trials was combined with those from the previous version of this review for a total of 10,018
women (23 trials). Of note, two previously included trials were excluded from this current review due to methodological concerns.
The majority of trials contributing information to this review were found to be at high risk of bias. The quality of evidence ranged
from very low to moderate, and for most outcomes was assessed as low to very low quality.
Our results showed that compared to no uterotonics or placebo, oxytocin may reduce the risk of blood loss (quality of evidence:
low) and the need for additional uterotonics (quality of evidence: moderate). The effect of oxytocin compared with ergot alkaloids is
uncertain with regards to blood loss (quality of evidence: very low), need for additional uterotonics (quality of evidence: very low), and
need for blood transfusion (quality of evidence: very low), but may increase the risk of a third stage greater than 30 minutes (quality of
evidence: moderate). Whether or not this translates into increased risk of needing a manual placental removal is uncertain (quality of
evidence: very low). This potential risk of retained placenta must be weighed against a possible increased risk of side effects with ergot
alkaloids, including diastolic hypertension (quality of evidence: low), vomiting (quality of evidence: very low), and headaches (quality
of evidence: very low). While the combination of oxytocin and ergometrine may slightly reduce the risk of blood loss compared to
ergot alkaloids (quality of evidence: low), the certainty of this conclusion is low given the poor quality of contributing studies.
What does this mean?
Oxytocin may reduce blood loss and the need for additional uterotonics when given prophylactically in the third stage of labour, and
therefore could be considered as a component of AMTSL. The side-effect profile may be more favourable than ergot alkaloids, which
must be weighed against a possible increased risk of third stage greater than 30 minutes and unclear benefit of oxytocin or ergot alkaloids
with regards to blood loss.
More placebo-controlled, randomised, double-blinded trials are needed to improve the quality of data used to compare oxytocin versus
ergot alkaloids. Future studies should aim to include important outcomes such as maternal mortality, shock, transfer to a higher level of
care, serious side effects, and other patient-centred outcomes. A large complex review analysing all available data fromdifferent uterotonic
medications (network meta-analysis) will help to inform future choice of uterotonic and the best route and dose of administration.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Oxytocin compared to no uterotonics or placebo for the third stage of labour to prevent postpartum haemorrhage
Patient or population: women in the third stage of labour
Setting: hospital labour wards and home births in France, Germany, the Netherlands, Sweden, South Af rica, Tunisia, and the UK
Intervention: oxytocin
Comparison: no uterotonics or placebo
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with no uteroton-
ics
Risk with oxytocin
Blood loss 500 mL or
more af ter delivery
Study populat ion RR 0.51
(0.37 to 0.72)
4162
(6 RCTs)
⊕⊕©©
LOW 12
239 per 1000 122 per 1000
(89 to 172)
Need for addit ional
uterotonics
Study populat ion RR 0.54
(0.36 to 0.80)
3135
(4 RCTs)
⊕⊕⊕©
MODERATE 3
114 per 1000 62 per 1000
(41 to 91)
Maternal all-cause mor-
tality
- - - - - This outcome was not
reported in any of the
included studies
Blood loss 1000 mL or
more af ter delivery
Study populat ion RR 0.59
(0.42 to 0.83)
4123
(5 RCTs)
⊕⊕©©
LOW 14
48 per 1000 29 per 1000
(20 to 41)
Blood transfusion Study populat ion RR 0.88
(0.44 to 1.78)
3081
(3 RCTs)
⊕⊕©©
LOW 56
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12 per 1000 10 per 1000
(5 to 21)
Third stage greater than
30 minutes
Study populat ion RR 2.55
(0.88 to 7.44)
1947
(1 RCT)
⊕⊕⊕©
MODERATE 4
6 per 1000 16 per 1000
(5 to 45)
Diastolic blood pres-
sure > 100 mm Hg be-
tween delivery of the
baby and discharge
f rom the labour ward
Study populat ion - - - This outcome was not
reported in any of the
included studies
- -
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io;
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Lack of blinding in the majority of trials raises concern for biased outcome assessment as most trials ut ilised visual
est imation of blood loss (risk of bias -1)
2 Large variat ions in ef fect and non-overlapping 95% conf idence intervals; I2 = 75% indicat ing substant ial heterogeneity
(inconsistency -1)
3 Lack of part icipant blinding in some trials may bias decisions to administer addit ional uterotonics (risk of bias -1)
4 Few events and wide 95% conf idence intervals (imprecision -1)
5 Lack of personnel blinding may bias decisions to administer blood transfusions (risk of bias -1)
6 Wide 95% conf idence intervals including line of no ef fect (imprecision -1)
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B A C K G R O U N D
Description of the condition
The third stage of labour is defined as the time from the birth of
the baby to expulsion of the placenta. Following delivery of the
baby, the uterine muscle contracts, resulting in gradual placental
separation and expulsion as well as contraction of uterine muscle
around maternal vessels within the placental bed. Activation of
the maternal coagulation system occurs in tandem. The degree
of blood loss following delivery is most directly related to how
quickly and efficiently these processes occur.
Postpartum haemorrhage (PPH) has commonly been defined by
theWorld Health Organization (WHO) and other expert author-
ities as blood loss of 500 mL or more from the genital tract within
24 hours of birth (Borovac-Pinheiro 2018; WHO 2018). How-
ever, there is currently no single definition for PPH that has been
agreed upon internationally, and multiple guidelines and defini-
tions exist (Borovac-Pinheiro 2018). A significant issue complicat-
ing the use of blood loss thresholds to define PPH is the challenge
surrounding quantification of blood loss. Visual estimation has
historically been standard practice, but has been shown to lead to
underestimation of large volume blood loss by up to 30% to 50%,
and overestimation of small volume blood loss regardless of level of
training (Dildy 2004; Hogan 2010; Stafford 2008). Gravimetric
methods of quantification, such as calibrated drapes and weighing
of pads, may be more accurate and are being increasingly adopted
by obstetric centres (Al Kadri 2011; Toledo 2007).
The impact of any amount of blood loss for an individual woman
may be modified by her overall health status, underlying medi-
cal conditions, haemodynamic status and access to healthcare re-
sources. Women experiencing excessive blood loss after delivery
are at increased risk of significant complications including the
need for blood transfusion, hysterectomy and loss of fertility, pro-
longed hospitalisation, transfer to the intensive care unit, shock,
and multi-organ failure.
Description of the intervention
Techniques to prevent PPHmay target any aspect of the third stage
of labour. A recent review determined that active management
of the third stage of labour (AMTSL), defined as prophylactic
administration of a uterotonic, early umbilical cord clamping and
controlled cord traction, decreases the risk of blood loss greater
than 1000 mL (Begley 2019), although the evidence was found to
be of very low quality. While AMTSL is recommended by many
organisations and has become standard practice in most obstetric
centres, performance of individual components varies. Based on
recent evaluations of individual components of the AMTSL, the
WHO regards controlled cord traction as optional, routine early
cord clamping as generally contraindicated, and uterotonics as
the main intervention that should be offered to all women in
the third stage of labour (WHO 2012). The WHO and other
authorities currently consider oxytocin to be the uterotonic of
choice (WHO 2018). Of note, a recent network meta-analysis
examined the effectiveness and side effects of multiple uterotonic
agents (Gallos 2018). They concluded that all uterotonics were
effective for preventing PPH, but that ergometrine-oxytocin and
misoprostol plus oxytocinmight bemore efficacious than oxytocin
alone, at the expense of a greater risk of side effects. They also
concluded that carbetocin may be more effective than oxytocin
without an increase in side effects.
Oxytocin is a naturally occurring uterotonic, and first became
available for use in 1953 (Du Vigneaud 1953). Oxytocin binds to
receptors within the myometrium to facilitate frequent and pro-
longed uterine contractions within minutes, with a short half-life
of two to four minutes. It may be administered intravenously (IV,
typically diluted in an infusion) or intramuscularly (IM). When
given in high volumes it may result in an anti-diuretic effect lead-
ing to hyponatraemia, headache, vomiting, drowsiness or convul-
sions. It can be stored at room temperature for a limited period of
time, although long-term storage is recommended in the dark at
four to eight degrees Celsius.
Ergometrine was discovered as the uterotonic component of ergot
in 1932 (Moir 1932). It became popular for routine management
of PPH in the early 1950s (Moir 1955). Methylergometrine and
ergometrine are the most commonly used ergot alkaloids. They
bind to adrenergic myometrial receptors and increase uterine tone,
leading to frequent and then sustained uterine contractions. The
onset of action is rapid, within two to 10 minutes, with a half-life
of approximately three hours. They are most commonly admin-
istered by the IM or oral route, but can be given IV. Side effects
include hypertension, nausea and emesis, and other side effects
related to vasoconstriction of vascular smooth muscle. To prevent
rapid deterioration, formulations need to be stored in the dark at
four to eight degrees Celsius; ergot alkaloids are more unstable at
room temperature and with light exposure than oxytocin.
A combination of ergometrine and oxytocin (Syntometrine) was
synthesised in 1963 (Embrey 1963). Syntometrine is comprised of
oxytocin 5 international units (IU) and ergometrine 0.5 mg, and
is typically given IM although can be given IV. The pharmacologic
properties reflect those of its individual components. It is available
in some countries, although not currently available in the USA.
How the intervention might work
Uterotonic drugs increase the tone of the uterine muscles, result-
ing in uterine contractions. These contractions produce shearing
forces that aid in placental separation, and also result in myome-
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trial contraction around the involuting placental bed. After pla-
cental separation, expulsion is assisted by continued contractions.
By enhancing these mechanisms, uterotonics facilitate rapid pla-
cental delivery and contribute to minimising blood loss in the
third stage.
Why it is important to do this review
Haemorrhage during childbirth is the leading cause of maternal
mortality worldwide, accounting for approximately 25% of ma-
ternal deaths, or over half a million women in mostly low- and
middle-income countries (Say 2014). PPH accounts for a greater
proportion of maternal deaths in countries with a low sociodemo-
graphic index (46%) compared to countries with a high sociode-
mographic index (9%), reflecting a combination of issues includ-
ing variations in quality and access to care, and population risk
factors (Kassebaum 2016; Say 2014). Continuing efforts to deter-
mine the most effective PPH prevention strategies are necessary
to improve maternal health worldwide.
The last version of this Cochrane Review of the prophylactic use
of oxytocin for preventing PPH was in 2013. This updated review
is needed to inform updated guidelines from the WHO on pre-
vention of PPH, and adds to existing Cochrane systematic reviews
examining the use of various medications as prophylaxis in the
third stage of labour (Gallos 2018, Liabsuetrakul 2018; Novikova
2015; Tunçalp 2012).
O B J E C T I V E S
To determine the effectiveness of prophylactic oxytocin to prevent
postpartum haemorrhage (PPH) and other adverse maternal out-
comes in the third stage of labour.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised, cluster- or quasi-randomised controlled trials
comparing prophylactic oxytocin with another uterotonic (ergot
alkaloids) or no uterotonic/placebo for the management of the
third stage of labour were considered for inclusion. Studies re-
ported as abstracts have not been included if there was insufficient
information for data extraction and ’Risk of bias’ assessment.
Types of participants
All trials including pregnant women anticipating a vaginal deliv-
ery were considered. Studies where participants received the pro-
phylactic uterotonic after delivery of the placenta were excluded.
Types of interventions
The purpose of this review is to compare three interventions:
1. use of prophylactic oxytocin at any dose for the third stage
of labour versus no uterotonics or placebo;
2. use of prophylactic oxytocin at any dose for the third stage
of labour versus ergot alkaloids;
3. use of prophylactic oxytocin-ergometrine (Synometrine)
versus ergot alkaloids.
The current review concentrates on oxytocin given by injection
into a maternal vein (IV) or muscle (IM). Other uterotonic agents
administered to the mother by IV or IM are addressed in Gallos
2018 (all uterotonics) and Su 2012 (carbetocin, oxytocin and oxy-
tocin-ergometrine). The role of prophylactic prostaglandins or er-
got alkaloids and uterotonics given through the umbilical vein, for
the treatment of blood loss or retained placenta, are the subjects
of other reviews and were not included here (Liabsuetrakul 2018;
Mori 2012; Tunçalp 2012). Similarly, endogenous oxytocin (nip-
ple stimulation) is not included in this review.
Types of outcome measures
Outcomes noted with an asterisk are core prevention of PPH out-
comes. Outcomes in bold text are the main outcomes that were
assessed using the GRADE approach.
Primary outcomes
1. Blood loss 500 mL or more after delivery*
2. Need for additional uterotonics*
3. Maternal all-cause mortality
Secondary outcomes
1. Blood loss 1000 mL or more after delivery*
2. Blood transfusion
3. Third stage greater than 30 minutes
4. Diastolic blood pressure > 100 mm Hg between delivery
of the baby and discharge from the labour ward
5. Mean blood loss (mL)
6. Maternal haemoglobin (Hb) < 7 g/dL 24 to 48 hours
postpartum
7. Mean length of third stage (minutes)
8. Manual removal of the placenta
9. Vomiting between delivery of the baby and discharge from
the labour ward*
10. Headache between delivery of the baby and discharge from
the labour ward*
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11. Shock*
12. Transfer to a higher level of care*
13. Mortality from causes other than bleeding
14. Maternal satisfaction with therapy*
15. Quality of life*
16. Breastfeeding
Search methods for identification of studies
The following search methods section of this review is based on a
standard template used by Cochrane Pregnancy and Childbirth.
Electronic searches
For this update, we searchedCochrane Pregnancy and Childbirth’s
Trials Register by contacting their Information Specialist (6March
2019).
The Register is a database containing over 25,000 reports of con-
trolled trials in the field of pregnancy and childbirth. It represents
over 30 years of searching. For full current search methods used
to populate Pregnancy and Childbirth’s Trials Register including
the detailed search strategies for CENTRAL, MEDLINE, Em-
base and CINAHL; the list of handsearched journals and confer-
ence proceedings, and the list of journals reviewed via the current
awareness service, please follow this link.
Briefly, the Cochrane Pregnancy and Childbirth’s Trials Register
is maintained by their Information Specialist and contains trials
identified from:
1. monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE (Ovid);
3. weekly searches of Embase (Ovid);
4. monthly searches of CINAHL (EBSCO);
5. handsearches of 30 journals and the proceedings of major
conferences;
6. weekly current awareness alerts for a further 44 journals
plus monthly BioMed Central email alerts.
Search results are screened by two people and the full text of
all relevant trial reports identified through the searching activi-
ties described above is reviewed. Based on the intervention de-
scribed, each trial report is assigned a number that corresponds
to a specific Pregnancy and Childbirth review topic (or topics),
and is then added to the Register. The Information Specialist
searches the Register for each reviewusing this topic number rather
than keywords. This results in a more specific search set that has
been fully accounted for in the relevant review sections (Included
studies; Excluded studies; Studies awaiting classification; Ongoing
studies).
In addition, we searched ClinicalTrials.gov and the WHO Inter-
national Clinical Trials Registry Platform (ICTRP) for unpub-
lished, planned and ongoing trial reports (6 March 2019) using
the search methods described in Appendix 1.
Searching other resources
We searched the reference lists of retrieved studies.
We did not apply any language or date restrictions.
Data collection and analysis
For methods used in the previous version of this review, see
Westhoff 2013.
For this update, the following methods were used for assessing the
reports that were identified as a result of the updated search.
The followingmethods section of this review is based on a standard
template used by Cochrane Pregnancy and Childbirth.
Selection of studies
Two review authors independently assessed for inclusion all the
potential studies identified as a result of the search strategy. We
resolved any disagreement through discussion or, if required, we
consulted a third review author.
Data extraction and management
Wedesigned a form to extract data. For eligible studies, two review
authors extracted the data using the agreed form. We resolved dis-
crepancies through discussion or, if required, we consulted a third
review author. Data were entered into Review Manager software
(RevMan 2014) and checked for accuracy. When information re-
garding any of the above was unclear, we planned to contact au-
thors of the original reports to provide further details.
Assessment of risk of bias in included studies
Two review authors independently assessed risk of bias for each
study using the criteria outlined in theCochrane Handbook for Sys-
tematic Reviews of Interventions (Higgins 2011). Any disagreement
was resolved by discussion or by involving a third assessor.
(1) Random sequence generation (checking for possible
selection bias)
We described for each included study the method used to generate
the allocation sequence in sufficient detail to allow an assessment
of whether it should produce comparable groups.
We assessed the method as:
• low risk of bias (any truly random process, e.g. random
number table; computer random number generator);
• high risk of bias (any non-random process, e.g. odd or even
date of birth; hospital or clinic record number);
• unclear risk of bias.
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(2) Allocation concealment (checking for possible selection
bias)
We described for each included study the method used to con-
ceal allocation to interventions prior to assignment and assessed
whether intervention allocation could have been foreseen in ad-
vance of, or during recruitment, or changed after assignment.
We assessed the methods as:
• low risk of bias (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or non-
opaque envelopes, alternation; date of birth);
• unclear risk of bias.
(3.1) Blinding of participants and personnel (checking for
possible performance bias)
We described for each included study the methods used, if any, to
blind study participants and personnel from knowledge of which
intervention a participant received. We considered that studies
were at low risk of bias if they were blinded, or if we judged that
the lack of blinding unlikely to affect results. We assessed blinding
separately for different outcomes or classes of outcomes.
We assessed the methods as:
• low, high or unclear risk of bias for participants;
• low, high or unclear risk of bias for personnel.
(3.2) Blinding of outcome assessment (checking for possible
detection bias)
We described for each included study the methods used, if any, to
blind outcome assessors from knowledge of which intervention a
participant received. We assessed blinding separately for different
outcomes or classes of outcomes.
We assessed methods used to blind outcome assessment as:
• low, high or unclear risk of bias.
(4) Incomplete outcome data (checking for possible attrition
bias due to the amount, nature and handling of incomplete
outcome data)
We described for each included study, and for each outcome or
class of outcomes, the completeness of data including attrition and
exclusions from the analysis. We stated whether attrition and ex-
clusions were reported and the numbers included in the analysis at
each stage (compared with the total randomised participants), rea-
sons for attrition or exclusion where reported, and whether miss-
ing data were balanced across groups or were related to outcomes.
Where sufficient information was reported, or could be supplied
by the trial authors, we planned to re-include missing data in the
analyses which we undertook.
We assessed methods as:
• low risk of bias (e.g. no missing outcome data; missing
outcome data balanced across groups);
• high risk of bias (e.g. numbers or reasons for missing data
imbalanced across groups; ‘as treated’ analysis done with
substantial departure of intervention received from that assigned
at randomisation);
• unclear risk of bias.
(5) Selective reporting (checking for reporting bias)
We described for each included study how we investigated the
possibility of selective outcome reporting bias and what we found.
We assessed the methods as:
• low risk of bias (where it is clear that all of the study’s pre-
specified outcomes and all expected outcomes of interest to the
review have been reported);
• high risk of bias (where not all the study’s pre-specified
outcomes have been reported; one or more reported primary
outcomes were not pre-specified; outcomes of interest are
reported incompletely and so cannot be used; study fails to
include results of a key outcome that would have been expected
to have been reported);
• unclear risk of bias.
(6) Other bias (checking for bias due to problems not
covered by (1) to (5) above)
We described for each included study any important concerns we
had about other possible sources of bias.
(7) Overall risk of bias
We made explicit judgements about whether studies were at high
risk of bias, according to the criteria given in the Handbook (
Higgins 2011). With reference to (1) to (6) above, we planned to
assess the likely magnitude and direction of the bias and whether
we considered it is likely to impact on the findings. In future
updates, we will explore the impact of the level of bias through
undertaking sensitivity analyses - see Sensitivity analysis.
Assessment of the quality of the evidence using the
GRADE approach
We assessed the quality of evidence using the GRADE approach
as outlined in the GRADE handbook in order to assess the quality
of the body of evidence. Where data were available, we planned
to use GRADE to assess the overall quality of the evidence for our
main comparisons.
1. Prophylactic oxytocin at any dose for the third stage of
labour versus placebo.
2. Prophylactic oxytocin at any dose for the third stage of
labour versus ergot alkaloids.
3. Prophylactic oxytocin-ergometrine versus ergot alkaloids.
We assessed the following outcomes.
1. Blood loss 500 mL or more after delivery
2. Need for additional uterotonics
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3. Maternal all-cause mortality
4. Blood loss 1000 mL or more after delivery
5. Blood transfusion
6. Third stage greater than 30 minutes
7. Diastolic blood pressure > 100 mm Hg between delivery of
the baby and discharge from the labour ward
Grade outcomes are included in our review ’Summary of Findings’
tables: Summary of findings for the main comparison; Summary
of findings 2; Summary of findings 3.
We used the GRADEpro Guideline Development Tool to import
data from Review Manager 5.3 (RevMan 2014) in order to create
’Summary of findings’ tables. A summary of the intervention effect
and a measure of quality for each of the above outcomes was be
produced using theGRADE approach as outlined in the GRADE
handbook. The GRADE approach uses five considerations (study
limitations, consistency of effect, imprecision, indirectness and
publication bias) to assess the quality of the body of evidence
for each outcome. The evidence can be downgraded from ’high
quality’ by one level for serious (or by two levels for very serious)
limitations, depending on assessments for risk of bias, indirectness
of evidence, serious inconsistency, imprecision of effect estimates
or potential publication bias.
Measures of treatment effect
Dichotomous data
For dichotomous data, we presented results as summary risk ratio
with 95% confidence intervals.
Continuous data
For continuous data, we used themean difference if outcomeswere
measured in the same way between trials. In future, if necessary,
we plan to use the standardised mean difference to combine trials
that measure the same outcome, but use different methods.
Unit of analysis issues
There were no cluster-randomised or cross-over trials in-
cluded in this review. Three of the included studies had
more than two treatment groups (De Groot 1996; Ilancheran
1990; Vaughan Williams 1974). For these studies, we in-
cluded each pair-wise comparison separately, but divided shared
groups approximately equally amongst the comparisons ac-
cording to the Cochrane Handbook for Systematic Reviews of
Interventions Version 5.1.0 (section 16.5.4).
Dealing with missing data
For included studies, levels of attrition were noted. In future up-
dates, if more eligible studies are included, the impact of including
studies with high levels of missing data in the overall assessment
of treatment effect will be explored by using sensitivity analysis.
For all outcomes, analyses were carried out, as far as possible, on
an intention-to-treat basis, i.e. we attempted to include all partici-
pants randomised to each group in the analyses. The denominator
for each outcome in each trial was the number randomised minus
any participants whose outcomes were known to be missing.
Assessment of heterogeneity
We assessed statistical heterogeneity in each meta-analysis using
the Tau², I² and Chi² statistics. We regarded heterogeneity as sub-
stantial if an I² was greater than 40% and either the Tau² was
greater than zero, or there was a low P value (less than 0.10) in the
Chi² test for heterogeneity.
Assessment of reporting biases
Meta-analyses containing 10 or more studies were investigated us-
ing funnel plots to assess reporting bias. Funnel plot asymmetry
was assessed visually. If asymmetry was suggested by a visual assess-
ment, we considered exploratory analyses to investigate it where
appropriate.
Data synthesis
We carried out statistical analysis using the Review Manager soft-
ware (RevMan 2014).We used fixed-effect meta-analysis for com-
bining data where it was reasonable to assume that studies were
estimating the same underlying treatment effect: i.e. where trials
were examining the same intervention, and the trials’ populations
and methods were judged sufficiently similar.
If there was clinical heterogeneity sufficient to expect that the un-
derlying treatment effects differed between trials, or if substan-
tial statistical heterogeneity was detected, we used random-effects
meta-analysis to produce an overall summary, if an average treat-
ment effect across trials was considered clinically meaningful. The
random-effects summary was treated as the average of the range
of possible treatment effects and we discussed the clinical impli-
cations of treatment effects differing between trials. If the average
treatment effect was not clinicallymeaningful, we did not combine
trials. Where we used random-effects analyses, the results were
presented as the average treatment effect with 95% confidence in-
tervals, and the estimates of Tau² and I².
Subgroup analysis and investigation of heterogeneity
If we identified substantial heterogeneity, we planned to investigate
it using subgroup analyses and sensitivity analyses. We considered
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whether an overall summary was meaningful, and if it was, used
random-effects analysis to produce it.
We carried out the following subgroup analyses.
1. Management of the third stage: use of oxytocin with or
without active management of the third stage of labour
(AMTSL)
2. Route of administration: oxytocin given IV versus IM.
3. Dose of administration: oxytocin at a dose of at least 10 IU
versus less than 10 IU
The following outcomes were used in subgroup analyses.
1. Blood loss 500 mL or more after delivery
2. Need for additional uterotonics
3. Maternal all-cause mortality
We assessed subgroup differences by interaction tests available
within RevMan (RevMan 2014). We reported the results of sub-
group analyses quoting the Chi² statistic and P value, and the in-
teraction test I² value.
Sensitivity analysis
We planned to carry out sensitivity analyses to explore the effect
of risk of bias assessed by concealment of allocation, high attrition
rates, or both, with studies at high risk of bias for these domains
being temporarily excluded from the analyses in order to assess
whether this makes any difference to the overall result.
R E S U L T S
Description of studies
Results of the search
See Figure 1.
The updated search in March 2019 search retrieved 27 trial re-
ports. Of the 27 trials, six met the inclusion criteria for the review,
10 were excluded (12 reports), four are awaiting further classifi-
cation (five reports), and two trials are ongoing. We added two
new reports to already excluded studies. We also reassessed and
excluded two studies that were previously included because we
assessed that they were not randomised. This updated review in-
cludes six new randomised trials, for a total of 23 trials included
in the meta-analyses.
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Figure 1. Study flow diagram
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Included studies
Methods and setting
This review includes 24 trials, with a total of 10,018 women par-
ticipating in the 23 included randomised studies comparing oxy-
tocin versus no uterotonics or placebo, oxytocin versus ergot al-
kaloids, or oxytocin and ergometrine versus ergot alkaloids. Seven
of the 23 included trials were deemed to be quasi-randomised
(Adhikari 2007; Boopathi 2014; Dhananjaya 2014; Francis 1965;
Pierre 1992; Saito 2007; Sorbe 1978).
This review includes trials from low-, middle-, and high-income
countries. Nearly all births were attended by midwives or physi-
cians in birth centres or hospitals, although one trial included
women who had a home birth attended by an independent
midwife (De Groot 1996). Trials were conducted in Egypt and
South Africa (Abdel-Aleem 2010), Nepal (Adhikari 2007), India
(Boopathi 2014; Dhananjaya 2014; Modi 2014; Singh 2009),
Tunisia (Jerbi 2007), and Nigeria (Ezeama 2014; Jago 2007; Orji
2008). The remainder of the trials were conducted in high-in-
come countries including France (Pierre 1992), Germany (Bader
2000), Japan (Saito 2007), the Netherlands (De Groot 1996;
Poeschmann 1991), New Zealand (Moodie 1976), Singapore
(Ilancheran 1990), Sweden (Nordstrom 1997; Sorbe 1978), the
UK (Bonham 1963; Francis 1965; Vaughan Williams 1974), and
the USA (McGinty 1956).
Dates of study and sources of trial funding
The trial reports spanned 1956 to 2014. Dates of study were re-
ported for most trials except in five trials where the dates were
not explicitly stated (Ilancheran 1990; McGinty 1956; Moodie
1976; Singh 2009; Vaughan Williams 1974). Sources of funding
included the County Council and County Health Authority Re-
search and Development Foundation in the County of Jamtland,
Sweden (Nordstrom 1997). Methergine was provided by Sandoz
Pharmaceuticals (McGinty 1956), and Sulprostone provided by
Schering-Plough B.V. (Poeschmann 1991). Please see the table
Characteristics of included studies for further details.
Participants
All participants in this study delivered vaginally. Instrumental de-
liveries were exclusion criteria in many studies (Adhikari 2007;
Bader 2000; Bonham 1963; Boopathi 2014; De Groot 1996;
Francis 1965; Jago 2007; Singh 2009), but not explicitly stated
as exclusion criteria in the remaining studies. One study included
onlywomenwith forceps or vacuumdelivery (Moodie 1976). Full-
term pregnancies were an inclusion criteria in six studies (Adhikari
2007; Ilancheran 1990; Jerbi 2007; Modi 2014; Poeschmann
1991; Singh 2009), while two studies included women at a ges-
tational age of 28 weeks or greater (Dhananjaya 2014; Ezeama
2014). Gestational age criteria were not explicitly stated in the
remainder of the studies.
The majority of studies excluded women with multiple gesta-
tions (Adhikari 2007; Bader 2000; Bonham 1963; Boopathi 2014;
De Groot 1996; Ezeama 2014; Francis 1965; Jago 2007; Jerbi
2007; Modi 2014; Moodie 1976; Nordstrom 1997; Pierre 1992;
Poeschmann 1991; Saito 2007; Singh 2009). Women who re-
ceived oxytocin during the course of labour were excluded in
six studies (Bader 2000; Bonham 1963; De Groot 1996; Francis
1965; Saito 2007; Singh 2009).
Many studies attempted to account for postpartum haemorrhage
risk by excluding women with risk factors including grand mul-
tiparity (Bonham 1963; Jerbi 2007; Modi 2014; Saito 2007),
history of postpartum haemorrhage (Bonham 1963; Dhananjaya
2014; Francis 1965; Jerbi 2007;Orji 2008; Saito 2007), and blood
coagulation disorders (Boopathi 2014; Dhananjaya 2014; Modi
2014). Anticoagulation therapy was considered an exclusion cri-
teria in four studies (De Groot 1996; Jago 2007; Jerbi 2007; Saito
2007). Several studies did not explicitly state exclusion criteria but
excluded women with complications or factors associated with in-
creased blood loss (Adhikari 2007; Bader 2000; VaughanWilliams
1974). See Characteristics of included studies for details.
Interventions and comparisons
Nine trials compared oxytocin versus nouterotonics (Abdel-Aleem
2010; Bader 2000; Ilancheran 1990; Jerbi 2007; Pierre 1992;
Vaughan Williams 1974 or placebo (De Groot 1996; Nordstrom
1997; Poeschmann 1991). The oxytocin was administered im-
mediately after delivery of either the baby or the anterior shoul-
der, and we excluded any trials where administration was given
after placental delivery. Oxytocin was given IV (Bader 2000;
Ilancheran 1990; Jerbi 2007; Nordstrom 1997; Pierre 1992) and
IM (Abdel-Aleem 2010; De Groot 1996; Poeschmann 1991;
Vaughan Williams 1974), at doses ranging from 3 to 5 IU (Bader
2000; De Groot 1996; Jerbi 2007; Pierre 1992; Poeschmann
1991; Vaughan Williams 1974) up to 10 IU (Abdel-Aleem 2010;
Nordstrom 1997), with one trial not explicitly stating the med-
ication dosage (Ilancheran 1990). The comparison group varied
amongst the trials, with some comparing oxytocin with expectant
management (Bader 2000; De Groot 1996; Nordstrom 1997) or
administration of a normal saline placebo (Poeschmann 1991),
and others comparing oxytocin with active management alone
(Abdel-Aleem 2010; Jerbi 2007; Pierre 1992; Vaughan Williams
1974). Abdel-Aleem 2010 had three intervention groups where
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women received oxytocin, oxytocin with uterine massage, or uter-
ine massage as part of active management alone. For our analysis
we combined the first two groups into the oxytocin intervention
group, which we felt was acceptable because other included trials
applied active management including uterine massage to both in-
tervention and placebo groups.
Fifteen trials compared oxytocin with ergot alkaloids (Adhikari
2007; Boopathi 2014;DeGroot 1996; Dhananjaya 2014; Ezeama
2014; Ilancheran 1990; Jago 2007; McGinty 1956; Modi 2014;
Moodie 1976; Orji 2008; Saito 2007; Singh 2009; Sorbe 1978;
Vaughan Williams 1974). Oxytocin was administered by IV in
eight of the trials (Ilancheran 1990; Jago 2007; McGinty 1956;
Moodie 1976; Orji 2008; Singh 2009; Sorbe 1978; Vaughan
Williams 1974), and by IM route in the remaining trials, at either
5 IU (De Groot 1996; McGinty 1956; Moodie 1976; Saito 2007;
Singh 2009) or 10 IU doses. Eight studies used ergometrine either
orally (De Groot 1996), IV (Ilancheran 1990; McGinty 1956;
Moodie 1976; Orji 2008; Sorbe 1978; Vaughan Williams 1974)
or IM route (Ezeama 2014; Jago 2007). The remaining stud-
ies used methylergometrine by IV (Boopathi 2014; Modi 2014;
Singh 2009) or IM route (Adhikari 2007; Dhananjaya 2014; Saito
2007); all at a 0.2 mg dose. Doses of IV or IM ergometrine ranged
from 0.2 mg (McGinty 1956; Orji 2008; Sorbe 1978) to 0.5
mg (Ezeama 2014; Jago 2007; Moodie 1976; Vaughan Williams
1974), with one study reporting a 0.4 mg oral dose (De Groot
1996). One study did not report specific doses but described that
all medications were given at “standard doses” (Ilancheran 1990).
Active management or at least one component of the active man-
agement of the third stage of labour (AMTSL) was applied to both
treatment groups in the eight studies (Adhikari 2007; Boopathi
2014; Ezeama 2014; Modi 2014; Orji 2008; Saito 2007; Singh
2009; VaughanWilliams 1974). One trial utilised expectant man-
agement of the third stage (De Groot 1996), and the remaining
six trials did not describe management of the third stage.
There were four trials that compared the effects of oxytocin-
ergometrine versus ergot alkaloids (Bonham 1963; Francis
1965; Ilancheran 1990; Vaughan Williams 1974). Oxytocin-er-
gometrinewas givenby IMroute at a dose of 0.5mgof ergometrine
and5 IUof oxytocin in three studies (Bonham 1963; Francis 1965;
VaughanWilliams 1974), although in one the study itwas given IV
at a “standard dose” (Ilancheran 1990). Ergometrine 0.5 mg was
given IM (Bonham 1963; Francis 1965) or IV (VaughanWilliams
1974). In one study, ergometrine was given IV at a “standard dose”
(Ilancheran 1990). Two trials described AMTSL (Bonham 1963;
Vaughan Williams 1974), while the remaining two trials did not
specifically describe third stage management.
One trial, Fugo 1958, met the criteria for inclusion but no data
from this trial were used because the protocol called for manual
removal of the placenta at 10 minutes after delivery of the infant
and we felt that the methodology of this trial had high risk of bias
and was not translatable into clinical practice.
Outcomes
A range of outcomes were reported in the included trials. Six-
teen trials reported blood loss of 500 mL or more after de-
livery (Abdel-Aleem 2010; Bonham 1963; Boopathi 2014; De
Groot 1996; Dhananjaya 2014; Ezeama 2014; Francis 1965;
Ilancheran 1990; Modi 2014; Nordstrom 1997; Orji 2008;
Pierre 1992; Poeschmann 1991; Saito 2007; Singh 2009; Sorbe
1978), and seven trials reported blood loss of 1000 mL or more
(Abdel-Aleem 2010; De Groot 1996; Nordstrom 1997; Pierre
1992; Poeschmann 1991; Saito 2007; Sorbe 1978). Mean blood
loss was reported in 14 studies (Bader 2000; Boopathi 2014;
De Groot 1996; Dhananjaya 2014; Ezeama 2014; Jago 2007;
Modi 2014;Nordstrom1997;Orji2008; Poeschmann 1991; Saito
2007; Singh 2009; Sorbe 1978; Vaughan Williams 1974).
Blood losswasmeasured gravimetrically (calibrated drapes or other
containers) in four studies (Boopathi 2014; Francis 1965; Modi
2014; Sorbe 1978), and by pad weights in six studies (Bader 2000;
Dhananjaya 2014; Ezeama 2014; Orji 2008; Poeschmann 1991;
Singh 2009). Three studies used a combination of gravimetric
assessment and pad weights (De Groot 1996; Nordstrom 1997;
Saito 2007). Three studies described collection of the blood in
drapes or bins but did not specifically describe how the blood
loss amount was determined (Abdel-Aleem 2010; Pierre 1992;
Vaughan Williams 1974). Bonham 1963 reported that blood loss
was estimated by “adding to the measured quantity a figure for
loss on linen and swabs used during the perineal repair,” implying
a combination of gravimetric and visual estimation. The method
of blood loss determination was not specifically described in the
remaining studies two (Ilancheran 1990; Jago 2007).
Several studies reported surrogate outcomes for significant blood
loss including need for a blood transfusion (Abdel-Aleem 2010;
Adhikari 2007; Boopathi 2014; De Groot 1996; Dhananjaya
2014; Ezeama 2014; Nordstrom 1997; Saito 2007; Singh 2009)
and maternal haemoglobin (Hb) concentration < 7 g/dL 24 to
48 hours postpartum (Jerbi 2007; Nordstrom 1997). The need
for additional uterotonics was examined in 11 studies (Abdel-
Aleem 2010; Adhikari 2007; Boopathi 2014; De Groot 1996;
Dhananjaya 2014; Ezeama 2014; Nordstrom 1997; Orji 2008;
Poeschmann 1991; Saito 2007; Singh 2009).
Many studies reported outcomes related to timing of placental
delivery. A third stage of labour greater than 30 minutes was re-
ported in three studies (Abdel-Aleem 2010; Ezeama 2014; Singh
2009), while others reported the mean length of the third stage
(Bader 2000; Boopathi 2014; Dhananjaya 2014; Ezeama 2014;
Jerbi 2007;Modi 2014;Orji 2008; Poeschmann 1991; Saito 2007;
Singh 2009; Sorbe 1978). The need for manual placental removal
was reported in 14 trials (Abdel-Aleem 2010; Adhikari 2007;
Bonham 1963; Boopathi 2014; De Groot 1996; Ezeama 2014;
Jerbi 2007;Nordstrom1997;Orji 2008; Pierre 1992; Poeschmann
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1991; Saito 2007; Singh 2009; Sorbe 1978).
Many studies examined maternal side effects, including elevated
diastolic blood pressure (Ezeama 2014; Jago 2007; McGinty
1956), headache (Adhikari 2007; Dhananjaya 2014; Ezeama
2014; Orji 2008; Saito 2007), and vomiting (Adhikari 2007;
Boopathi 2014; Dhananjaya 2014; Ezeama 2014; Moodie 1976;
Orji 2008; Saito 2007).
We included the important outcomes of maternal all-cause mor-
tality and mortality from causes other than bleeding in our study.
Only Bonham 1963 reported the outcome of maternal mortality,
however there were no events in either of the treatment groups.
The remainder of the studies did not include maternal mortality
as an outcome. Similarly, several other important outcomes were
not reported in any of the trials, including incidence of shock,
transfer to a higher level of care, maternal satisfaction with treat-
ment, quality of life indices or breastfeeding outcomes.
Trial author’s declarations of interest
The authors from five trials reported no declarations of interest
(Abdel-Aleem 2010; Boopathi 2014; Ezeama 2014; Modi 2014;
Singh 2009), while this information was not reported in the re-
maining studies.
Excluded studies
The details of all excluded studies are outlined in the table
Characteristics of excluded studies. In this updated version of the
review, we excluded seven new studies. Six studies had compari-
son groups that were not in the scope of this review (Jans 2017;
Neri-Mejia 2016; Nuamsiri 2016; Oguz Orhan 2014; Quibel
2016; Sunil 2016). Sharma 2014 was not a randomised trial. In
addition, two studies that were included in the previous version of
this review were excluded in this version as we felt that they could
not be classified as either randomised or quasi-randomised studies
(Barbaro 1961; Soiva 1964). One trial included a large group of
women who were not randomised (data were collected retrospec-
tively) and whose outcome data were inseparable from those that
were randomised (Soiva 1964).
Risk of bias in included studies
See Figure 2; Figure 3.
Figure 2. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Random sequence generation and allocation concealment were
felt to be adequate and at low risk of bias in six of the 24 in-
cluded studies (Abdel-Aleem2010;DeGroot 1996; Ezeama2014;
Nordstrom 1997; Orji 2008; Singh 2009). In one study, we were
unable to characterise risk of bias for sequence generation due
to lack of description, although allocation concealment methods
were adequate (Poeschmann 1991). In another study, random se-
quence generation was adequate but there was insufficient de-
tail regarding allocation concealment to make a judgement (Jago
2007). We assessed that six of the studies were at high risk of bias
in both sequence generation and allocation concealment domains
(Adhikari 2007; Boopathi 2014; Francis 1965; Pierre 1992; Saito
2007; Sorbe 1978). All of these studies were assessed to be quasi-
randomised due to the use of randomisation techniques that may
have allowed for prediction or anticipation of study group assign-
ment. Similarly, allocation treatment was either not concealed or
performed in such a way (alternation or rotation) that could al-
low for possible identification. Another study was deemed to be
at high risk of bias due to quasi-randomisation, with insufficient
information to assess allocation concealment (Dhananjaya 2014).
There was not enough information to assess sequence generation
or allocation concealment for nine studies (Bader 2000; Bonham
1963; Fugo 1958; Ilancheran 1990; Jerbi 2007; McGinty 1956;
Modi 2014; Moodie 1976; Vaughan Williams 1974).
Blinding
Blinding of participants and personnel was assessed to be at high
risk of bias in the majority of the included studies (16 of the 23
studies). Trials did not explicitly state a lack of blinding however
due to the describedmethods it was presumed that blinding would
not have been possible (different dosages or routes of administra-
tion without use of placebos) (Abdel-Aleem 2010; Adhikari 2007;
Bader 2000; Bonham 1963; Boopathi 2014; De Groot 1996;
Dhananjaya 2014; Ilancheran 1990; Jago 2007; Jerbi 2007; Modi
2014; Orji 2008; Pierre 1992; Saito 2007; Sorbe 1978; Vaughan
Williams 1974). Only six trials were deemed to be at low risk
of bias in this domain (Ezeama 2014; Francis 1965; Fugo 1958;
Nordstrom 1997; Poeschmann 1991; Singh 2009), with the re-
maining trials having inadequate description to assess risk of bias.
Blinding of outcome assessment was adequate in five studies as
blinding of outcome assessors was explicitly described (Ezeama
2014; Francis 1965; Fugo 1958; Nordstrom 1997; Singh 2009).
Five studieswere judged to be at high risk of bias in this domain due
to lack of blinding (Adhikari 2007; Boopathi 2014; Dhananjaya
2014; Modi 2014; Sorbe 1978). There was not adequate detail to
assess the remaining studies with regards to detection bias.
Incomplete outcome data
We assessed that all participants who were randomised in the stud-
ies were accounted for in outcome data and analysis in 13 tri-
als (Abdel-Aleem 2010; Bonham 1963; De Groot 1996; Ezeama
2014; Fugo 1958; Jerbi 2007; McGinty 1956; Moodie 1976;
Nordstrom 1997; Orji 2008; Pierre 1992; Poeschmann 1991;
Singh 2009). Three trials were judged to be at high risk of attri-
tion bias. One study excluded an unknown number of women af-
ter randomisation, however the authors did not clarify how many
were lost from each group and how this attrition was addressed
in the methods (Adhikari 2007). In another study there were 20
patients excluded after randomisation (of 180 enrolled) for vari-
ous reasons, including need for surgical intervention (forceps or
vacuum), unusually high levels of blood loss of unknown origin
and placenta delivery times longer than 30 minutes after deliver
(Bader 2000). We felt that excluding patients for high blood loss
or evidence of retained placenta would place this study at high risk
of bias given the nature of the clinical question being addressed.
In a third study, the authors did not explicitly state how many
patients were included in the analysis (Modi 2014). They reported
that women with perineal and cervical lacerations were excluded
from the study, however according to their results the majority of
their patients received an episiotomy, which would have resulted
in exclusion of significant numbers of patients after randomisa-
tion.
Selective reporting
Two studies were felt to be at low risk of reporting bias (Bader
2000; Fugo 1958). One study was deemed to be at high risk of
selective reporting (Modi 2014), as some adverse outcomes of in-
terest were reported incompletely. The authors report “side effects
of various uterotonics” as outcomes, however data regarding vom-
iting, nausea, shivering, fever, headache and hypertension were
incompletely reported for the oxytocin and methylergometrine
groups. One other study was also judged to be at high risk for
reporting bias (Singh 2009). The authors reported “adverse effects
of the drugs” as secondary outcomes, and in the methods describe
collection of data regarding postpartum haemoglobin level, how-
ever the data are not fully presented. They also report that “the
methylergometrine group had the highest incidence of nausea and
vomiting” but did not report this data completely. The remaining
studies did not have enough detail provided to assess this domain.
Other potential sources of bias
No other potential sources of bias were identified in any of the
included trials.
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Effects of interventions
See: Summary of findings for the main comparison Oxytocin
compared to no uterotonics or placebo for the third stage of
labour to prevent postpartumhaemorrhage;Summaryoffindings
2 Oxytocin compared to ergot alkaloids for the third stage of
labour to prevent postpartumhaemorrhage;Summaryoffindings
3 Oxytocin + ergometrine compared to ergot alkaloids for the
third stage of labour to prevent postpartum haemorrhage
See: Summary of findings for the main comparison; Summary of
findings 2; Summary of findings 3.
Thes results are based on 23 studies with a total of 10,018 women.
1) Oxytocin versus no uterotonics or placebo
Primary outcomes
Blood loss greater than 500 mL
Prophylactic oxytocin compared with no uterotonics or placebo
may reduce the risk of blood loss of 500 mL or more after deliv-
ery (average risk ratio (RR) 0.51, 95% confidence interval (CI)
0.37 to 0.72; 4162 women; 6 studies; Tau² = 0.10, I² = 75%;
quality of evidence: low), Analysis 1.1. There were no subgroup
differences observed between active and expectant management
(Analysis 2.1), intravenous or intramuscular oxytocin (Analysis
2.2) or different doses of oxytocin (Analysis 2.3) for this outcome.
Need for additional uterotonics
Prophylactic oxytocin probably reduces the need for additional
uterotonics (average RR 0.54, 95%CI 0.36 to 0.80; 3135 women;
4 studies; Tau² =0.07, I² = 44%; quality of evidence: moderate),
Analysis 1.2.Therewere no subgroupdifferences observed between
active and expectant management (Analysis 2.4), intravenous or
intramuscular oxytocin (Analysis 2.5) or different doses of oxy-
tocin (Analysis 2.6) for this outcome.
Secondary outcomes
Prophylactic oxytocin compared with no uterotonics or placebo
may reduce the risk of blood loss 1000 mL or more after delivery
(RR 0.59, 95% CI 0.42 to 0.83; 4123 women; 5 studies; quality
of evidence: low),Analysis 1.3. There may be no difference in the
risk of needing a blood transfusion in women receiving oxytocin
compared to no uterotonics or placebo (RR 0.88, 95% CI 0.44 to
1.78; 3081 women; 3 studies; quality of evidence: low), Analysis
1.4, and there is probably no difference in the risk of developing a
postpartum haemoglobin (Hb) < 7 g/dL (RR 0.64, 95% CI 0.18
to 2.26; 1073 women; 2 studies; quality of evidence: moderate),
Analysis 1.7. It is unclear if oxytocin is associated with a reduction
in mean blood loss (mean blood loss in mL: -99.13, 95% CI -
181.40 to -16.85; 1359 women; 5 studies; quality of evidence:
very low), Analysis 1.6.
Oxytocin may be associated with an increased risk of a third stage
greater than 30 minutes (RR 2.55, 95% CI 0.88 to 7.44; 1947
women; 1 study; quality of evidence: moderate), Analysis 1.5.
However the CI is wide and crosses 1.0, which indicates that there
may be little or no difference between oxytocin and no uterotonic
or placebo. This result is based on a single study of 1947 women,
where 20 of 1289 women in the oxytocin group experienced this
outcome versus four of 658 women in the no uterotonics group.
It is uncertain whether oxytocin affects the mean length of the
third stage of labour (mean length of the third stage of labour in
minutes: -3.61, 95% CI -9.06 to 1.83; 294 women; 3 studies;
quality of evidence: very low), Analysis 1.8, or the risk of needing
manual removal of the placenta (RR 1.27, 95% CI 0.89 to 1.82;
4281 women; 6 studies; quality of evidence: very low), Analysis
1.9, given the very low certainty of this evidence.
Outcomes not reported
The following pre-specified outcomes were not reported for this
comparison as none of the included trials reported these outcomes:
maternal all-cause mortality, diastolic blood pressure > 100 mgHg
between delivery of the baby and discharge from the labour ward,
vomiting between delivery of the baby and discharge from the
labour ward, headache between delivery of the baby and discharge
from the labour ward, shock, transfer to a higher level of care,
mortality from causes other than bleeding, maternal satisfaction
with therapy, quality of life, breastfeeding.
2) Oxytocin versus ergot alkaloids
Primary outcomes
Blood loss greater than 500 mL
It is uncertain whether oxytocin reduces the likelihood of blood
loss 500 mL or more after delivery (average RR 0.84, 95% CI
0.56 to 1.25; 3082 women; 10 studies; Tau² = 0.14, I² = 49%;
quality of evidence: very low), Analysis 3.1, compared to ergot
alkaloids, because the certainty of this evidence is very low. There
were no subgroup differences observed between active and ex-
pectant management (Analysis 4.1), intravenous or intramuscular
oxytocin (Analysis 4.2) or different doses of oxytocin (Analysis
4.3) for this outcome.
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Need for additional uterotonics
It is also unclear whether oxytocin reduces the need for additional
uterotonics compared to ergot alkaloids (average RR 0.89, 95%
CI 0.43 to 1.81; 2178 women; 8 studies; Tau² = 0.76, I² = 79%;
quality of evidence: very low), Analysis 3.2, due to the very low
certainty of this evidence. There were no differences observed in
any of the prespecified subgroups (Analysis 4.4; Analysis 4.5;
Analysis 4.6).
Secondary outcomes
Similarly, the quality of evidence was very low for the outcomes
of blood loss of 1000 mL or more after delivery (RR 1.13, 95%
CI 0.63 to 2.01; 1577 women; 3 studies; quality of evidence: very
low), Analysis 3.3, need for blood transfusion (average RR 1.37,
95% CI 0.34 to 5.51; 1578 women; 7 studies; Tau² = 1.34, I² =
45%; quality of evidence: very low), Analysis 3.4, as well as mean
blood loss (mean blood loss in mL: -13.97, 95% CI -43.70 to
15.76; 3598 women; 11 studies; quality of evidence: very low),
Analysis 3.7, making any benefit of oxytocin over ergot alkaloids
uncertain.
Oxytocin probably increases the risk of a third stage greater than
30 minutes compared to ergot alkaloids (RR 4.69, 95% CI 1.63
to 13.45; 450 women; 2 studies; quality of evidence: moderate),
Analysis 3.5, although it is uncertain whether or not this translates
into an increased risk of manual placental removal (average RR
1.10, 95% CI 0.39 to 3.10; 3127 women; 8 studies; Tau² = 1.07,
I² = 76%; quality of evidence: very low), Analysis 3.9. It is unclear
whether or not oxytocin affects the mean length of the third stage
of labour (mean length of the third stage in minutes: 0.09, 95%
CI -0.44 to 0.61; 2892 women; 8 studies; quality of evidence: very
low), Analysis 3.8.
Oxytocin may be associated with a lower risk of diastolic blood
pressure > 100 mm Hg after delivery (average RR 0.28, 95% CI
0.04 to 2.05; 960 women; 3 studies; Tau² = 1.23, I² = 50%; quality
of evidence: low), Analysis 3.6, although the 95% CI is very wide
and indicates that there may possibly be little or no risk reduction.
Oxytocin is probably associated with a lower risk of vomiting than
ergot alkaloids (RR 0.09, 95% CI 0.05 to 0.14; 1991 women; 7
studies; quality of evidence: moderate), Analysis 3.10. The impact
of oxytocin on headaches is uncertain (average RR 0.19, 95% CI
0.03 to 1.02; 1543 women; 5 studies; Tau² = 2.54, I² = 72%;
quality of evidence: very low), Analysis 3.11.
Outcomes not reported
The following pre-specified outcomes were not reported for this
comparison as none of the included trials reported these outcomes:
maternal all-cause mortality, maternal Hb concentration < 7 g/dL
24 to 48 hours postpartum, shock, transfer to a higher level of care,
mortality from causes other than bleeding, maternal satisfaction
with therapy, quality of life, breastfeeding.
3) Oxytocin-ergometrine versus ergot alkaloids
Primary outcomes
Blood loss greater than 500 mL
Oxytocin-ergometrine may slightly reduce the risk of blood loss
greater than 500 mL or more after delivery compared to ergot
alkaloids (RR 0.44, 95% CI 0.20 to 0.94; 1168 women; 3 studies;
quality of evidence: low), Analysis 5.1. This outcome is based on
data from only quasi-randomised trials deemed to be at high risk
of bias.
Maternal all-cause mortality
One study reported maternal all-cause mortality as an outcome,
however no events in either the oxytocin-ergometrine group (391
women) or the ergot alkaloid group (416 women) were reported,
so an effect could not be estimated.
Secondary outcomes
The effect of oxytocin-ergometrine compared to ergot alkaloids
on mean blood loss is uncertain (mean blood loss in mL: 61.00,
95% CI -0.90 to 122.90; 27 women; 1 study; quality of evidence:
very low), Analysis 5.3, and there may be no difference in the risk
of manual removal of the placenta (RR 1.06, 95%CI 0.31 to 3.65;
807 women; 1 study; quality of evidence: low), Analysis 5.2.
The need for additional uterotonics, blood loss greater than 1000
mL or more after delivery, blood transfusion, third stage greater
than 30 minutes and diastolic hypertension were not outcomes
reported in the included studies.
Outcomes not reported
The following pre-specified outcomes were not reported for this
comparison as none of the included trials reported these outcomes:
need for additional uterotonics, blood loss 1000 mL or more after
delivery, blood transfusion, third stage greater than 30 minutes,
diastolic blood pressure > 100 mgHg between delivery of the baby
and discharge from the labour ward, maternal Hb concentration <
7 g/dL 24 to 48 hours postpartum, vomiting between delivery of
the baby and discharge from the labour ward, headaches between
delivery of the baby and discharge from the labour ward, shock,
transfer to a higher level of care, mortality from causes other than
bleeding, maternal satisfaction with therapy, quality of life, breast-
feeding.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Oxytocin compared to ergot alkaloids for the third stage of labour to prevent postpartum haemorrhage
Patient or population: women in the third stage of labour
Setting: hospital labour wards and home births in the Netherlands, Sweden, South Af rica, Japan, Singapore, India, Nepal, Tunisia, Nigeria, New Zealand, the UK and the USA
Intervention: oxytocin
Comparison: ergot alkaloids
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with ergot alka-
loids
Risk with oxytocin
Blood loss 500 mL or
more af ter delivery
Study populat ion RR 0.84
(0.56 to 1.25)
3082
(10 RCTs)
⊕©©©
VERY LOW 12
116 per 1000 97 per 1000
(65 to 145)
Need for addit ional
uterotonics
Study populat ion RR 0.89
(0.43 to 1.81)
2178
(8 RCTs)
⊕©©©
VERY LOW 234
94 per 1000 84 per 1000
(40 to 170)
Maternal all-cause mor-
tality
Study populat ion - - - This outcome was not
reported in any of the
included studies- -
Blood loss 1000 mL or
more af ter delivery
Study populat ion RR 1.13
(0.63 to 2.01)
1577
(3 RCTs)
⊕©©©
VERY LOW 12
32 per 1000 36 per 1000
(20 to 64)
Blood transfusion Study populat ion RR 1.37
(0.34 to 5.51)
1578
(7 RCTs)
⊕©©©
VERY LOW 356
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13 per 1000 18 per 1000
(4 to 71)
Third stage > 30 min-
utes
Study populat ion RR 4.69
(1.63 to 13.45)
450
(2 RCTs)
⊕⊕⊕©
MODERATE 7
18 per 1000 84 per 1000
(29 to 240)
Diastolic blood pres-
sure > 100 mm Hg be-
tween delivery of the
baby and discharge
f rom the labour ward
Study populat ion RR 0.28
(0.04 to 2.05)
960
(3 RCTs)
⊕⊕©©
LOW 68
44 per 1000 12 per 1000
(2 to 90)
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io;
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Studies with serious methodological lim itat ions in mult iple domains (risk of bias -2)
2 Wide 95% conf idence intervals including line of no ef fect (imprecision -1)
3 Studies with serious methodological lim itat ions (risk of bias -1)
4 Large variat ions in ef fect and non-overlapping 95% conf idence intervals; I2 = 79% indicat ing substant ial heterogeneity
(inconsistency -1)
5 Large variat ions in ef fect; I2 = 45% indicat ing substant ial heterogeneity (inconsistency -1)
6 Wide 95% conf idence intervals including line of no ef fect, and few events (imprecision -1)
7 Wide 95% conf idence interval and few events, including one study with no events (imprecision -1)
8 Unclear allocat ion concealment in majority of studies (risk of bias -1)
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Oxytocin + ergometrine compared to ergot alkaloids for the third stage of labour to prevent postpartum haemorrhage
Patient or population: women in the third stage of labour
Setting: hospital labour wards in Sweden, Singapore, Tunisia, and the UK
Intervention: oxytocin + ergometrine
Comparison: ergot alkaloids
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with ergot alka-
loids
Risk with oxytocin + er-
gometrine
Blood loss 500 mL or
more af ter delivery
Study populat ion RR 0.44
(0.20 to 0.94)
1168
(3 RCTs)
⊕⊕©©
LOW 12
37 per 1000 16 per 1000
(7 to 34)
Need for addit ional
uterotonics
Study populat ion - - - This outcome was not
reported in any of the
included studies- -
Maternal all-cause mor-
tality
Study populat ion not est imable 807
(1 RCT)
⊕⊕⊕©
MODERATE 3
It was not possible to
obtain ef fect est imates
as there were no events
reported
0 per 1000 0 per 1000
(0 to 0)
Blood loss 1000 mL or
more af ter delivery
Study populat ion - - - This outcome was not
reported in any of the
included studies- -
Blood transfusion Study populat ion - - - This outcome was not
reported in any of the
included studies- -
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Third stage > 30 min-
utes
Study populat ion - - - This outcome was not
reported in any of the
included studies- -
Diastolic blood pres-
sure > 100 mm Hg be-
tween delivery of the
baby and discharge
f rom the labour ward
Study populat ion - - - This outcome was not
reported in any of the
included studies
- -
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io;
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Lack of blinding of est imated outcome assessment, and concern regarding randomisat ion methods (risk of bias -1)
2 Few events and wide 95% conf idence intervals (imprecision -1)
3 No events reported for this outcome (imprecision -1)
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D I S C U S S I O N
Summary of main results
Compared to no uterotonics or placebo, oxytocin may reduce the
risk of blood loss greater than 500 mL and greater than 1000 mL
(low-quality evidence), and probably reduces the need for addi-
tional uterotonics (moderate-quality evidence). Oxytocin proba-
bly does not affect the risk of developing severe anaemia (hae-
moglobin (Hb) < 7 g/dL) (moderate-quality evidence), and may
not affect the risk of needing a blood transfusion (low-quality ev-
idence). The use of oxytocin may be associated with an increased
risk of a third stage of labour greater than 30 minutes (moderate-
quality evidence), although whether that translates into greater
risk of needing a manual placental removal is uncertain (very low-
quality evidence).
It is unclear whether oxytocin affects the risk of excessive blood
loss after delivery compared to ergot alkaloids, as the quality of
evidence for outcomes related to blood loss (blood loss greater than
500 mL, blood loss greater than 1000 mL, need for additional
uterotonics, need for blood transfusion, mean blood loss) was very
low. Oxytocin probably increases the risk of a third stage of labour
greater than 30 minutes (moderate-quality evidence), however it
is uncertain whether or not this translates into an increased risk
of manual placental removal or a difference in the mean length of
the third stage of labour (very low-quality evidence). This must
be weighed against potential side effects, as ergot alkaloids are
probably associated with a higher risk of vomiting (moderate-
quality evidence), and may be associated with a higher risk of
diastolic hypertension (low-quality evidence).
The combination of oxytocin and ergometrine compared to ergot
alkaloids alonemay be associated with a slight reduction in the risk
of blood loss greater than 500 mL, based on low-quality evidence
from only quasi-randomised trials at high risk of bias. The effect
on mean blood loss is uncertain (very low-quality evidence), and
there may be no difference in the risk of manual placental removal
(low-quality evidence).
Overall completeness and applicability of
evidence
Population
The patient population in the majority of the studies were women
in relatively good health, as many studies excluded women with
medical co-morbidities (diabetes, hypertensive disease, renal dis-
ease, pre-existing anaemia). Although many women with risk fac-
tors associated with an increased risk of postpartum haemorrhage
(PPH) were also excluded (prior PPH, grand multiparity, multiple
gestations), generalising these data to those specific patient groups
seems reasonable as similar etiologies for PPH are likely to exist
in a lower-risk population. Gestational age criteria were explicitly
stated in aminority of the included studies, ranging from inclusion
of full-term patients only and inclusion of patients at 28 weeks’
gestation or greater. Women who delivered by caesarean section
were not included in the analysis, and many studies also excluded
women with an operative vaginal delivery.
Intervention
Oxytocin was given by intramuscular (IM) and intravenous (IV)
route at doses ranging from 5 international units (IU) to 10 IU in
the included trials, with most trials lacking clarification of whether
IV route was administered by bolus or infusion. While this is re-
flective of practice in some centres, many also choose to use higher
doses administered by IV infusion for variable periods of time
following delivery. When comparing oxytocin to no uterotonics,
active management or some component of active management of
the third stage of labour (AMTSL) was applied to the comparator
group in approximately half of the studies, but none of the studies
applied active management to the oxytocin treatment groups.
Comparators
In this review oxytocin was compared to either no uterotonics
or placebo or ergot alkaloids (alone or in combination with er-
gometrine). As current recommendations from the World Health
Organization and multiple obstetric professional organisations
recommend the use of active management of the third stage in-
cluding the use of a uterotonic, most recent studies evaluate the
use of oxytocin compared to another uterotonic agent instead of
placebo. Ergot alkaloids (methylergometrine or ergometrine) were
given in the majority of studies by either IV or IM route and doses
ranging from 0.2 mg to 0.5 mg, which reflects typical practice in
most centres. Oxytocin-ergometrine (Syntometrine) was given at
the standard dose in the included trials; currently this medication
is currently unavailable in the USA. Also of note, approximately
half of the studies comparing oxytocin with ergometrine applied
active management to all treatment groups, while most of the re-
maining studies did not explicitly state their practice regarding
active management.
Outcomes
Most studies included direct blood loss evaluation with some form
of gravimetric measurement described. While most studies did
not explicitly describe over what period of time the blood loss
was measured, the few that did mention this described measure-
ment of blood loss accumulated within one hour of delivery. Most
studies reported blood loss greater than 500 mL, in line with the
most commonly utilised definition of PPH, although a third of
the studies did specifically report blood loss greater than 1000 mL.
Outcomes related to retained placenta were examined in many tri-
als, with most reporting data either for manual placental removal
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or a third stage greater than 30 minutes. None of the included
studies included surrogate outcomes for significant maternal mor-
bidity from haemorrhage such as transfer to higher level of care or
shock, and only one reported maternal mortality as an outcome
(although there were no events in either group).
Setting
The evidence in this review is based upon trials from a wide range
of low- to high-income countries in hospital settings, although
one trial included an undisclosed number of women who deliv-
ered at home attended by a midwife (De Groot 1996). All studies
included data from patients at tertiary medical hospitals, many of
them teaching hospitals, although several also included patients
recruited from community hospitals.
Summary
Overall, the evidence in this review is directly applicable to healthy
women at lower risk of PPH, delivering vaginally in hospital set-
tings at greater than 28 weeks. Extending applicability of these
findings with regards to impact on blood loss seems reasonable
in women undergoing caesarean delivery, and those with certain
risk factors (prior PPH, multiple gestations, grand multiparity).
Women with coagulation disorders or other haematological issues
(those on anticoagulation) may have different or additional mech-
anisms underlying postpartum bleeding, and should still receive
the usual third stage management although additional therapies
may be necessary in the event of PPH depending on the underling
disorder. Application of the findings to women delivering outside
of a hospital but with access to uterotonic medications is also rea-
sonable given expected similarities in the underlying mechanisms
of PPH.
We had planned to assess multiple outcomes for each of our three
comparisons, with the goal of evaluating effects of interventions
that would reflect a wide range of potential maternal morbidity. In
this updated version of the review, we incorporated several addi-
tional important outcomes that have been recommended as part
of a core outcome set for reporting in PPH prevention studies
(Meher 2018). It is important to note that none of the included
trials reported many of our pre-specified outcomes, including ma-
ternal mortality (all-cause and from causes other than bleeding),
shock, transfer to a higher level of care, patient-reported outcomes
(maternal satisfaction with therapy and quality of life) and neona-
tal outcomes (breastfeeding).
Most studies that compared oxytocin versus no uterotonics or with
ergot alkaloids included multiple important outcomes and surro-
gate outcomes aimed at assessing blood loss. Data on complica-
tions of delayed placental deliveryweremore limited for trials com-
paring oxytocin with no uterotonics, with only one trial reporting
outcomes for a third stage greater than 30 minutes (Abdel-Aleem
2010), although several trials did report on the incidence of man-
ual placental removal (Abdel-Aleem 2010; De Groot 1996; Jerbi
2007; Nordstrom 1997; Pierre 1992; Poeschmann 1991). In con-
trast, most of the trials comparing oxytocin with ergot alkaloids re-
ported third stage placental complications including mean length
of the third stage and manual placental removal, although only
two specifically reported the outcome of third stage greater than
30 minutes (Ezeama 2014; Singh 2009). Potential adverse effects
of oxytocin were not reported in trials comparing oxytocin with no
uterotonics, possibly secondary to the relatively favourable side-
effect profile of oxytocin when given in smaller limited doses. As
ergot alkaloids have been associated with multiple side effects due
to vasoconstriction (De Groot 1998; Liabsuetrakul 2018), many
studies reported outcomes for side effects including diastolic hy-
pertension, vomiting and headaches.
Overall, evidence on oxytocin-ergometrine compared to ergot al-
kaloids was very limited, with only four trials identified that in-
cluded this comparison (total of 1198 women). Data on a limited
number of outcomes were reported, including blood loss greater
than 500 mL, mean blood loss and manual removal of the pla-
centa.
Quality of the evidence
We graded the evidence for all outcomes using the GRADE ap-
proach, and reported the findings for the outcomes we deemed
most important in our ’Summary of findings’ tables (Summary
of findings for the main comparison; Summary of findings 2;
Summary of findings 3). See the ’Risk of Bias’ summary (Figure 3)
for our detailed assessment of risk of bias for each of the included
studies.
Evidence for the comparison of oxytocin versus no uterotonics or
placebo ranged from very low tomoderate quality. For our primary
outcomes, the evidence was deemed to be of low tomoderate qual-
ity due to risk of bias due to lack of blinding, as well as substan-
tial heterogeneity. For secondary outcomes including blood loss
greater than 1000 mL and need for blood transfusion, the quality
of evidence was downgraded to low due to lack of blinding and
wide confidence intervals resulting in imprecision. The evidence
for a third stage greater than 30 minutes was based on data from
single study and assessed as moderate quality, due to concern over
imprecision as confidence intervals were wide and there were very
few events. Other evidence evaluating retained placenta (mean
length of the third stage and need for manual placental removal)
was of very low quality due to serious concerns regarding risk of
bias in multiple domains, as well as both substantial heterogeneity
and imprecision.
Evidence for the comparison of oxytocin versus ergot alkaloids
ranged from very low to moderate quality, with the majority of
outcomes assessed as very low to low quality of evidence. Evidence
for our primary outcomes of blood loss greater than 500 mL and
need for additional uterotonics was downgraded to very low due
to serious methodological limitations increasing the risk of bias,
wide confidence intervals resulting in imprecision and substan-
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tial heterogeneity leading demonstrating inconsistency. Secondary
outcomes of blood loss of 1000 mL or more and need for trans-
fusion were also assessed as very low quality for the same reasons.
The evidence for risk of third stage greater than 30 minutes was
deemed of moderate quality due to lack of precision (there were
wide confidence intervals, few events and one of the two studies
had no reported events). Evidence for manual placental removal
was of very low quality due to serious methodological limitations
across multiple domains, wide confidence intervals and substan-
tial heterogeneity. Evidence for various side effects was assessed
as low quality for elevated diastolic blood pressure due to con-
cerns regarding heterogeneity and wide confidence intervals, and
as moderate quality for vomiting due to risk of bias concerns in re-
porting trials. Evidence for headaches was of very low quality due
to serious methodological concerns, as well as serious imprecision
and inconsistency amongst trials. We produced funnel plots for
analyses that included 10 or more studies (Analysis 3.1, Figure 4;
Analysis 3.7, Figure 5), and neither raised concern for publication
bias.
Figure 4. Funnel plot of comparison: 3 Oxytocin versus ergot alkaloids, outcome: 3.1 Blood loss 500 mL or
more after delivery.
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Figure 5. Funnel plot of comparison: 3 Oxytocin versus ergot alkaloids, outcome: 3.7 Mean blood loss (mL).
Evidence for the comparison of oxytocin-ergometrine versus ergot
alkaloids was very limited, but ranged from very low to low quality.
For all three outcomes with data reported, there were concerns
regarding lack of blinding and randomisation methods increasing
the risk of bias, as well as wide confidence intervals combined with
few events concerning for imprecision.
Potential biases in the review process
We attempted to minimise the introduction of bias in this review
by adhering to the Cochrane methods at all stages of data col-
lection and analysis. Two review authors independently assessed
trials for inclusion, extracted data and assessed risk of bias. Any
discrepancies were resolved by discussion or by involvement of a
third author. GRADE assessment for quality of evidence was as-
sessed by two review authors.
Agreements and disagreements with other
studies or reviews
This is themost comprehensive published systematic review specif-
ically comparing oxytocin with no uterotonics or ergot alkaloids
for the prevention of PPH. The findings are overall consistent with
findings from other related studies that have included oxytocin
as a comparison group. One review compared oxytocin with no
intervention or standard care in the third stage of labour in out-
of-hospital settings and found that oxytocin probably decreased
the incidence of PPH greater than 500 mL, although evidence
for all other outcomes was lacking or the interpretation was lim-
ited due to low quality of evidence (Pantoja 2016). A recent net-
workmeta-analysis was undertaken to investigate and rank various
uterotonic regimens according to their effectiveness and side-ef-
fect profiles (Gallos 2018). They identified oxytocin-ergometrine,
oxytocin combined with misoprostol, and carbetocin, as being the
most effective drugs for reducing postpartum blood loss compared
to oxytocin. The regimens associated with the highest risk of side
effects compared to oxytocin alone were oxytocin-ergometrine (in-
creased risk of nausea, vomiting,and diarrhoea), and oxytocin plus
misoprostol (increased risk of nausea, vomiting, shivering, fever,
and diarrhoea).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Prophylactic oxytocin may reduce the risk of blood loss and de-
crease the need for additional uterotonics, and could be considered
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as a component of the active management of the third stage of
labour (AMTSL). It is unclear whether prophylactic oxytocin re-
duces postpartum blood loss compared to ergot alkaloids, however
it may be associated with fewer side effects. This must be weighed
against a possible increased risk of a third stage greater than 30
minutes, although whether or not this translates into greater need
for manual placental removal is uncertain given the low quality
of the evidence. The combination of oxytocin and ergometrine
may slightly reduce the risk of postpartum blood loss compared
to ergot alkaloids, however the certainty of this conclusion is low
given the lack of randomised trials and imprecision.
Implications for research
The majority of evidence for outcomes in this review was of low
quality, with many trials deemed at high risk of bias due to lack
of blinding, concerns regarding allocation concealment, as well
as quasi-randomisation. More high-quality randomised controlled
trials with adequate blinding of participants and use of gravimetric
techniques for blood loss measurement, are needed. High-qual-
ity randomised controlled trials examining oxytocin dosing and
route of administration, as well as oxytocin in comparison to other
available regimens will be important in determining optimal man-
agement of the third stage of labour. Additionally, future trials
should examine a range of outcomes that include, not only out-
comes directly related to blood loss and side effects, but include
those outcomes that have been recommended as part of a core
outcome set for reporting in postpartum haemorrhage (PPH) pre-
vention studies (Meher 2018). Such outcomes include maternal
mortality (all-cause and from causes other than bleeding), shock,
transfer to a higher level of care, patient-reported outcomes (ma-
ternal satisfaction with therapy and quality of life) and neonatal
outcomes (breastfeeding). A network meta-analysis of uterotonics
for PPH prevention plans to address issues around optimal dosing
and routes of oxytocin and other uterotonics.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Abdel-Aleem 2010
Methods Randomised controlled trial.
Women were randomly allocated to 1 of 3 groups by selecting the next number in a
computer-generated random number sequence. The allocated group was noted inside
opaque sealed envelopes. Not blinded
Participants 1964 pregnant woman who were expected to have a vaginal delivery at Women’s Health
Center Assiut, Egypt and the Department of Obstetrics and Gynecology, East London
Hospital Complex, East London South Africa between September 1, 2006 and February
28, 2009. Women were excluded for medical complications as follows; hypertension,
diabetes, previous caesarean section, abdominal wall not thin enough to allow adequate
palpation of uterus after delivery
Interventions All interventions were given after delivery of the anterior shoulder or after delivery of
the neonate
1) 10 IU IM oxytocin (643 women)
2) Sustained uterine massage shortly after delivery performed by the research midwives;
massage was sustained for 30 minutes an involved manual stimulation of the whole
surface of the uterus (662 women)
3) Combined management with 10 IU IM oxytocin plus uterine massage (659 women)
In all 3 groups active management was performed: the umbilical cord was clamped soon
after delivery of the neonate and the placenta was delivered by controlled cord traction
when the uterus became contracted. A plastic drape or a low profile plastic bedpan was
placed under the mother’s buttocks after delivery of the neonate to collect the blood
lost within 30 minutes of delivery. For the group that did not initially receive oxytocin,
injections of oxytocin were given if blood loss > 500 mL occurred during the 30-minute
collection time
Comparison for review is groups 1 and 3 combined (1302 women) vs group 2 (662
women)
Outcomes Blood loss > 300 mL, > 500 mL or > 1000 mL within 30 minutes of delivery, delivery
of the placenta within 30 minutes of neonate delivery, use of additional uterotonics or
other procedures to manage haemorrhage, Hb level after 12-24 hours of < 8 g in 100
mL or < 10 g in 100 mL (South Africa only), blood transfusion, MRP or placenta not
delivered in 30minutes, maternal morbidity (including admission to higher level of care)
, and adverse effects (nausea, vomiting, pain or discomfort)
Notes Dates of study: September 2006-February 2009
Funding sources: not reported
Declarations of interest: none
Risk of bias
Bias Authors’ judgement Support for judgement
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Abdel-Aleem 2010 (Continued)
Random sequence generation (selection
bias)
Low risk Women were randomly allocated to 1 of
3 groups by selecting the next number in
a computer-generated random number se-
quence
Allocation concealment (selection bias) Low risk The allocated group was noted inside
opaque sealed envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No mention of blinding procedures, but
given the nature of the treatments it would
not have been possible to blind either par-
ticipants or personnel
Assessment of blood loss leading to assess-
ment of need for use of additional utero-
tonics can be subjective. Uterine massage
too can vary amongst providers
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No mention of blinding procedures for
outcome assessment. Some outcomes are
subjectively assessed and lack of blinding
could impact on outcomes, but others are
objectively measured and lack of blinding
would have little impact
Incomplete outcome data (attrition bias)
All outcomes
Low risk Minimal loss. Loss similar (n = 3 to 7) in
each arm.
Selective reporting (reporting bias) Unclear risk All appear to be reported that are listed in
methods text, however trial protocol not
available
Other bias Unclear risk Unclear.
Adhikari 2007
Methods Quasi-randomised controlled trial.
Women were allotted consecutively into Group A or B in the second stage when quote:
“delivery imminent.” Participants were not blinded
Participants Women presenting for delivery at the Tribhuvan University Teaching Hospital in Nepal
over a 1-year period in 2004
All women with parity < 5, singleton live pregnancy at or above 37 weeks, cephalic, with
spontaneous onset of labour and spontaneous vaginal delivery without complicating
factors were included. Women with the following were excluded: parity > 4, multiple
gestation, < 37 weeks, women with “complicating factors” (not specified). Women were
excluded if they had an instrumental or caesarean delivery, precipitous labour or lack of
postpartum blood sample
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Adhikari 2007 (Continued)
Interventions Immediately after delivery participants received:
A. oxytocin 10 IU IM (n = 100) or
B. methylergometrine 0.2 mg IM (n = 100)
All received early cord clamping, cord traction, and uterine massage
Outcomes Mean decrease in Hb/Hct measurements between admission in labour and 24 hours
postpartum, incidence of PPH (defined as peripartum fall in Hct of 10%), need for
additional uterotonics, need for exploration and uterine evacuation, blood transfusion,
nausea, vomiting, headache, retained placenta (need for manual removal), rise in blood
pressure (systolic > 15 mmHg and diastolic > 10 mmHg)
Notes Dates of study: 2004
Funding sources: not reported
Declarations of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quasi-randomisation, quote:“women were
allotted consecutively into two groups at
the second stage of labour…if the first
woman was enrolled into Group A then the
next would be in Group B and so on.”
Allocation concealment (selection bias) High risk Alternation of assignment into Group A
and B: quote: “women were allotted con-
secutively into two groups at the second
stage of labour…if the first woman was en-
rolled into Group A then the next would
be in Group B and so on.”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not blinded.
Incomplete outcome data (attrition bias)
All outcomes
High risk Women were excluded after randomisa-
tion, however the authors do not clarify
how many were lost from each group and
how this attrition was addressed
Selective reporting (reporting bias) Unclear risk Insufficient information to assess.
Other bias Unclear risk Unclear.
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Bader 2000
Methods Randomised controlled trial.
Women were randomly allocated. No further information is given aside from confirma-
tion that the allocation was randomised
Not blinded.
Participants 180 women in the third stage of labour at the Gynaecological Clinic of the University
of Witten/Herdecke, part of the Marienhospital Witten
Primary grounds for exclusion included complicated pregnancies requiring oxytocin
stimulation during delivery, multiple pregnancies, weight over 100 kg, uterus myomato-
sus, previous treatment with oxytocin and conditions tending to increase blood loss
Secondary grounds were the need for surgical intervention (forceps or vacuum) in de-
livery, unusually high levels of blood loss of unknown origin and placenta delivery times
longer than 30 minutes after delivery
Interventions After delivery of the fetus, women were randomly assigned to receive:
1) acupuncture: 2 needles (0.3 x 25 mm) applied 1.5 cm on either side of the navel
(point Ni16);
2) oxytocin: 3 units administered intravenously directly after delivery;
3) control: no treatment.
After the birth, waterproof bedding was laid down in order to measure blood loss. The
time between delivery of the baby and delivery of the placenta was measured in minutes.
After delivery of the placenta the waterproof bedding was removed and weighed (to
measure blood loss). The Hb levels of each patient were measured on arrival in the
delivery room and on leaving the hospital
The midwives involved were advised not to interfere postpartum with the uterus and
umbilical cord--expectant management
Comparison for review is group 2 vs group 3.
Outcomes Primary outcomes included blood loss and the length of the placental delivery period.
The duration of the birth and the delivery period were also recorded
Notes Only the oxytocin and control group data are used in the analysis
Dates of study: 1998 to 1999 specified in secondary reference
Funding sources: not reported
Declarations of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomisation not described
other than quote: “allocation was ran-
domised”
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk The treatment was not blinded
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Bader 2000 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It is not stated whether outcome assessors
were blinded.
Incomplete outcome data (attrition bias)
All outcomes
High risk There were a total of 20 exclusions on var-
ious secondary exclusion grounds: 1 in the
control group, 12 in the acupuncture group
and 7 in the oxytocin group, leaving a total
of 160 patients
Selective reporting (reporting bias) Low risk All outcomes reported.
Other bias Unclear risk Unclear.
Bonham 1963
Methods Randomised controlled trial.
Selection of drug was made by random numbers. Timing of randomisation not stated.
Not blinded.
Participants All vaginal deliveries April 1961 toOctober 1962 in hospital in London, except: multiple
pregnancies, previous PPH or manual removal, forceps and breech deliveries must be
post-randomisation exclusions but does not state how many were randomised), parity 4
or more, induction or augmentation with syntocinon
Interventions (1) IM 0.5 mg ergometrine + 5 units synthetic oxytocin, given at crowning of the head
(n = 391).
(2) IM 0.5 mg ergometrine, given at crowning of the head (n = 416).
[Third group of ergometrine + hyaluronidase not considered for this review.]
Women were also selected in random 2-week groups to either controlled cord traction
(n = 199 ergometrine + oxytocin vs 217 ergometrine alone) or maternal effort/fundal
pressure (192 vs 199)--combination of both active and expectant management.
No information about timing of cord clamping/cutting.
Blood loss was estimated by adding to the measured quantity a figure for loss on linen
and swabs used during the perineal repair
Outcomes Primary PPH (> 568 mL estimated by adding to measured quantity a figure for loss
on linen and swabs used for perineal repair); mean blood loss (154 vs 178 mL, SD not
given); mean length of third stage (6.3 vs 6.2 minutes, SD not given); prolonged third
stage (> 30 minutes); MRP
Notes Dates of study: April 1961 - September 1962
Funding sources: not reported
Declarations of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
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Bonham 1963 (Continued)
Random sequence generation (selection
bias)
Unclear risk Randomisation by numbers; procedure not
described in detail.
Allocation concealment (selection bias) Unclear risk Not described.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding of the intervention was not possi-
ble because differing numbers of ampoules
were needed for different trial arms
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding not mentioned.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition described; no loss of data.
Selective reporting (reporting bias) Unclear risk Protocol unseen
Other bias Unclear risk Unclear.
Boopathi 2014
Methods Quasi-randomised controlled trial.
Women were assigned to groups based on an even or odd inpatient number
Participants Women presenting for delivery at a labour ward in India between April 2012 and January
2013
Women presenting with a singleton term cephalic pregnancy with spontaneous labour
onset, no contraindications to oxytocin or methylergometrine and no known risk factors
for PPH were included. Women with the following were excluded: operative deliveries,
multiple pregnancy, fetal demise, Rh alloimmunisation, hypertension, anaemia (Hb <
9 g/dL), heart disease, past history of third stage complications, prior caesarean section,
disorders of blood coagulation
Interventions Immediately after delivery participants received:
A. oxytocin 10 IU IM (n = 150) or
B. methylergometrine 0.2 mg IV (n = 150)
All received early cord clamping and intermittent cord traction. Following placental
delivery, a conical graduated plastic collection bag was placed below patient and blood
loss was measured after 1 hour
Outcomes Incidence of PPH (measured blood loss > 500 mL), pre-delivery and post-delivery Hct,
need for additional uterotonics, duration of the third stage, measured blood loss by
calibrated drapes, blood transfusion, side effects including nausea and vomiting, high
blood pressure
40Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Boopathi 2014 (Continued)
Notes Dates of study: April 2012 - January 2013
Funding sources: self funded by corresponding author
Declarations of interest: none
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quasi-
randomisation: quote: “eligible women …
were assigned to 2 groups at a random of
150 in each group.Women with even inpa-
tient number were allotted to Group 1 and
odd inpatient number allotted to Group 2.
”
Allocation concealment (selection bias) High risk Participants assigned to 2 groups based on
even or odd inpatient numbers
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not blinded.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Women were excluded from the study fol-
lowing randomisation if there was quote:
“profuse bleeding following episiotomy.
” Unclear how many women from each
group were excluded and how this attrition
was addressed
Selective reporting (reporting bias) Unclear risk Insufficient information to assess.
Other bias Unclear risk Unclear.
De Groot 1996
Methods Randomised controlled trial.
Hospital pharmacy supplied numbered boxes of tablets and ampoules according to com-
puter-generated randomisation list. Informed consent asked in early labour. Assigned
before delivery of baby’s head. Double-blind for oral ergometrine vs placebo and un-
blinded for ergometrine and/or placebo vs oxytocin. Randomisation 1:2:2, oxytocin to
ergometrine to placebo. Multicentre
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De Groot 1996 (Continued)
Participants 2 university hospitals, a midwifery school and independent midwives attending home
births in and around Nijmegen, the Netherlands. Women expecting to deliver in one of
these settings, and who did not develop following exclusion criteria: refusal, cardiovascu-
lar disease/hypertension, multiple pregnancy, non-cephalic presentation, polyhydram-
nios, tocolysis 2 hours prior to delivery, anticoagulant therapy, stillbirth, APH, chemical
induction or augmentation (oxytocin, prostaglandins), instrumental/operative delivery
(some of thesemust have been post-randomisation exclusions), anaemiaHb < 6.8mmol/
L (timing not stated), previous third stage complications.
4 of 371 women were assigned to the study erroneously (3 forceps, 1 augmentation)
and were excluded post-randomisation. Otherwise eligible women wishing a natural
childbirth refused to enter the trial (numbers not stated)
Interventions All 3 interventions given immediately after birth of baby:
(1) IM 5 IU oxytocin (n = 78);
(2) oral 0.4 mg ergometrine (n = 146);
(3) oral placebo (143).
Other third stage management expectant (although no information given about timing
of cord clamping/cutting). When mother feels contractions or there are signs of separa-
tion, maternal effort encouraged, adopting position to aid gravity. If necessary, flat hand
on abdomen to act as brace to aid pushing. Re-attempt if placenta does not deliver spon-
taneously. If haemorrhage, administer extra oxytocics and/or controlled cord traction
Blood loss measured gravimetrically--fresh perineal pad under perineum to absorb blood
or fluid; gauzes and pads collected until 1 hour after delivery of placenta and weighed.
100 g increase in weight considered equivalent to 100 mL blood
Comparison for review is group 1 vs group 2 and group 1 vs group 3
Outcomes Mean blood loss (mL); PPH (> = 500 mL); severe PPH (> = 1000 mL); length of third
stage (11 (range 4-90), 15 (2-90), 14 (3-55) in oxytocin, ergometrine and placebo groups
respectively. No information about whether mean or median, and SD not given); blood
pressure 15, 30, 45 and 60 minutes after delivery of placenta, in institutional deliveries
only (oral ergometrine showed no significant elevation); use of further oxytocics; MRP;
transfusion
Notes Dates of study: July 1993 - July 1994
Funding sources: not reported
Declarations of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Numbered boxes of tablets and am-
poules according to computer-generated
randomisation list
Allocation concealment (selection bias) Low risk No difference could be detected between
boxes.
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De Groot 1996 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Drugs administered via different routes so
blinding not possible
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not mentioned in report
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attritionminimal and where outcome data
missing, adequate explanation given
Selective reporting (reporting bias) Unclear risk Protocol unseen
Other bias Unclear risk Unclear.
Dhananjaya 2014
Methods Quasi-randomised controlled trial.
Women were assigned to oxytocin IM or methylergometrine IM by random sampling
method alternatively during the third stage of labour
Participants Women presenting to the Sri Siddhartha Medical College Hospital between December
2011 and May 2013
Women after 28 weeks’ gestation anticipating a vaginal delivery were included. Women
with the following were excluded: grand multiparity, rhesus negative, heart disease, di-
abetes, bleeding disorders, precipitated labour, overdistended uterus, traumatic PPH,
PROM or chorioamnionitis, IUD, previous caesarean section or prior uterine scar, in-
ability to obtain informed consent
Interventions Immediately after delivery women received:
A. oxytocin 10 IU IM (n = 50) or
B. methylergometrine 0.2 mg IM (n = 50)
Blood was collected in drapes and pre-weighed mops following delivery, and blood loss
measured by weight. A sample of venous blood before and 24 hours after delivery was
obtained for Hb/Hct measurements
Outcomes Measured blood loss (mL), duration of the 3rd stage (minutes), mean percentage fall in
Hb and Hct (%), PPH (blood loss > 500 mL), need for additional uterotonics, blood
transfusion, nausea, vomiting, headache, diarrhoea
Notes Dates of study: December 2011 - May 2013.
Funding sources: not reported
Declarations of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
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Dhananjaya 2014 (Continued)
Random sequence generation (selection
bias)
High risk Study was quasi-randomised: quote: “se-
lection of cases were done by systematic
random sampling method, assigned to in-
tramuscular oxytocin… or intramuscular
methylergometrine… alternatively during
third stage”
Allocation concealment (selection bias) Unclear risk Insufficient information to assess. Method
of concealment is not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not blinded.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient information to assess.
Selective reporting (reporting bias) Unclear risk Insufficient information to assess.
Other bias Unclear risk Unclear.
Ezeama 2014
Methods Randomised double-blind controlled trial.
Participants were randomised using computer-generated randomisation numbers
Participants Women admitted to the labour and delivery ward at the Nnamdi Azikiwe University
Teaching Hospital in Nnewi, Nigeria between September 2011 and May 2012
Women in labour, without an epidural and anticipating a vaginal delivery were included.
Women with the following were excluded: anticipating a caesarean delivery, delivery <
28 weeks, multiple gestation, antepartum haemorrhage, hypertensive disorders, severe
anaemia, haemoglobinopathy
Interventions Immediately after delivery women received:
A. oxytocin 10 IU IM (n = 151) or
B. ergometrine 0.5 mg IM (n = 149)
All received AMTSL including cord traction and uterine massage. Following drug ad-
ministration, a fresh pad was placed and volume blood loss assessed after 1 hour by
weighing of pads and gauze
Outcomes Primary outcomes: blood loss > 500 mL, occurrence of adverse effects (headache, vom-
iting, increased diastolic pressure) within 30 minutes of the intervention
Secondary: use of additional uterotonics, blood transfusion, evacuation of retained prod-
ucts, manual removal of the placenta, PPH, pre- and post-delivery Hct
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Ezeama 2014 (Continued)
Notes Dates of study: September 2011 - May 2012
Funding sources: not reported
Declarations of interest: none
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation
was performed using “computer generated
randomisation numbers. Quote:” Eligible
patients were allocated the “next consecu-
tive randomisation number.”
Allocation concealment (selection bias) Low risk Randomisation was per-
formed using quote: “computer generated
randomisation numbers.” Eligible patients
were allocated the “next consecutive ran-
domisation number.” Drug ampoules were
“placed in opaque sealed envelopes.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blinded. Quote: “Person unin-
volved with the study prepared the study
drugs: 1-mLampoules containing either 10
IU oxytocin or 0.5 mg ergometrine. The
labels on the ampoules (which were sim-
ilar in size and color) were removed and
the ampoules were placed in opaque sealed
envelopes. The study drugs were adminis-
tered ... by a midwife who was not part of
the study.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blinded. See above.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data.
Selective reporting (reporting bias) Unclear risk Insufficient information to assess.
Other bias Unclear risk Unclear.
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Francis 1965
Methods Quasi-randomised controlled trial.
’Ampoules used in rotation and participants were unselected’.
Blinded.
Participants 2 maternity hospitals in Liverpool, UK. in 1961.
All women expected to deliver except those in whom an abnormal third stage was
anticipated (previous PPH, instrumental or breech deliveries, twin pregnancies, APH,
severe anaemia, IV oxytocin for induction or augmentation)
Interventions (1) 1 mL IM ergometrine-oxytocin (5 IU oxytocin + 0.5 mg per 1 mL ergometrine) after
delivery of baby and cord divided, AND 1 mL water after placental delivery (n = 171).
(2) 0.5 mg IM ergometrine after delivery of baby and cord divided, AND 1 mL water
after placental delivery (n = 183).
(3) 1mL IMwater after delivery of baby and cord divided, AND0.5 mg IM ergometrine
after placental delivery (n = 167).
The collection of blood commenced with birth of the baby and continued for 1 hour
after delivery. Swabs were rung out manually. Blood loss was measured in a graduated
jug
When signs of descent became apparent, the placenta delivered with uterine massage
and cord traction--active management.
Comparison in review is between groups 1 and 2.
Outcomes Blood loss (average 4.9, 6.4, 7.0 in groups 1, 2 and 3, respectively - no SD given); for
the review, loss of > 20 oz has been taken as PPH; retained placenta (> 20 minutes)
Notes Dates of study: during 1962
Funding sources: not reported
Declarations of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Treatments were rotated, no random se-
quence generated.
Allocation concealment (selection bias) High risk Although intervention administered using
identical vials, the rotation method used
means that allocation could possibly be
foreseen
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Vials were blinded to personnel and partic-
ipants.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The authors describe how observers were
not blinded in their initial trial and say that
this flaw was corrected in the second trial
(from which the review draws its data)
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Francis 1965 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The number of women originally recruited
and ‘randomised’ is not stated so it is not
possible to know attrition rate
Selective reporting (reporting bias) Unclear risk Difficult to assess. Report appears to re-
port outcomes as expected, however proto-
col unseen
Other bias Unclear risk Unclear.
Fugo 1958
Methods Randomised controlled trial.
Numbered identical drug packages administered in rotation. Number meaningless to
obstetrician.
Blinded.
Participants Women delivering in a hospital in Chicago, USA.
No details given of inclusion/exclusion criteria, but description of study participants
showed that half had labour over 8 hours, and 98% received some anaesthetic agent
Interventions All administered intravenously in 2 mL with anterior shoulder.
(1) 2 IU oxytocin (natural oxytocin) n = 168.
(2) 2 IU syntocinon (synthetic oxytocin) n = 156.
(3) 4 mg ergonovine 149.
(4) 80 mg U3772 (alpha, alpha diphenyl gamma dimethylamino N-methyl valeramide-
HCl) n = 151.
Blood lost when the placenta separated was collected in a basin containing 200 mL of
4% sodium oxalate solution as an anticoagulant and was measured in a graduated jug
Expectantmanagement of the third stage withMRP at 10minutes for teaching purposes.
Comparison for review is groups 1 and 2 combined vs group 3.
Outcomes Method of placental delivery (high% of manual removals for teaching purposes if haem-
orrhage or undelivered within 10 minutes); length of third stage (not significantly dif-
ferent between groups but data only given for those delivered spontaneously, i.e. within
10 minutes); blood loss with placenta; (1-hour postpartum average blood loss 50.2 vs
40.8 mL; no SDs given)
Notes Given the high number of manual placental removals for teaching purposes, the data
from this trial were not used due to concern for methodologic bias and lack of clinical
translatability of this trial as MRP this early in the third stage is not standard of care
Dates of study: during 1958
Funding sources: not reported
Declarations of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
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Fugo 1958 (Continued)
Random sequence generation (selection
bias)
Unclear risk Randomisation method not described.
Allocation concealment (selection bias) Unclear risk Not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical packages were used, identifiable
only by number, which was meaningless to
the obstetrician in charge of the case
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Identical packages were used, identifiable
only by number, which was meaningless to
the obstetrician in charge of the case
Incomplete outcome data (attrition bias)
All outcomes
Low risk No significant attrition.
Selective reporting (reporting bias) Low risk All outcomes reported.
Other bias Unclear risk Unclear.
Ilancheran 1990
Methods Randomised controlled trial.
’Consecutive participants divided equally into 4 subgroups, distribution being done on
a random basis’
Participants Women in spontaneous labour between 38 and 42 weeks’ gestation with normal vertex
deliveries in hospital in Singapore
Interventions Control group and 3 groups given IV uterotonic in ’standard’ doses with the delivery of
the anterior shoulder
A. No oxytocin in third stage (n = 5)
B. Oxytocin (n = 5)
C. Ergometrine-oxytocin (n = 5)
D. Ergometrine (n = 5)
Blood loss estimation technique not described.
Other methods to manage third stage of labour not described.
Comparisons for this review are: B vs A; B vs D; C vs D.
Outcomes Prostaglandin levels 5, 15 and 30 minutes after delivery, and PPH
Notes Dates of study: not reported
Funding sources: not reported
Declarations of interest: not reported
Risk of bias
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Ilancheran 1990 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomisation not described
Allocation concealment (selection bias) Unclear risk Not described.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No mention of blinding or who prepared
the “standard doses” of each drug. Assumed
care-givers knew allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not mentioned in report
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk It is unclear from the report whether any
attrition.
Selective reporting (reporting bias) Unclear risk Appears to report all outcomes pre-speci-
fied in methods, however protocol unseen
Other bias Unclear risk Unclear.
Jago 2007
Methods Randomised controlled trial.
Randomisation was performed using a computer-generated table of random numbers,
which were labelled on envelopes containing the drug (ergometrine or oxytocin)
Participants 510 consenting normotensive women with singleton pregnancies and no proteinuria at
a hospital in Nigeria
Excluded those with history of hypertensive disorders of pregnancy, hypertension,
chronic renal disease, endocrine disorders, vascular or cardiac disease, on anticoagulant
therapy, having epidural anaesthesia, with allergy to 1 of the drugs under study, and
those with intended instrumental/operative delivery
Interventions At delivery of the anterior shoulder:
A. oxytocin 10 IU IV (n = 256).
B. ergometrine 0.5 mg IM (n = 254).
Management of the third stage of labour not otherwise described
Technique for measurement of blood loss not described.
Outcomes Elevated blood pressure (> 140/90 mmHg). Estimated blood loss (mL)
Notes Dates of study: January 2001 - December 2002
Funding sources: not reported
Declarations of interest: not reported
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Jago 2007 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated table of random
numbers.
Allocation concealment (selection bias) Unclear risk Quote: “The numbers were clearly labelled
on envelopes containing a particular oxyto-
cic”, however it is unclear whether the en-
velopes were sealed and opaque
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding is not described, but it is unlikely
that personnel were blinded as different
quantities of each drug were administered
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding not described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Report does not include enough informa-
tion to assess whether there was attrition
Selective reporting (reporting bias) Unclear risk Protocol unseen.
Other bias Unclear risk No data.
Jerbi 2007
Methods Randomised controlled trial.
Not stated. Authors state: “...women were randomly allocated to...”
Participants 130 women with singleton pregnancies at term who were expected to deliver vaginally
in a hospital in Tunisia
Excluded: placenta previa, APH, non-cephalic presentation, history of PPH, intrauterine
death, parity > 5, caesarean section, uterine fibroids, anticoagulant therapy
Interventions At the time of delivery of the anterior shoulder:
A. oxytocin 5 IU IV (n = 65);
B. no oxytocin (n = 65).
Authors say that the comparison arms are active vs expectant management--active is
defined as receiving prophylactic oxytocin. The third stage of labour was managed in the
same way for all women: immediate cord clamping and cutting, controlled cord traction
and gentle fundal pressure
Outcomes Decrease in Hct, decrease in Hb concentration, duration of the third stage of labour
(min), MRP, maternal Hb concentration, postpartum anaemia
Total blood loss was not an outcome.
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Jerbi 2007 (Continued)
Notes Dates of study: February to March 2005.
Funding sources: not reported
Declarations of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomisation not described.
Authors only state: “...women were ran-
domly allocated to...”
Allocation concealment (selection bias) Unclear risk Not stated. Authors only state: “...women
were randomly allocated to...”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Intervention involves injection, the control
did not. There is no suggestion that the
control arm received a placebo injection
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not mentioned in report.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No loss to follow-up reported for the out-
comes included in the review
Selective reporting (reporting bias) Unclear risk Protocol unseen but outcomes pre-speci-
fied in methods section are reported
Other bias Unclear risk No data.
McGinty 1956
Methods Randomised trial.
’Cases picked at random’.
Unblinded.
Participants All vaginally delivered under pudendal block and demerol/scopolamine, in hospital in
the USA
Interventions Drug given at birth of anterior shoulder:
A. 1 mL normal saline intravenously (n = 50);
B. 0.2 mg methergine intravenously (n = 50);
C. 0.2 mg ergonovine intravenously (n = 50);
D. oxytocin 5 IU each intravenously and intramuscularly (n = 50).
Comparisons for this review:
D vs B and C. Data not provided for control group so this group was not included in
this review
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McGinty 1956 (Continued)
No information about other aspects of third stage management
Outcomes Diastolic and systolic blood pressure 5, 15 and 60minutes after administration; estimated
severe blood loss over 1000 mL mentioned for 1 women in methergine series and 1
in control group (not included in data tables as unlikely to have been systematically
recorded)
Notes Dates of study: not reported
Funding sources: quote: “All Methergine used in this study was supplied through the
courtesy of Sandoz Pharmaceuticals, New York, New York.”
Declarations of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Cases picked at random”. Ran-
domisation technique not described
Allocation concealment (selection bias) Unclear risk Allocation concealment not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not explicitly described, although some
instances where blinding of personnel
breached mentioned which suggests inade-
quate blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk 200 patients recruited, and data for all 200
individuals reported
Selective reporting (reporting bias) Unclear risk Protocol unseen.
Other bias Unclear risk Unclear.
Modi 2014
Methods Randomised controlled trial.
Patients were randomised into 4 groups.
Participants Women presenting to the Shri RamMurti Smarak Institute ofMedical Sciences, Bareilly,
Uttar Pradesh from 2012 to 2013
Women who were gravida < 4 with a singleton pregnancy between 37 and 42 weeks’
gestation, cephalic, with no high risk factors presenting for induction or in spontaneous
labour, were included. Women with the following were excluded: gestation < 37 weeks
or > 42 weeks, fetal demise, fetal growth restriction, hypertension, abruption, placenta
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Modi 2014 (Continued)
previa, multiple pregnancy, grand multipara, malpresentation, chorioamnionitis, known
blood coagulation disorder, known allergy to prostaglandins, history of medical disorders
including cardiac or renal disease, anaemia with Hb < 8, pulse rate > 100 bpm, blood
pressure < 90/60 mm Hg
Interventions Immediately after delivery women received:
A. oxytocin 10 IU IM (n = 25) or
B. methylergometrine 0.2 mg IV (n = 25)
All received controlled cord traction to facilitate placental delivery. Following delivery,
calibrated drapes were placed beneath the patient to measure blood loss
There were 2 additional intervention arms in this trial that were not relevant to this
review. 1 group received 15-methyl PGF2-alpha 125 mcg IM, and the other received
misoprostol 600 mcg PR
Outcomes Outcomes: duration of the third stage of labour, measured blood loss in the third stage,
decrease in mean Hb levels, post delivery heart rate and blood pressure, side effects of
various uterotonics including nausea, vomiting, shivering, fever, hypertension, tachycar-
dia.
Other outcomes that were not pre-specified: # of patients with blood loss > 500 mL, #
of patients requiring blood transfusion, use of additional uterotonics
Notes Dates of study: 2012 - 2013.
Funding sources: none
Declarations of interest: none
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomisation is unclear. Au-
thors state “patients were randomised into
four groups of 25 each” and “patients were
distributed in four different groups ran-
domly.”
Allocation concealment (selection bias) Unclear risk Method of randomisation is unclear. Au-
thors state “patients were randomised into
four groups of 25 each” and “patients were
distributed in four different groups ran-
domly.”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not blinded.
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Modi 2014 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk Authors do not explicitly state how many
patients were ultimately included in the
analysis. They donotmentionpatient attri-
tion, however they state that women with
perineal and cervical lacerations were ex-
cluded from the study. According to their
demographics table, the majority of pa-
tients received an episiotomy, which would
have resulted in exclusion of significant
numbers of patients after randomisation
Selective reporting (reporting bias) High risk Some adverse outcomes of interest are re-
ported incompletely. The authors report
“side effects of various uterotonics” as
outcomes, however data regarding vomit-
ing, nausea, shivering, fever, headache and
hypertension are incompletely reported
for the oxytocin and methylergometrine
groups
Other bias Unclear risk Unclear.
Moodie 1976
Methods Randomised trial.
Not stated, authors state “...the allocation being at random...”.
Participants 148 women with instrumental deliveries (143 forceps, 5 vacuum) under epidural anaes-
thesia in a hospital in New Zealand
Excluded multiple births and breech presentation.
Interventions At delivery of the anterior shoulder:
A. oxytocin 5 IU IV (n = 70);
B. ergometrine 0.5 mg IV (n = 78).
No mention of other aspects of the management of the third stage of labour
Outcomes Blood loss (mL).
Emetic sequelae (retching or vomiting and nausea).
Notes Blood loss was measured in only 54% of women (80/148), so this outcome was not
included in this review
Dates of study: not reported
Funding sources: not reported
Declarations of interest: not reported
Risk of bias
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Moodie 1976 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of random sequence generation
not described.
Allocation concealment (selection bias) Unclear risk Authors only state: “...the allocation being
at random...”.
Allocation described as random but se-
quence generation, and therefore pre-
dictability, unclear
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not mentioned in report
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not mentioned in report
Incomplete outcome data (attrition bias)
All outcomes
Low risk No (for nausea and vomiting). 46% of
women excluded from outcome “blood
loss”, thus this outcome was not included
in the review
Selective reporting (reporting bias) Unclear risk Protocol unseen.
Other bias Unclear risk No data.
Nordstrom 1997
Methods Double-blind randomised trial.
2 sets of ampoules prepared and numbered according to computer-generated schedule.
Contents unknown to women or caregivers
Participants Hospital in Sweden.
Singleton cephalic vaginal deliveries.
Interventions 1 mL IV after delivery of baby of either:
1) 10 IU oxytocin (n = 513)
2) saline (n = 487)
Passive (expectant) management of the placenta.
Blood loss was calculated by measuring collected blood and adding what was estimated
to have been absorbed by surgical cloths and tissues
Outcomes Blood loss; additional uterotonics (methylergometrine), Hb, blood transfusion; manual
placental removal
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Nordstrom 1997 (Continued)
Notes Dates of study: 16 December 1993 to 6 October 1994
Funding sources: Quote: “This study was supported by grants from the County Council
and County Health Authority Research and Development Foundation in the County of
Jämtland, Sweden.”
Declarations of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk 2 sets of ampoules prepared and numbered
according to computer-generated schedule
Allocation concealment (selection bias) Low risk No difference in appearance of ampoules,
prepared by pharmacy
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Intervention unknown towomen and care-
givers.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Intervention unknown to outcome asses-
sors.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No significant attrition.
Selective reporting (reporting bias) Unclear risk All outcomes reported but protocol unseen
Other bias Unclear risk Unclear.
Orji 2008
Methods Randomised controlled trial.
Eligible participants who gave informed consent were randomly allocated to either oxy-
tocin or ergometrine group. Allocation was done by opening a sealed envelope from a
pack that had been arranged serially. Not blinded
Participants 600 consenting women in labour with no illnesses or added risk in the active phase at 2
tertiary hospitals in Nigeria
Excluded those with hypertensive disorders of pregnancy, packed cell volume < 30%,
history of PPH, haemoglobinopathy, heart disease or caesarean section
Interventions At delivery of the anterior shoulder:
A. oxytocin 10 IU IV (n = 297);
B. ergometrine 0.25 mg IV (n = 303).
In both groups the third stage of labour was managed actively
Blood loss was measured using a pre-weighed guaze that was weighed again after delivery
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Orji 2008 (Continued)
Outcomes Primary outcomes: PPH (> 500 mL), severe PPH (> 1000 mL).
Secondary outcomes: retained placenta, need for blood transfusion, manual placental
removal, estimated blood loss (mL), nausea, vomiting, headaches, elevated blood pres-
sure, need for additional uterotonics
Notes Dates of study: January 2006 to September 2007
Funding sources: not reported
Declarations of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly assigned to previously deter-
mined sequence.
Allocation concealment (selection bias) Low risk Quote: “...sealed envelopes arranged seri-
ally...”.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not mentioned in report assumed not due
to different doses of drug being given
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not mentioned in report
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data appear to be reported for all partici-
pants. No loss to follow-up reported
Selective reporting (reporting bias) Unclear risk Protocol unseen but all outcomes pre-spec-
ified in methods text are reported
Other bias Unclear risk No data.
Pierre 1992
Methods Quasi-randomised trial.
Leaflets marked from 1-1000 alternate allocation quote: “this made possible a control of
selection bias at entry by the authors as the order in the trial had the same chronology
as the date and time of entry in the labour ward”
Participants Women expecting to deliver vaginally in hospital in France. Excluded breech presenta-
tions, twins, antepartum haemorrhage, refusal to participate in study
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Pierre 1992 (Continued)
Interventions Active management of third stage with (n = 488) and without 5 IU IV oxytocin (n =
488) with the anterior shoulder
Blood loss was estimated by placing a large plastic sheet under the patient’s bottom from
delivery of the infant until delivery of the placenta
Third stage managed actively.
Outcomes Blood loss, length of third stage, manual placental removal, maternal side effects
Notes Dates of study: March to October 1987
Funding sources: not reported
Declarations of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quasi-randomised. Numbered
leaflets given to all women via their files.Of
those who then consented to participation,
allocation based on odd/even numbers
Allocation concealment (selection bias) High risk Authors claim that clinicians could have no
control over order in which patients pre-
sented and thus allocation, however this
method is not incorruptible
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Intervention not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Notmentioned in report, although attempt
made to accurately and objectively measure
blood loss by collecting using a plastic sheet
Incomplete outcome data (attrition bias)
All outcomes
Low risk Loss to follow-up and failure to properly
administer interventions similar in both
arms. Attrition properly handled and ac-
counted for in report
Selective reporting (reporting bias) Unclear risk Protocol unseen.
Other bias Unclear risk Unclear.
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Poeschmann 1991
Methods Randomised trial.
Hospital pharmacy supplied numbered boxes. Allocation of boxes was by order of entry
to the labour ward. A nurse not working in the labour room prepared the injection
Participants April 1986 -88, 2 hospitals in the Netherlands.
Uncomplicated singleton term pregnancies in spontaneous labour with spontaneous
vaginal deliveries and Hobel score of less than 10
Interventions After birth of baby:
A. IM 5 IU oxytocin (n = 28);
B. 500 micrograms sulprostone;
C. saline (n = 24)
Comparison in this review is A vs C.
Cord was clamped within 1 minute of birth; otherwise expectant management of the
third stage was performed
Blood loss was calculated by measuring the amount of blood and clots collected in
the bedpan and by weighing the bloodstained swabs and linen obtained during 1 hour
postpartum
Outcomes Blood loss, need for additional uterotonics, length of third stage
Notes 77 women were entered into the trial; 3 were excluded because of induction of labour
(2) and vacuum extraction (1)
Dates of study: April 1986 to April 1988
Funding sources: quote: “Sulprostone was supplied by Schering bv. The Netherlands
without charge.”
Declarations of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk A random treatment allocation list was pre-
pared, however method of sequence gener-
ation not described. Randomised in blocks
of 30
Allocation concealment (selection bias) Low risk Allocation was by order of entry to ward,
but based on random list. The syringeswere
prepared elsewhere so the caregivers would
not have been able to pre-empt what treat-
ment was allocated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Nurse not working in labour room pre-
pared the injection. Injection type blinded
to participants and personnel
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Poeschmann 1991 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not mentioned in report.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All outcomes reported. Data for all partic-
ipants reported.
Selective reporting (reporting bias) Unclear risk Protocol unseen. Only blood loss pre-spec-
ified in methods text
Other bias Unclear risk No other obvious signs of bias but trial
stopped at 2 years due to organisational is-
sues
Saito 2007
Methods Quasi randomised: quote: “...women were allocated to a group in a temporal manner (.
..) selected weekly or monthly, as determined by each hospital, in alternate shifts”
Participants 343 consenting women with low risk of PPH at 4 hospitals in Japan
Excluded: contraindication for ergometrine, multiple pregnancies, non-cephalic presen-
tation, uterine fibroids or deformity, placenta previa, history of PPH, parity > 4, previous
caesarean section, severe anaemia, pre-eclampsia, epidural anaesthesia, use of oxytocics,
anticoagulation therapy, estimated baby weight < 2000 g or > 4000 g
Interventions Shortly after delivery of the baby:
A. oxytocin 5 IU IM (n = 156);
B. methylergometrine 0.2 mg IM (n = 187).
AMTSL in both groups. immediate cord clamping and cutting, controlled cord traction
Blood loss was calculated objectively by measuring the amount of collected blood and by
the weighting of surgical sponges, clothes and drapes by experienced attending midwives
who were not involved in the administration of prophylactic oxytocics
Outcomes Blood loss (mL), maternal blood pressure, nausea, vomiting, headache, chest pain, dys-
pnoea, duration of the third stage (minutes), additional uterotonics, blood transfusion,
manual placental removal
Notes Dates of study: September 2000 - April 2002
Funding sources: not reported
Declarations of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quasi random: quote: “...womenwere allo-
cated to a group in a temporal manner (...)
selected weekly or monthly, as determined
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Saito 2007 (Continued)
by each hospital, in alternate shifts.”
Allocation concealment (selection bias) High risk Inadequate. quote: “...women were allo-
cated to a group in a temporal manner (...)
selected weekly or monthly, as determined
by each hospital, in alternate shifts.”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not blinded, but quote: “Blood loss was
calculated objectively by measuring the
amount of collected blood and by the
weighing of surgical sponges, clothes and
drapes by experienced attending midwives
who were not involved in the administra-
tion of prophylactic oxytocics.”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk It is not possible to know from the study
report how many women were originally
randomised
Selective reporting (reporting bias) Unclear risk Protocol unseen. No outcomes were pre-
specified in methods with the exception of
estimated blood loss
Other bias Unclear risk Unclear.
Singh 2009
Methods Double-blind randomised controlled trial.
Computer-generated randomisation and concealment of treatment group allocations
were utilized
Participants Women presenting for delivery at the University College of Medical Sciences, Guru Teg
Bahadur Hospital
Women with a healthy singleton pregnancy in spontaneous or induced labour at term
were included.Womenwith the followingwere excluded: knownhypersensitivity or con-
traindication to prostaglandins, fetal demise, antepartum haemorrhage, multiple preg-
nancy, malpresentation, cardiac disease, Rhesus-negative mother, hypertensive disorders,
and severe anaemia (Hb < 7 g/dL), and those requiring oxytocin until the second stage
of labour
Interventions Immediately after delivery women received:
A. oxytocin 5 IU IV (n = 75) or
B. methylergometrine 0.2 mg IV (n = 75)
All received the allocated drug as well as placebo for the other possible treatment drugs.
All received placental cord traction until placental delivery. After infant delivery, a pre-
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Singh 2009 (Continued)
weighed linen and collection bag were placed beneath the patient and blood loss assessed
by weight after 1 hour. Hb and Hct were recorded upon admission and 24 hours after
delivery
Therewere 2 additional intervention arms in this trial thatwere not relevant to this review.
1 group received misoprostol 400 mcg sublingual, and the other received misoprostol
600 mcg sublingual
Outcomes Primary: blood loss during 3rd and 4th stage of labour
Secondary: duration of 3rd stage, need for additional uterotonics, need for blood trans-
fusion, adverse effects of drugs
Notes Dates of study: unclear
Funding sources: not reported
Declarations of interest: none
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised using quote: “computer-gen-
erated random numbers.”
Allocation concealment (selection bias) Low risk Quote: “Drug packets were sealed and
coded using a computer-generated random
number chart.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blinding of patients and person-
nel. Authors report “a duty nurse who was
not involved in the study opened the al-
lotted packet in a separate room.” The pa-
tients and investigator were blinded to the
packet contents. All patients received the
study drug as well as placebo for the other
interventions
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blinding of patients and person-
nel. Authors report “a duty nurse who was
not involved in the study opened the al-
lotted packet in a separate room.” The pa-
tients and investigator were blinded to the
packet contents. All patients received the
study drug as well as placebo for the other
interventions
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data.
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Singh 2009 (Continued)
Selective reporting (reporting bias) High risk Some adverse outcomes of interest are re-
ported incompletely. Authors report “ad-
verse effects of the drugs” as secondary
outcomes, and in methods describe col-
lection of data regarding postpartum Hb
level,” however the data are not fully pre-
sented. They also report that “themethyler-
gometrine group had the highest incidence
of nausea and vomiting” but do not report
the data completely
Other bias Unclear risk Unclear.
Sorbe 1978
Methods Quasi-randomised trial.
Alternate - odd and even numbers of mothers’ hospital records.
Not blinded.
Participants Hospital in Sweden.
Interventions Immediately after delivery of the anterior shoulder women received:
A. 10 IU IV oxytocin
B. 0.2 mg ergometrine IV
Expectant management of the third stage was routine.
Blood was collected in a specially designed bedpan which was placed under the buttocks
of the women immediately after the delivery of the child. The measurement of the blood
loss during the 2-hour period was then performed with a graduated glass
Outcomes Blood loss, manual placental removal, placental separation time
Notes Dates of study: during 1975 to 1976
Funding sources: not reported
Declarations of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Randomisation by odd/even hospital
record numbers.
Allocation concealment (selection bias) High risk Allocation would have been open with this
method. Assume allocation not concealed
given method of randomisation
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Sorbe 1978 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Does not appear to be blinded. Staff would
be aware of treatment. Blinding seems un-
likely from description of methods
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Assumed staff recorded outcomes. Blinding
not mentioned in report
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Denominators not always reported in all ta-
bles. Not possible to tell from study report
whether all participants reported on
Selective reporting (reporting bias) Unclear risk Protocol unseen.
Other bias Unclear risk Unclear.
Vaughan Williams 1974
Methods Randomised controlled trial.
Quote: “Patientswere randomly assigned to one of six treatment groups.”No information
about blinding or allocation concealment described
Participants 51 women in labour at the Royal Sussex County Hospital, Brighton, who required an
IV infusion. Inclusion criteria was no known antenatal complications and expectation
to have a spontaneous vaginal delivery. Patients with complications during labour were
excluded. Informed consent was obtained
Interventions Women were randomly assigned to 1 of 6 treatment groups:
1) no treatment, control;
2) 0.5 mg ergometrine IV with delivery of the anterior shoulder;
3) 0.5 mg ergometrine IV with delivery of the baby;
4) 10 IU oxytocin IV with delivery of the anterior shoulder;
5) ergometrine 0.5 mg plus 5 IU oxytocin IM with delivery of the anterior shoulder;
6) 10 mg diazepam IM in the late first stage of labour followed by ergometrine 0.5 mg
plus 5 IU oxytocin IM with delivery of the anterior shoulder
Placenta was delivered actively by controlled cord traction.
Blood loss was measured by collection in a kidney dish placed below the perineum after
delivery of the infant
Comparisons for this review are group 1 vs 4, groups 2 and 3 vs group 4, and groups 5
and 6 vs group 2 and 3
Outcomes Primary outcomes were mean CVP and blood loss.
Notes Dates of study: not reported
Funding sources: not reported
Declarations of interest: not reported
Risk of bias
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Vaughan Williams 1974 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomly assigned
to one of six treatment groups.” No infor-
mation about blinding or allocation con-
cealment described
Allocation concealment (selection bias) Unclear risk Allocation concealment not described.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding not mentioned, but assume no
blinding given description of treatment
when administering drugs.for each arm (no
mention of saline placebo for control)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assumed outcomes were measured by staff
as not specified. Method of measuring
blood loss not specified - could be subjec-
tive
Not mentioned in report.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Denominators not provided in results ta-
bles therefore difficult to assess. Not possi-
ble to tell if there was attrition from report
Selective reporting (reporting bias) Unclear risk Protocol not seen. Few outcomes reported.
CVP only outcome prespecified in text
Other bias Unclear risk Unclear.
APH: antepartum haemorrhage
AMTSL: active management of the third stage of labour
bpm: beats per minute
CVP: central venous pressure
Hb: haemoglobin
Hct: haematocrit
IM: intramuscular
IU: international units
IV: intravenous
MRP: manual removal of placenta
PPH: postpartum haemorrhage
PROM: prelabour rupture of membranes
SD: standard deviation
vs: versus
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Barbaro 1961 No randomisation of treatment groups.
Boucher 2004 Comparison of intramuscular carbetocin to a 2-hour IV oxytocin infusion administered after delivery of the
placenta
Dickinson 2009 Comparison of oxytocin, misoprostol and no additional medication for the third-stagemanagement after second
trimester medical termination
Docherty 1981 Oxytocin vs ergometrine-oxytocin (subject of separate review)
Dommisse 1980 No randomisation of treatment groups.
Dumoulin 1981 Oxytocin (different doses) vs ergometrine-oxytocin (subject of separate review)
Friedman 1957 Likely to be considerable bias after entry to study as 27% of the 1221 were ’deleted from the study’ as inadequate
observations were obtained. No other reasons given, and no indication of whether these women were missing
in similar proportions from the 5 intervention groups
Gerstenfeld 2001 Comparison of oxytocin with misoprostol (subject of separate review)
Hacker 1979 No randomisation of treatment groups.
Hoffman 2006b Comparison of oxytocin within the context of active vs expectant management (subject of a separate review)
Howard 1964 Oxytocin, methergine or placebo given after delivery of the placenta
Huh 2000 Excluded as only different timing of administration.
Irons 1994 Comparison of nipple stimulation to ergometrine-oxytocin which is not a subject of this review
Jackson 2001 Comparison of oxytocin administered before and after placental delivery so the only difference is timing of
administration
Jans 2017 Comparison of oxytocin to expectant management without placebo
Khan 1997 Comparison of prophylactic oxytocin within context of active management vs oxytocin after placental delivery
within context of expectant management (subject of separate review by Begley et al: Active versus expectant
management of third stage of labour - see Begley 2019).
Kundodyiwa 2001 Comparison of oxytocin with misoprostol (subject of separate review)
Lokugamage 2001 Comparison of oxytocin to misoprostol (subject of separate review) and at caesarean section
Muller 1996 5 IU IV oxytocin with crowning of head and Brandt-Andrews vs expectant. Abstract only, in French and
German. No clinical data available from authors
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(Continued)
Neri-Mejia 2016 Comparison of various oxytocin routes of delivery without a placebo group
Newton 1961 Oxytocin or placebo given after delivery of the placenta.
Nieminen 1963 No randomisation of treatment groups.
Nuamsiri 2016 Comparison of oxytocin plus ergometrine to oxytocin alone.
Oguz Orhan 2014 Comparison of different routes and timing of oxytocin administration
Parsons 2004 Comparison of oxytocin with misoprostol (subject of separate review)
Porter 1991 Comparison of different routes of administration of oxytocin
Quibel 2016 Comparison of oxytocin and misoprostol to oxytocin.
Ramirez 2001 Inadequate information available about randomisation and available only as abstract
Rouse 2011 Comparison between different doses of oxytocin without placebo or alternate uterotonic
Sariganont 1999 No randomisation of treatment groups.
Schaefer 2004 Excluded as only difference is timing of administration.
Schemmer 2001 Comparison of oxytocin administered before and after placental delivery so the only difference is timing of
administration
Sharma 2014 Treatment groups were not randomised.
Soiva 1964 Trial includes a large group of women who were not randomised (data were collected retrospectively) and whose
outcome data are inseparable from those that were randomised
Soriano 1995 Compares oxytocin with oxytocin plus ergometrine (subject of separate review)
Stanton 2010 Study withdrawn due to lack of IRB approval.
Stanton 2012 Manuscript published is of study protocol only, data planned to be analysed in 2013
Stanton 2013 Comparison groups outside scope of this review.
Stearn 1963 Allocation was to 2 different consultants, 1 of whom gave all patients ergometrine-oxytocin, and the other to
give ’normal’ cases ergometrine with hyalase and abnormal given IV ergometrine
Suhrabi 2013 Comparison groups outside scope of this review.
Sunil 2016 Comparison of oxytocin to carboprost.
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(Continued)
Symes 1984 Compares oxytocin with oxytocin plus ergometrine (subject of separate review)
Tessier 2000 Excluded as only different routes of administration.
Thornton 1988 Strong likelihood of post-entry bias as alternate allocation used for 65, but 40 were withdrawn 40 as did not
meet inclusion criteria, leaving 10 and 15 in trial comparing oxytocin vs no oxytocin within active management.
Primary outcome plasma oxytocin concentration
Tita 2012 Comparison between different doses of oxytocin without placebo or alternate uterotonic
Vasegh 2005 Comparison of active vs expectant management of the third stage of labour (subject of a separate review). Study
design information not available
Yuen 1995 Oxytocin vs ergometrine-oxytocin (subject of separate review)
IRB: Institutional Review Board
IU: international unit
IV: intravenous
vs: versus
Characteristics of studies awaiting assessment [ordered by study ID]
Draycott 2014
Methods Randomised controlled trial
Participants Female patients age 18 and over undergoing vaginal delivery at > 24 weeks’ gestation
Interventions Carbetocin 100 mcg IM versus Syntocinon 10 IU IM versus Syntometrine 500 mcg/5 IU IM given in the third stage
of labour
Outcomes Primary: requirement of additional uterotonics within 24 hours of delivery
Secondary: estimated blood loss at delivery, transfusion, manual placental removal, need for surgical intervention
to manage PPH, maternal hypertension or hypotension, self-reported quality of life, pain, vomiting, need for anti-
emetic, headache, maternal experience of side effects
Notes Study completed October 2018
68Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Narenji 2012
Methods Randomised trial
Participants Female patients age 18-35 undergoing vaginal delivery between 37-42 weeks’ gestation
Interventions Breast pump stimulation versus oxytocin 30 IU in 1000 mL Ringer’s solution infusion administered during the third
stage of labour
Outcomes Duration of the third stage of labour, blood loss during the third stage and 24 hours after delivery, Hb and Hct
(before and 24 hours after delivery), breastfeeding, pain
Notes Published December 2018 after completion of analysis for this updated review
Shahbazian 2013
Methods Randomised trial
Participants Pregnant patients with singleton gestations undergoing vaginal delivery
Interventions Misoprostol 400 mcg sublingual versus methylergonovine 0.2 mg IM versus oxytocin 20 IU IV infusion given during
the third stage of labour
Outcomes Duration of the third stage of labour, Hb fall 24 hours postpartum, amount of haemorrhage during the third and
fourth stage of labour, side effects
Notes Persian language paper pending translation. Abstract available in English but not enough information provided for
data extraction
Suthutvoravut 2012
Methods Randomised trial
Participants Females age 18-34 undergoing vaginal delivery at 37-41 weeks’ gestation
Interventions Oxytocin 20 IU infusion versus ergometrine 0.2 mg IV given in the third stage of labour
Outcomes Postpartum blood loss, duration of the third stage, maternal hypertension, maternal heart rate, postpartum haemor-
rhage, atony, need for additional uterotonic drugs
Notes Trial data became available after completion of analysis for this updated review
Hb: haemoglobin
Hct: haematocrit
IM: intramuscular
IU: international units
IV: intravenous
PPH: postpartum haemorrhage
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Characteristics of ongoing studies [ordered by study ID]
Hermesch 2014
Trial name or title Postpartum hemorrhage prevention in patients with preeclampsia (PHP3 study)
Methods Blinded, placebo-controlled randomised controlled trial
Participants Female patients age 13-45 undergoing vaginal or cesarean delivery at greater than or equal to 20 weeks’
gestation with a diagnosis of preeclampsia receiving magnesium sulphate for 24 hours postpartum
Interventions Normal saline placebo versus oxytocin
Outcomes Primary outcome is postpartumHct collected 24hours after delivery (or pre-transfusion). Secondary outcomes
include primary PPH (> 500 mL), estimated blood loss at time of delivery, and 2- hour postpartum blood
loss
Starting date February 2015
Contact information Amy Hermesch, MD, amy.hermesch@ucdenver.edu
Notes
Yogev 2014
Trial name or title Management of the third stage of labor
Methods Randomised trial
Participants Female patients 18-45 at 34-41 weeks’ gestation
Interventions 10 IU IV oxytocin versus 10 IU IM oxytocin versus 10 IU IM oxytocin plus 10 IU IV oxytocin in the third
stage of labour
Outcomes Primary outcome is change in Hb concentration during labour.
Secondary outcome is CBC on the first and second day after delivery
Starting date September 2015
Contact information Yariv Yogev, yarivy@clalit.org.il
Notes
CBC: complete blood count
Hb: haemoglobin
Hct: haematocrit
IM: intramuscular
IU: international units
70Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
IV: intravenous
PPH: postpartum haemorrhage
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D A T A A N D A N A L Y S E S
Comparison 1. Oxytocin versus no uterotonics or placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Blood loss 500 mL or more after
delivery
6 4162 Risk Ratio (M-H, Random, 95% CI) 0.51 [0.37, 0.72]
2 Need for additional uterotonics 4 3135 Risk Ratio (M-H, Random, 95% CI) 0.54 [0.36, 0.80]
3 Blood loss 1000 mL or more
after delivery
5 4123 Risk Ratio (M-H, Fixed, 95% CI) 0.59 [0.42, 0.83]
4 Blood transfusion 3 3081 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.44, 1.78]
5 Third stage greater than 30
minutes
1 1947 Risk Ratio (M-H, Fixed, 95% CI) 2.55 [0.88, 7.44]
6 Mean blood loss (mL) 5 1359 Mean Difference (IV, Random, 95% CI) -99.13 [-181.40, -
16.85]
7 Maternal haemoglobin
concentration (Hb) < 7 g/dL
24-48 hours PP
2 1073 Risk Ratio (M-H, Fixed, 95% CI) 0.64 [0.18, 2.26]
8 Mean length of third stage
(minutes)
3 294 Mean Difference (IV, Random, 95% CI) -3.61 [-9.06, 1.83]
9 Manual removal of the placenta 6 4281 Risk Ratio (M-H, Fixed, 95% CI) 1.27 [0.89, 1.82]
Comparison 2. Oxytocin versus no uterotonics or placebo-subgroup analyses
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Blood loss 500 mL or more after
delivery; active v. expectant
management
5 4154 Risk Ratio (M-H, Random, 95% CI) 0.52 [0.37, 0.73]
1.1 Active management 2 2920 Risk Ratio (M-H, Random, 95% CI) 0.39 [0.22, 0.72]
1.2 Expectant management 3 1234 Risk Ratio (M-H, Random, 95% CI) 0.62 [0.48, 0.81]
2 Blood loss 500 mL or more after
delivery; IM v. IV oxytocin
6 4162 Risk Ratio (M-H, Random, 95% CI) 0.52 [0.37, 0.73]
2.1 IV oxytocin 3 1978 Risk Ratio (M-H, Random, 95% CI) 0.41 [0.21, 0.79]
2.2 IM oxytocin 3 2184 Risk Ratio (M-H, Random, 95% CI) 0.63 [0.46, 0.87]
3 Blood loss 500 mL or more after
delivery; oxytocin dose < 10 IU
v. 10 IU
5 4154 Risk Ratio (M-H, Random, 95% CI) 0.52 [0.37, 0.73]
3.1 Oxytocin dose < 10 IU 3 1204 Risk Ratio (M-H, Random, 95% CI) 0.52 [0.24, 1.14]
3.2 Oxytocin dose 10 IU 2 2950 Risk Ratio (M-H, Random, 95% CI) 0.56 [0.47, 0.66]
4 Need for additional uterotonics;
active v. expectant management
4 3135 Risk Ratio (M-H, Random, 95% CI) 0.54 [0.36, 0.80]
4.1 Active management 1 1901 Risk Ratio (M-H, Random, 95% CI) 0.39 [0.26, 0.58]
4.2 Expectant management 3 1234 Risk Ratio (M-H, Random, 95% CI) 0.64 [0.42, 0.99]
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5 Need for additional uterotonics;
IM v. IV oxytocin
4 3135 Risk Ratio (M-H, Random, 95% CI) 0.54 [0.36, 0.80]
5.1 IV oxytocin 1 1000 Risk Ratio (M-H, Random, 95% CI) 0.57 [0.39, 0.82]
5.2 IM oxytocin 3 2135 Risk Ratio (M-H, Random, 95% CI) 0.54 [0.24, 1.19]
6 Need for additional uterotonics;
oxytocin dose < 10 IU v. 10 IU
4 3135 Risk Ratio (M-H, Random, 95% CI) 0.54 [0.36, 0.80]
6.1 Oxytocin dose < 10 IU 2 234 Risk Ratio (M-H, Random, 95% CI) 0.76 [0.22, 2.63]
6.2 Oxytocin dose 10 IU 2 2901 Risk Ratio (M-H, Random, 95% CI) 0.48 [0.33, 0.68]
Comparison 3. Oxytocin versus ergot alkaloids
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Blood loss 500 mL or more after
delivery
10 3082 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.56, 1.25]
2 Need for additional uterotonics 8 2178 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.43, 1.81]
3 Blood loss 1000 mL or more
after delivery
3 1577 Risk Ratio (M-H, Fixed, 95% CI) 1.13 [0.63, 2.01]
4 Blood transfusion 7 1578 Risk Ratio (M-H, Random, 95% CI) 1.37 [0.34, 5.51]
5 Third stage > 30 minutes 2 450 Risk Ratio (M-H, Fixed, 95% CI) 4.69 [1.63, 13.45]
6 Diastolic blood pressure > 100
mmHg between delivery of the
baby and discharge from the
labour ward
3 960 Risk Ratio (M-H, Random, 95% CI) 0.28 [0.04, 2.05]
7 Mean blood loss (mL) 11 3598 Mean Difference (IV, Random, 95% CI) -13.97 [-43.70, 15.
76]
8 Mean length of third stage
(minutes)
8 2892 Mean Difference (IV, Random, 95% CI) 0.09 [-0.44, 0.61]
9 Manual removal of the placenta 8 3127 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.39, 3.10]
10 Vomiting between delivery of
the baby and discharge from
the labour ward
7 1991 Risk Ratio (M-H, Fixed, 95% CI) 0.09 [0.05, 0.14]
11 Headaches between delivery of
the baby and discharge from
the labour ward
5 1543 Risk Ratio (M-H, Random, 95% CI) 0.19 [0.03, 1.02]
Comparison 4. Oxytocin versus ergot alkaloids--subgroup analyses
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Blood loss 500 mL or more after
delivery; active v. expectant
management
8 2977 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.60, 1.35]
1.1 Active management 6 1743 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.47, 2.43]
1.2 Expectant management 2 1234 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.61, 1.10]
73Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
2 Blood loss 500 mL or more after
delivery; IM v. IV oxytocin
10 3087 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.56, 1.25]
2.1 IM oxytocin 6 1278 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.48, 2.16]
2.2 IV oxytocin 4 1809 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.56, 1.05]
3 Blood loss 500 mL or more after
delivery; oxytocin dose < 10 IU
v. 10 IU
9 3077 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.56, 1.29]
3.1 Oxytocin dose < 10 IU 3 678 Risk Ratio (M-H, Random, 95% CI) 0.66 [0.46, 0.95]
3.2 Oxytocin dose 10 IU 6 2399 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.54, 2.17]
4 Need for additional uterotonics;
active v. expectant management
7 2078 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.48, 2.09]
4.1 Active management 6 1893 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.40, 2.32]
4.2 Expectant management 1 185 Risk Ratio (M-H, Random, 95% CI) 1.25 [0.57, 2.72]
5 Need for additional uterotonics;
IM v. IV oxytocin
8 2178 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.41, 1.82]
5.1 IM oxytocin 6 1428 Risk Ratio (M-H, Random, 95% CI) 1.16 [0.47, 2.83]
5.2 IV oxytocin 2 750 Risk Ratio (M-H, Random, 95% CI) 0.41 [0.13, 1.26]
6 Need for additional uterotonics;
oxytocin dose < 10 IU v. 10 IU
8 2180 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.41, 1.83]
6.1 Oxytocin dose < 10 IU 3 678 Risk Ratio (M-H, Random, 95% CI) 0.52 [0.18, 1.45]
6.2 Oxytocin dose 10 IU 5 1502 Risk Ratio (M-H, Random, 95% CI) 1.22 [0.42, 3.48]
Comparison 5. Oxytocin + ergometrine versus ergot alkaloids
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Blood loss 500 mL or more after
delivery
3 1168 Risk Ratio (M-H, Fixed, 95% CI) 0.44 [0.20, 0.94]
2 Manual removal of the placenta 1 807 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.31, 3.65]
3 Mean blood loss (mL) 1 27 Mean Difference (IV, Fixed, 95% CI) 61.0 [-0.90, 122.90]
4 Maternal all-cause mortality 1 807 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 6. Oxytocin + ergometrine versus ergot alkaloids--subgroup analyses
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Blood loss 500 mL or more after
delivery; active v. expectant
management
1 354 Risk Ratio (M-H, Fixed, 95% CI) 0.48 [0.15, 1.52]
1.1 Active management 1 354 Risk Ratio (M-H, Fixed, 95% CI) 0.48 [0.15, 1.52]
1.2 Expectant management 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Blood loss 500 mL or more after
delivery; IM v. IV oxytocin
3 1168 Risk Ratio (M-H, Fixed, 95% CI) 0.44 [0.20, 0.94]
2.1 IM oxytocin 2 1161 Risk Ratio (M-H, Fixed, 95% CI) 0.44 [0.20, 0.94]
2.2 IV oxytocin 1 7 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Comparison 7. Oxytocin versus no uterotonics or placebo--subgroup analyses
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Blood loss 500 mL or more after
delivery; active v. expectant
management
5 4154 Risk Ratio (M-H, Random, 95% CI) 0.52 [0.37, 0.73]
1.1 Active management 2 2920 Risk Ratio (M-H, Random, 95% CI) 0.39 [0.22, 0.72]
1.2 Expectant management 3 1234 Risk Ratio (M-H, Random, 95% CI) 0.62 [0.48, 0.81]
2 Blood loss 500 mL or more after
delivery; IM v. IV oxytocin
6 4162 Risk Ratio (M-H, Random, 95% CI) 0.52 [0.37, 0.73]
2.1 IV oxytocin 3 1978 Risk Ratio (M-H, Random, 95% CI) 0.41 [0.21, 0.79]
2.2 IM oxytocin 3 2184 Risk Ratio (M-H, Random, 95% CI) 0.63 [0.46, 0.87]
3 Blood loss 500 mL or more after
delivery; oxytocin dose < 10 IU
v. 10 IU
5 4154 Risk Ratio (M-H, Random, 95% CI) 0.52 [0.37, 0.73]
3.1 Oxytocin dose < 10 IU 3 1204 Risk Ratio (M-H, Random, 95% CI) 0.52 [0.24, 1.14]
3.2 Oxytocin dose 10 IU 2 2950 Risk Ratio (M-H, Random, 95% CI) 0.56 [0.47, 0.66]
4 Need for additional uterotonics;
active v. expectant management
4 3135 Risk Ratio (M-H, Random, 95% CI) 0.54 [0.36, 0.80]
4.1 Active management 1 1901 Risk Ratio (M-H, Random, 95% CI) 0.39 [0.26, 0.58]
4.2 Expectant management 3 1234 Risk Ratio (M-H, Random, 95% CI) 0.64 [0.42, 0.99]
5 Need for additional uterotonics;
IM v. IV oxytocin
4 3135 Risk Ratio (M-H, Random, 95% CI) 0.54 [0.36, 0.80]
5.1 IV oxytocin 1 1000 Risk Ratio (M-H, Random, 95% CI) 0.57 [0.39, 0.82]
5.2 IM oxytocin 3 2135 Risk Ratio (M-H, Random, 95% CI) 0.54 [0.24, 1.19]
6 Need for additional uterotonics;
oxytocin dose < 10 IU v. 10 IU
4 3135 Risk Ratio (M-H, Random, 95% CI) 0.54 [0.36, 0.80]
6.1 Oxytocin dose < 10 IU 2 234 Risk Ratio (M-H, Random, 95% CI) 0.76 [0.22, 2.63]
6.2 Oxytocin dose 10 IU 2 2901 Risk Ratio (M-H, Random, 95% CI) 0.48 [0.33, 0.68]
75Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.1. Comparison 1 Oxytocin versus no uterotonics or placebo, Outcome 1 Blood loss 500 mL or
more after delivery.
Review: Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage
Comparison: 1 Oxytocin versus no uterotonics or placebo
Outcome: 1 Blood loss 500 mL or more after delivery
Study or subgroup Oxytocin Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Abdel-Aleem 2010 63/1291 65/659 22.6 % 0.49 [ 0.35, 0.69 ]
De Groot 1996 13/39 55/143 18.0 % 0.87 [ 0.53, 1.41 ]
Ilancheran 1990 0/3 0/5 Not estimable
Nordstrom 1997 104/513 175/487 26.1 % 0.56 [ 0.46, 0.70 ]
Pierre 1992 37/488 126/482 22.3 % 0.29 [ 0.21, 0.41 ]
Poeschmann 1991 7/28 10/24 11.1 % 0.60 [ 0.27, 1.33 ]
Total (95% CI) 2362 1800 100.0 % 0.51 [ 0.37, 0.72 ]
Total events: 224 (Oxytocin), 431 (Control)
Heterogeneity: Tau2 = 0.10; Chi2 = 16.23, df = 4 (P = 0.003); I2 =75%
Test for overall effect: Z = 3.86 (P = 0.00011)
Test for subgroup differences: Not applicable
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Analysis 1.2. Comparison 1 Oxytocin versus no uterotonics or placebo, Outcome 2 Need for additional
uterotonics.
Review: Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage
Comparison: 1 Oxytocin versus no uterotonics or placebo
Outcome: 2 Need for additional uterotonics
Study or subgroup Oxytocin Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Abdel-Aleem 2010 41/1260 53/641 38.5 % 0.39 [ 0.26, 0.58 ]
De Groot 1996 7/39 26/143 19.3 % 0.99 [ 0.46, 2.10 ]
Nordstrom 1997 40/513 67/487 40.4 % 0.57 [ 0.39, 0.82 ]
Poeschmann 1991 0/28 2/24 1.7 % 0.17 [ 0.01, 3.42 ]
Total (95% CI) 1840 1295 100.0 % 0.54 [ 0.36, 0.80 ]
Total events: 88 (Oxytocin), 148 (Control)
Heterogeneity: Tau2 = 0.07; Chi2 = 5.39, df = 3 (P = 0.15); I2 =44%
Test for overall effect: Z = 3.05 (P = 0.0023)
Test for subgroup differences: Not applicable
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Analysis 1.3. Comparison 1 Oxytocin versus no uterotonics or placebo, Outcome 3 Blood loss 1000 mL or
more after delivery.
Review: Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage
Comparison: 1 Oxytocin versus no uterotonics or placebo
Outcome: 3 Blood loss 1000 mL or more after delivery
Study or subgroup Oxytocin Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Abdel-Aleem 2010 4/1260 4/659 6.5 % 0.52 [ 0.13, 2.08 ]
De Groot 1996 3/39 16/143 8.5 % 0.69 [ 0.21, 2.24 ]
Nordstrom 1997 32/513 43/487 54.7 % 0.71 [ 0.45, 1.10 ]
Pierre 1992 7/488 21/482 26.2 % 0.33 [ 0.14, 0.77 ]
Poeschmann 1991 2/28 3/24 4.0 % 0.57 [ 0.10, 3.14 ]
Total (95% CI) 2328 1795 100.0 % 0.59 [ 0.42, 0.83 ]
Total events: 48 (Oxytocin), 87 (Control)
Heterogeneity: Chi2 = 2.57, df = 4 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 2.99 (P = 0.0028)
Test for subgroup differences: Not applicable
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Analysis 1.4. Comparison 1 Oxytocin versus no uterotonics or placebo, Outcome 4 Blood transfusion.
Review: Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage
Comparison: 1 Oxytocin versus no uterotonics or placebo
Outcome: 4 Blood transfusion
Study or subgroup Oxytocin Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Abdel-Aleem 2010 8/1257 7/642 59.1 % 0.58 [ 0.21, 1.60 ]
De Groot 1996 1/39 3/143 8.2 % 1.22 [ 0.13, 11.43 ]
Nordstrom 1997 7/513 5/487 32.7 % 1.33 [ 0.42, 4.16 ]
Total (95% CI) 1809 1272 100.0 % 0.88 [ 0.44, 1.78 ]
Total events: 16 (Oxytocin), 15 (Control)
Heterogeneity: Chi2 = 1.22, df = 2 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.36 (P = 0.72)
Test for subgroup differences: Not applicable
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Analysis 1.5. Comparison 1 Oxytocin versus no uterotonics or placebo, Outcome 5 Third stage greater
than 30 minutes.
Review: Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage
Comparison: 1 Oxytocin versus no uterotonics or placebo
Outcome: 5 Third stage greater than 30 minutes
Study or subgroup Oxytocin Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Abdel-Aleem 2010 20/1289 4/658 100.0 % 2.55 [ 0.88, 7.44 ]
Total (95% CI) 1289 658 100.0 % 2.55 [ 0.88, 7.44 ]
Total events: 20 (Oxytocin), 4 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.72 (P = 0.086)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 Oxytocin versus no uterotonics or placebo, Outcome 6 Mean blood loss (mL).
Review: Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage
Comparison: 1 Oxytocin versus no uterotonics or placebo
Outcome: 6 Mean blood loss (mL)
Study or subgroup Oxytocin Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Bader 2000 53 229.79 (143.66) 59 226.89 (148.7) 25.5 % 2.90 [ -51.28, 57.08 ]
De Groot 1996 39 499 (454) 143 520 (419) 13.9 % -21.00 [ -179.17, 137.17 ]
Nordstrom 1997 513 409 (3.45) 487 527 (412) 27.2 % -118.00 [ -154.59, -81.41 ]
Poeschmann 1991 28 374 (279) 24 548 (376) 11.9 % -174.00 [ -356.51, 8.51 ]
Vaughan Williams 1974 3 99 (72) 10 305 (60) 21.4 % -206.00 [ -295.56, -116.44 ]
Total (95% CI) 636 723 100.0 % -99.13 [ -181.40, -16.85 ]
Heterogeneity: Tau2 = 6133.53; Chi2 = 21.50, df = 4 (P = 0.00025); I2 =81%
Test for overall effect: Z = 2.36 (P = 0.018)
Test for subgroup differences: Not applicable
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Analysis 1.7. Comparison 1 Oxytocin versus no uterotonics or placebo, Outcome 7 Maternal haemoglobin
concentration (Hb) < 7 g/dL 24-48 hours PP.
Review: Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage
Comparison: 1 Oxytocin versus no uterotonics or placebo
Outcome: 7 Maternal haemoglobin concentration (Hb) < 7 g/dL 24-48 hours PP
Study or subgroup Oxytocin Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Jerbi 2007 1/65 2/65 32.7 % 0.50 [ 0.05, 5.38 ]
Nordstrom 1997 3/485 4/458 67.3 % 0.71 [ 0.16, 3.15 ]
Total (95% CI) 550 523 100.0 % 0.64 [ 0.18, 2.26 ]
Total events: 4 (Oxytocin), 6 (Control)
Heterogeneity: Chi2 = 0.06, df = 1 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 Oxytocin versus no uterotonics or placebo, Outcome 8 Mean length of third
stage (minutes).
Review: Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage
Comparison: 1 Oxytocin versus no uterotonics or placebo
Outcome: 8 Mean length of third stage (minutes)
Study or subgroup Oxytocin Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Bader 2000 53 11.85 (6.46) 59 12.46 (6.69) 33.8 % -0.61 [ -3.05, 1.83 ]
Jerbi 2007 65 2.5 (4.3) 65 10.6 (5) 35.2 % -8.10 [ -9.70, -6.50 ]
Poeschmann 1991 28 9.9 (7.4) 24 11.7 (6.4) 31.0 % -1.80 [ -5.55, 1.95 ]
Total (95% CI) 146 148 100.0 % -3.61 [ -9.06, 1.83 ]
Heterogeneity: Tau2 = 21.22; Chi2 = 29.27, df = 2 (P<0.00001); I2 =93%
Test for overall effect: Z = 1.30 (P = 0.19)
Test for subgroup differences: Not applicable
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Analysis 1.9. Comparison 1 Oxytocin versus no uterotonics or placebo, Outcome 9 Manual removal of the
placenta.
Review: Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage
Comparison: 1 Oxytocin versus no uterotonics or placebo
Outcome: 9 Manual removal of the placenta
Study or subgroup Oxytocin Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Abdel-Aleem 2010 24/1289 6/658 15.2 % 2.04 [ 0.84, 4.97 ]
De Groot 1996 0/39 0/143 Not estimable
Jerbi 2007 1/65 1/65 1.9 % 1.00 [ 0.06, 15.65 ]
Nordstrom 1997 18/513 11/487 21.5 % 1.55 [ 0.74, 3.26 ]
Pierre 1992 32/488 32/482 61.4 % 0.99 [ 0.62, 1.59 ]
Poeschmann 1991 0/28 0/24 Not estimable
Total (95% CI) 2422 1859 100.0 % 1.27 [ 0.89, 1.82 ]
Total events: 75 (Oxytocin), 50 (Control)
Heterogeneity: Chi2 = 2.49, df = 3 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 1.31 (P = 0.19)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 Oxytocin versus no uterotonics or placebo-subgroup analyses, Outcome 1
Blood loss 500 mL or more after delivery; active v. expectant management.
Review: Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage
Comparison: 2 Oxytocin versus no uterotonics or placebo-subgroup analyses
Outcome: 1 Blood loss 500 mL or more after delivery; active v. expectant management
Study or subgroup Oxytocin Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Active management
Abdel-Aleem 2010 68/1291 65/659 22.7 % 0.53 [ 0.39, 0.74 ]
Pierre 1992 37/488 126/482 22.2 % 0.29 [ 0.21, 0.41 ]
Subtotal (95% CI) 1779 1141 45.0 % 0.39 [ 0.22, 0.72 ]
Total events: 105 (Oxytocin), 191 (Control)
Heterogeneity: Tau2 = 0.16; Chi2 = 6.41, df = 1 (P = 0.01); I2 =84%
Test for overall effect: Z = 3.03 (P = 0.0024)
2 Expectant management
De Groot 1996 13/39 55/143 17.9 % 0.87 [ 0.53, 1.41 ]
Nordstrom 1997 104/513 175/487 26.1 % 0.56 [ 0.46, 0.70 ]
Poeschmann 1991 7/28 10/24 11.0 % 0.60 [ 0.27, 1.33 ]
Subtotal (95% CI) 580 654 55.0 % 0.62 [ 0.48, 0.81 ]
Total events: 124 (Oxytocin), 240 (Control)
Heterogeneity: Tau2 = 0.01; Chi2 = 2.50, df = 2 (P = 0.29); I2 =20%
Test for overall effect: Z = 3.62 (P = 0.00030)
Total (95% CI) 2359 1795 100.0 % 0.52 [ 0.37, 0.73 ]
Total events: 229 (Oxytocin), 431 (Control)
Heterogeneity: Tau2 = 0.10; Chi2 = 16.25, df = 4 (P = 0.003); I2 =75%
Test for overall effect: Z = 3.78 (P = 0.00016)
Test for subgroup differences: Chi2 = 1.90, df = 1 (P = 0.17), I2 =47%
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Analysis 2.2. Comparison 2 Oxytocin versus no uterotonics or placebo-subgroup analyses, Outcome 2
Blood loss 500 mL or more after delivery; IM v. IV oxytocin.
Review: Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage
Comparison: 2 Oxytocin versus no uterotonics or placebo-subgroup analyses
Outcome: 2 Blood loss 500 mL or more after delivery; IM v. IV oxytocin
Study or subgroup Oxytocin Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 IV oxytocin
Ilancheran 1990 0/3 0/5 Not estimable
Nordstrom 1997 104/513 175/487 26.1 % 0.56 [ 0.46, 0.70 ]
Pierre 1992 37/488 126/482 22.2 % 0.29 [ 0.21, 0.41 ]
Subtotal (95% CI) 1004 974 48.3 % 0.41 [ 0.21, 0.79 ]
Total events: 141 (Oxytocin), 301 (Control)
Heterogeneity: Tau2 = 0.21; Chi2 = 10.75, df = 1 (P = 0.001); I2 =91%
Test for overall effect: Z = 2.65 (P = 0.0081)
2 IM oxytocin
Abdel-Aleem 2010 68/1291 65/659 22.7 % 0.53 [ 0.39, 0.74 ]
De Groot 1996 13/39 55/143 17.9 % 0.87 [ 0.53, 1.41 ]
Poeschmann 1991 7/28 10/24 11.0 % 0.60 [ 0.27, 1.33 ]
Subtotal (95% CI) 1358 826 51.7 % 0.63 [ 0.46, 0.87 ]
Total events: 88 (Oxytocin), 130 (Control)
Heterogeneity: Tau2 = 0.02; Chi2 = 2.63, df = 2 (P = 0.27); I2 =24%
Test for overall effect: Z = 2.83 (P = 0.0047)
Total (95% CI) 2362 1800 100.0 % 0.52 [ 0.37, 0.73 ]
Total events: 229 (Oxytocin), 431 (Control)
Heterogeneity: Tau2 = 0.10; Chi2 = 16.25, df = 4 (P = 0.003); I2 =75%
Test for overall effect: Z = 3.78 (P = 0.00016)
Test for subgroup differences: Chi2 = 1.34, df = 1 (P = 0.25), I2 =26%
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Analysis 2.3. Comparison 2 Oxytocin versus no uterotonics or placebo-subgroup analyses, Outcome 3
Blood loss 500 mL or more after delivery; oxytocin dose < 10 IU v. 10 IU.
Review: Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage
Comparison: 2 Oxytocin versus no uterotonics or placebo-subgroup analyses
Outcome: 3 Blood loss 500 mL or more after delivery; oxytocin dose < 10 IU v. 10 IU
Study or subgroup Oxytocin Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Oxytocin dose < 10 IU
De Groot 1996 13/39 55/143 17.9 % 0.87 [ 0.53, 1.41 ]
Pierre 1992 37/488 126/482 22.2 % 0.29 [ 0.21, 0.41 ]
Poeschmann 1991 7/28 10/24 11.0 % 0.60 [ 0.27, 1.33 ]
Subtotal (95% CI) 555 649 51.2 % 0.52 [ 0.24, 1.14 ]
Total events: 57 (Oxytocin), 191 (Control)
Heterogeneity: Tau2 = 0.40; Chi2 = 14.03, df = 2 (P = 0.00090); I2 =86%
Test for overall effect: Z = 1.63 (P = 0.10)
2 Oxytocin dose 10 IU
Abdel-Aleem 2010 68/1291 65/659 22.7 % 0.53 [ 0.39, 0.74 ]
Nordstrom 1997 104/513 175/487 26.1 % 0.56 [ 0.46, 0.70 ]
Subtotal (95% CI) 1804 1146 48.8 % 0.56 [ 0.47, 0.66 ]
Total events: 172 (Oxytocin), 240 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.08, df = 1 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 6.56 (P < 0.00001)
Total (95% CI) 2359 1795 100.0 % 0.52 [ 0.37, 0.73 ]
Total events: 229 (Oxytocin), 431 (Control)
Heterogeneity: Tau2 = 0.10; Chi2 = 16.25, df = 4 (P = 0.003); I2 =75%
Test for overall effect: Z = 3.78 (P = 0.00016)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.87), I2 =0.0%
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Analysis 2.4. Comparison 2 Oxytocin versus no uterotonics or placebo-subgroup analyses, Outcome 4 Need
for additional uterotonics; active v. expectant management.
Review: Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage
Comparison: 2 Oxytocin versus no uterotonics or placebo-subgroup analyses
Outcome: 4 Need for additional uterotonics; active v. expectant management
Study or subgroup Oxytocin Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Active management
Abdel-Aleem 2010 41/1260 53/641 38.5 % 0.39 [ 0.26, 0.58 ]
Subtotal (95% CI) 1260 641 38.5 % 0.39 [ 0.26, 0.58 ]
Total events: 41 (Oxytocin), 53 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 4.61 (P < 0.00001)
2 Expectant management
De Groot 1996 7/39 26/143 19.3 % 0.99 [ 0.46, 2.10 ]
Nordstrom 1997 40/513 67/487 40.4 % 0.57 [ 0.39, 0.82 ]
Poeschmann 1991 0/28 2/24 1.7 % 0.17 [ 0.01, 3.42 ]
Subtotal (95% CI) 580 654 61.5 % 0.64 [ 0.42, 0.99 ]
Total events: 47 (Oxytocin), 95 (Control)
Heterogeneity: Tau2 = 0.03; Chi2 = 2.39, df = 2 (P = 0.30); I2 =16%
Test for overall effect: Z = 1.99 (P = 0.047)
Total (95% CI) 1840 1295 100.0 % 0.54 [ 0.36, 0.80 ]
Total events: 88 (Oxytocin), 148 (Control)
Heterogeneity: Tau2 = 0.07; Chi2 = 5.39, df = 3 (P = 0.15); I2 =44%
Test for overall effect: Z = 3.05 (P = 0.0023)
Test for subgroup differences: Chi2 = 2.66, df = 1 (P = 0.10), I2 =62%
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Analysis 2.5. Comparison 2 Oxytocin versus no uterotonics or placebo-subgroup analyses, Outcome 5 Need
for additional uterotonics; IM v. IV oxytocin.
Review: Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage
Comparison: 2 Oxytocin versus no uterotonics or placebo-subgroup analyses
Outcome: 5 Need for additional uterotonics; IM v. IV oxytocin
Study or subgroup Oxytocin Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 IV oxytocin
Nordstrom 1997 40/513 67/487 40.4 % 0.57 [ 0.39, 0.82 ]
Subtotal (95% CI) 513 487 40.4 % 0.57 [ 0.39, 0.82 ]
Total events: 40 (Oxytocin), 67 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.00 (P = 0.0027)
2 IM oxytocin
Abdel-Aleem 2010 41/1260 53/641 38.5 % 0.39 [ 0.26, 0.58 ]
De Groot 1996 7/39 26/143 19.3 % 0.99 [ 0.46, 2.10 ]
Poeschmann 1991 0/28 2/24 1.7 % 0.17 [ 0.01, 3.42 ]
Subtotal (95% CI) 1327 808 59.6 % 0.54 [ 0.24, 1.19 ]
Total events: 48 (Oxytocin), 81 (Control)
Heterogeneity: Tau2 = 0.26; Chi2 = 4.92, df = 2 (P = 0.09); I2 =59%
Test for overall effect: Z = 1.54 (P = 0.12)
Total (95% CI) 1840 1295 100.0 % 0.54 [ 0.36, 0.80 ]
Total events: 88 (Oxytocin), 148 (Control)
Heterogeneity: Tau2 = 0.07; Chi2 = 5.39, df = 3 (P = 0.15); I2 =44%
Test for overall effect: Z = 3.05 (P = 0.0023)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.91), I2 =0.0%
0.001 0.01 0.1 1 10 100 1000
Favours Oxytocin Favours Control
88Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.6. Comparison 2 Oxytocin versus no uterotonics or placebo-subgroup analyses, Outcome 6 Need
for additional uterotonics; oxytocin dose < 10 IU v. 10 IU.
Review: Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage
Comparison: 2 Oxytocin versus no uterotonics or placebo-subgroup analyses
Outcome: 6 Need for additional uterotonics; oxytocin dose < 10 IU v. 10 IU
Study or subgroup Oxytocin Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Oxytocin dose < 10 IU
De Groot 1996 7/39 26/143 19.3 % 0.99 [ 0.46, 2.10 ]
Poeschmann 1991 0/28 2/24 1.7 % 0.17 [ 0.01, 3.42 ]
Subtotal (95% CI) 67 167 21.0 % 0.76 [ 0.22, 2.63 ]
Total events: 7 (Oxytocin), 28 (Control)
Heterogeneity: Tau2 = 0.33; Chi2 = 1.27, df = 1 (P = 0.26); I2 =21%
Test for overall effect: Z = 0.44 (P = 0.66)
2 Oxytocin dose 10 IU
Abdel-Aleem 2010 41/1260 53/641 38.5 % 0.39 [ 0.26, 0.58 ]
Nordstrom 1997 40/513 67/487 40.4 % 0.57 [ 0.39, 0.82 ]
Subtotal (95% CI) 1773 1128 79.0 % 0.48 [ 0.33, 0.68 ]
Total events: 81 (Oxytocin), 120 (Control)
Heterogeneity: Tau2 = 0.03; Chi2 = 1.73, df = 1 (P = 0.19); I2 =42%
Test for overall effect: Z = 4.08 (P = 0.000045)
Total (95% CI) 1840 1295 100.0 % 0.54 [ 0.36, 0.80 ]
Total events: 88 (Oxytocin), 148 (Control)
Heterogeneity: Tau2 = 0.07; Chi2 = 5.39, df = 3 (P = 0.15); I2 =44%
Test for overall effect: Z = 3.05 (P = 0.0023)
Test for subgroup differences: Chi2 = 0.49, df = 1 (P = 0.48), I2 =0.0%
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Analysis 3.1. Comparison 3 Oxytocin versus ergot alkaloids, Outcome 1 Blood loss 500 mL or more after
delivery.
Review: Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage
Comparison: 3 Oxytocin versus ergot alkaloids
Outcome: 1 Blood loss 500 mL or more after delivery
Study or subgroup Oxytocin Ergot Alkaloids Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Boopathi 2014 10/150 4/150 8.6 % 2.50 [ 0.80, 7.80 ]
De Groot 1996 12/39 54/146 19.5 % 0.83 [ 0.50, 1.39 ]
Dhananjaya 2014 1/50 6/50 3.3 % 0.17 [ 0.02, 1.33 ]
Ezeama 2014 12/151 3/149 7.6 % 3.95 [ 1.14, 13.70 ]
Ilancheran 1990 0/2 1/3 1.9 % 0.44 [ 0.03, 7.52 ]
Modi 2014 0/25 0/25 Not estimable
Orji 2008 12/297 18/303 15.0 % 0.68 [ 0.33, 1.39 ]
Saito 2007 17/156 38/187 19.1 % 0.54 [ 0.32, 0.91 ]
Singh 2009 0/75 2/75 1.6 % 0.20 [ 0.01, 4.10 ]
Sorbe 1978 48/506 63/543 23.5 % 0.82 [ 0.57, 1.17 ]
Total (95% CI) 1451 1631 100.0 % 0.84 [ 0.56, 1.25 ]
Total events: 112 (Oxytocin), 189 (Ergot Alkaloids)
Heterogeneity: Tau2 = 0.14; Chi2 = 15.76, df = 8 (P = 0.05); I2 =49%
Test for overall effect: Z = 0.87 (P = 0.38)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 Oxytocin versus ergot alkaloids, Outcome 2 Need for additional uterotonics.
Review: Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage
Comparison: 3 Oxytocin versus ergot alkaloids
Outcome: 2 Need for additional uterotonics
Study or subgroup Oxytocin Ergot Alkaloids Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Adhikari 2007 5/100 4/100 11.2 % 1.25 [ 0.35, 4.52 ]
Boopathi 2014 11/150 3/150 11.4 % 3.67 [ 1.04, 12.88 ]
De Groot 1996 7/39 21/146 14.5 % 1.25 [ 0.57, 2.72 ]
Dhananjaya 2014 1/50 6/50 7.1 % 0.17 [ 0.02, 1.33 ]
Ezeama 2014 35/151 11/149 15.4 % 3.14 [ 1.66, 5.95 ]
Orji 2008 18/297 30/303 15.8 % 0.61 [ 0.35, 1.07 ]
Saito 2007 8/156 23/187 14.5 % 0.42 [ 0.19, 0.91 ]
Singh 2009 2/75 11/75 10.1 % 0.18 [ 0.04, 0.79 ]
Total (95% CI) 1018 1160 100.0 % 0.89 [ 0.43, 1.81 ]
Total events: 87 (Oxytocin), 109 (Ergot Alkaloids)
Heterogeneity: Tau2 = 0.76; Chi2 = 32.70, df = 7 (P = 0.00003); I2 =79%
Test for overall effect: Z = 0.33 (P = 0.74)
Test for subgroup differences: Not applicable
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Analysis 3.3. Comparison 3 Oxytocin versus ergot alkaloids, Outcome 3 Blood loss 1000 mL or more after
delivery.
Review: Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage
Comparison: 3 Oxytocin versus ergot alkaloids
Outcome: 3 Blood loss 1000 mL or more after delivery
Study or subgroup Oxytocin Ergot Alkaloids Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
De Groot 1996 4/39 12/146 24.8 % 1.25 [ 0.43, 3.66 ]
Saito 2007 3/156 1/187 4.5 % 3.60 [ 0.38, 34.23 ]
Sorbe 1978 13/506 15/543 70.8 % 0.93 [ 0.45, 1.94 ]
Total (95% CI) 701 876 100.0 % 1.13 [ 0.63, 2.01 ]
Total events: 20 (Oxytocin), 28 (Ergot Alkaloids)
Heterogeneity: Chi2 = 1.32, df = 2 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.41 (P = 0.68)
Test for subgroup differences: Not applicable
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Analysis 3.4. Comparison 3 Oxytocin versus ergot alkaloids, Outcome 4 Blood transfusion.
Review: Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage
Comparison: 3 Oxytocin versus ergot alkaloids
Outcome: 4 Blood transfusion
Study or subgroup Oxytocin Ergot Alkaloids Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Adhikari 2007 2/100 1/100 17.9 % 2.00 [ 0.18, 21.71 ]
Boopathi 2014 2/150 1/150 17.8 % 2.00 [ 0.18, 21.82 ]
De Groot 1996 1/39 1/146 15.3 % 3.74 [ 0.24, 58.51 ]
Dhananjaya 2014 0/50 4/50 14.3 % 0.11 [ 0.01, 2.01 ]
Ezeama 2014 9/151 1/149 20.7 % 8.88 [ 1.14, 69.23 ]
Saito 2007 0/156 0/187 Not estimable
Singh 2009 0/75 3/75 14.0 % 0.14 [ 0.01, 2.72 ]
Total (95% CI) 721 857 100.0 % 1.37 [ 0.34, 5.51 ]
Total events: 14 (Oxytocin), 11 (Ergot Alkaloids)
Heterogeneity: Tau2 = 1.34; Chi2 = 9.05, df = 5 (P = 0.11); I2 =45%
Test for overall effect: Z = 0.44 (P = 0.66)
Test for subgroup differences: Not applicable
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Analysis 3.5. Comparison 3 Oxytocin versus ergot alkaloids, Outcome 5 Third stage > 30 minutes.
Review: Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage
Comparison: 3 Oxytocin versus ergot alkaloids
Outcome: 5 Third stage > 30 minutes
Study or subgroup Oxytocin Ergot Alkaloids Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ezeama 2014 19/151 4/149 100.0 % 4.69 [ 1.63, 13.45 ]
Singh 2009 0/75 0/75 Not estimable
Total (95% CI) 226 224 100.0 % 4.69 [ 1.63, 13.45 ]
Total events: 19 (Oxytocin), 4 (Ergot Alkaloids)
Heterogeneity: not applicable
Test for overall effect: Z = 2.87 (P = 0.0041)
Test for subgroup differences: Not applicable
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Analysis 3.6. Comparison 3 Oxytocin versus ergot alkaloids, Outcome 6 Diastolic blood pressure > 100 mm
Hg between delivery of the baby and discharge from the labour ward.
Review: Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage
Comparison: 3 Oxytocin versus ergot alkaloids
Outcome: 6 Diastolic blood pressure > 100 mm Hg between delivery of the baby and discharge from the labour ward
Study or subgroup Oxytocin Ergot Alkaloids Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Ezeama 2014 0/151 7/149 31.1 % 0.07 [ 0.00, 1.14 ]
Jago 2007 0/256 0/254 Not estimable
McGinty 1956 4/50 15/100 68.9 % 0.53 [ 0.19, 1.52 ]
Total (95% CI) 457 503 100.0 % 0.28 [ 0.04, 2.05 ]
Total events: 4 (Oxytocin), 22 (Ergot Alkaloids)
Heterogeneity: Tau2 = 1.23; Chi2 = 2.02, df = 1 (P = 0.16); I2 =50%
Test for overall effect: Z = 1.25 (P = 0.21)
Test for subgroup differences: Not applicable
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Analysis 3.7. Comparison 3 Oxytocin versus ergot alkaloids, Outcome 7 Mean blood loss (mL).
Review: Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage
Comparison: 3 Oxytocin versus ergot alkaloids
Outcome: 7 Mean blood loss (mL)
Study or subgroup Oxytocin Ergot Alkaloids
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Boopathi 2014 150 196.57 (192.3) 150 149.33 (145.4) 9.6 % 47.24 [ 8.66, 85.82 ]
De Groot 1996 39 499 (454) 146 476 (340) 2.8 % 23.00 [ -129.79, 175.79 ]
Dhananjaya 2014 50 219 (86.3) 50 345 (109.5) 9.6 % -126.00 [ -164.64, -87.36 ]
Ezeama 2014 151 301.8 (109.2) 149 287.1 (84.4) 10.8 % 14.70 [ -7.37, 36.77 ]
Jago 2007 256 171.9 (81.6) 254 150.2 (63.6) 11.3 % 21.70 [ 9.01, 34.39 ]
Modi 2014 25 223.2 (122.5) 25 131.8 (72.04) 8.2 % 91.40 [ 35.69, 147.11 ]
Orji 2008 297 245.7 (95.4) 303 246.6 (77.6) 11.2 % -0.90 [ -14.83, 13.03 ]
Saito 2007 156 288.2 (209.9) 187 354.4 (209.3) 9.1 % -66.20 [ -110.75, -21.65 ]
Singh 2009 75 154.7 (45.7) 75 223.48 (73.7) 11.0 % -68.78 [ -88.41, -49.15 ]
Sorbe 1978 506 273 (247) 543 306 (271) 10.2 % -33.00 [ -64.35, -1.65 ]
Vaughan Williams 1974 4 99 (72) 7 124 (60) 6.0 % -25.00 [ -108.39, 58.39 ]
Total (95% CI) 1709 1889 100.0 % -13.97 [ -43.70, 15.76 ]
Heterogeneity: Tau2 = 1999.10; Chi2 = 127.80, df = 10 (P<0.00001); I2 =92%
Test for overall effect: Z = 0.92 (P = 0.36)
Test for subgroup differences: Not applicable
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Analysis 3.8. Comparison 3 Oxytocin versus ergot alkaloids, Outcome 8 Mean length of third stage
(minutes).
Review: Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage
Comparison: 3 Oxytocin versus ergot alkaloids
Outcome: 8 Mean length of third stage (minutes)
Study or subgroup Oxytocin Ergot Alkaloids
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Boopathi 2014 150 3.45 (2.75) 150 2.31 (1.06) 12.9 % 1.14 [ 0.67, 1.61 ]
Dhananjaya 2014 50 8.69 (1.41) 50 8.67 (1.63) 12.1 % 0.02 [ -0.58, 0.62 ]
Ezeama 2014 151 7.46 (2.07) 149 6.95 (1.26) 13.3 % 0.51 [ 0.12, 0.90 ]
Modi 2014 25 4.72 (1.02) 25 3.84 (0.99) 12.4 % 0.88 [ 0.32, 1.44 ]
Orji 2008 297 5.88 (1.26) 303 6.46 (2.01) 13.9 % -0.58 [ -0.85, -0.31 ]
Saito 2007 156 5.4 (3) 187 5.3 (2.9) 11.9 % 0.10 [ -0.53, 0.73 ]
Singh 2009 75 6.17 (1.33) 75 6.83 (1.28) 13.2 % -0.66 [ -1.08, -0.24 ]
Sorbe 1978 506 9.5 (7.1) 543 10.3 (6.9) 10.4 % -0.80 [ -1.65, 0.05 ]
Total (95% CI) 1410 1482 100.0 % 0.09 [ -0.44, 0.61 ]
Heterogeneity: Tau2 = 0.49; Chi2 = 69.64, df = 7 (P<0.00001); I2 =90%
Test for overall effect: Z = 0.33 (P = 0.74)
Test for subgroup differences: Not applicable
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Analysis 3.9. Comparison 3 Oxytocin versus ergot alkaloids, Outcome 9 Manual removal of the placenta.
Review: Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage
Comparison: 3 Oxytocin versus ergot alkaloids
Outcome: 9 Manual removal of the placenta
Study or subgroup Oxytocin Ergot Alkaloids Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Singh 2009 0/75 0/75 Not estimable
Boopathi 2014 0/150 0/150 Not estimable
Adhikari 2007 0/100 1/100 7.5 % 0.33 [ 0.01, 8.09 ]
De Groot 1996 1/39 2/146 11.0 % 1.87 [ 0.17, 20.11 ]
Saito 2007 4/156 2/187 15.4 % 2.40 [ 0.45, 12.92 ]
Ezeama 2014 19/151 3/149 19.4 % 6.25 [ 1.89, 20.67 ]
Sorbe 1978 10/506 32/543 23.3 % 0.34 [ 0.17, 0.68 ]
Orji 2008 12/297 21/303 23.4 % 0.58 [ 0.29, 1.16 ]
Total (95% CI) 1474 1653 100.0 % 1.10 [ 0.39, 3.10 ]
Total events: 46 (Oxytocin), 61 (Ergot Alkaloids)
Heterogeneity: Tau2 = 1.07; Chi2 = 20.56, df = 5 (P = 0.00098); I2 =76%
Test for overall effect: Z = 0.18 (P = 0.86)
Test for subgroup differences: Not applicable
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Analysis 3.10. Comparison 3 Oxytocin versus ergot alkaloids, Outcome 10 Vomiting between delivery of
the baby and discharge from the labour ward.
Review: Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage
Comparison: 3 Oxytocin versus ergot alkaloids
Outcome: 10 Vomiting between delivery of the baby and discharge from the labour ward
Study or subgroup Oxytocin Ergot Alkaloids Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Adhikari 2007 1/100 1/100 0.6 % 1.00 [ 0.06, 15.77 ]
Boopathi 2014 0/150 10/150 5.8 % 0.05 [ 0.00, 0.81 ]
Dhananjaya 2014 0/50 4/50 2.5 % 0.11 [ 0.01, 2.01 ]
Ezeama 2014 1/151 4/149 2.2 % 0.25 [ 0.03, 2.18 ]
Moodie 1976 0/70 31/78 16.5 % 0.02 [ 0.00, 0.28 ]
Orji 2008 12/297 132/303 72.4 % 0.09 [ 0.05, 0.16 ]
Saito 2007 0/156 0/187 Not estimable
Total (95% CI) 974 1017 100.0 % 0.09 [ 0.05, 0.14 ]
Total events: 14 (Oxytocin), 182 (Ergot Alkaloids)
Heterogeneity: Chi2 = 5.42, df = 5 (P = 0.37); I2 =8%
Test for overall effect: Z = 9.49 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 3.11. Comparison 3 Oxytocin versus ergot alkaloids, Outcome 11 Headaches between delivery of
the baby and discharge from the labour ward.
Review: Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage
Comparison: 3 Oxytocin versus ergot alkaloids
Outcome: 11 Headaches between delivery of the baby and discharge from the labour ward
Study or subgroup Oxytocin Ergot Alkaloids Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Adhikari 2007 2/100 4/100 22.9 % 0.50 [ 0.09, 2.67 ]
Dhananjaya 2014 0/50 7/50 16.1 % 0.07 [ 0.00, 1.14 ]
Ezeama 2014 4/151 9/149 25.9 % 0.44 [ 0.14, 1.39 ]
Orji 2008 0/297 54/303 16.4 % 0.01 [ 0.00, 0.15 ]
Saito 2007 1/156 2/187 18.6 % 0.60 [ 0.05, 6.55 ]
Total (95% CI) 754 789 100.0 % 0.19 [ 0.03, 1.02 ]
Total events: 7 (Oxytocin), 76 (Ergot Alkaloids)
Heterogeneity: Tau2 = 2.54; Chi2 = 14.18, df = 4 (P = 0.01); I2 =72%
Test for overall effect: Z = 1.93 (P = 0.053)
Test for subgroup differences: Not applicable
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Analysis 4.1. Comparison 4 Oxytocin versus ergot alkaloids--subgroup analyses, Outcome 1 Blood loss 500
mL or more after delivery; active v. expectant management.
Review: Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage
Comparison: 4 Oxytocin versus ergot alkaloids–subgroup analyses
Outcome: 1 Blood loss 500 mL or more after delivery; active v. expectant management
Study or subgroup Oxytocin Ergot Alkaloids Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Active management
Boopathi 2014 10/150 4/150 9.0 % 2.50 [ 0.80, 7.80 ]
Ezeama 2014 12/151 3/149 7.9 % 3.95 [ 1.14, 13.70 ]
Modi 2014 0/25 0/25 Not estimable
Orji 2008 12/297 18/303 15.8 % 0.68 [ 0.33, 1.39 ]
Saito 2007 17/156 38/187 20.1 % 0.54 [ 0.32, 0.91 ]
Singh 2009 0/75 2/75 1.7 % 0.20 [ 0.01, 4.10 ]
Subtotal (95% CI) 854 889 54.7 % 1.07 [ 0.47, 2.43 ]
Total events: 51 (Oxytocin), 65 (Ergot Alkaloids)
Heterogeneity: Tau2 = 0.54; Chi2 = 13.48, df = 4 (P = 0.01); I2 =70%
Test for overall effect: Z = 0.15 (P = 0.88)
2 Expectant management
De Groot 1996 12/39 54/146 20.5 % 0.83 [ 0.50, 1.39 ]
Sorbe 1978 48/506 63/543 24.8 % 0.82 [ 0.57, 1.17 ]
Subtotal (95% CI) 545 689 45.3 % 0.82 [ 0.61, 1.10 ]
Total events: 60 (Oxytocin), 117 (Ergot Alkaloids)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 1.31 (P = 0.19)
Total (95% CI) 1399 1578 100.0 % 0.90 [ 0.60, 1.35 ]
Total events: 111 (Oxytocin), 182 (Ergot Alkaloids)
Heterogeneity: Tau2 = 0.14; Chi2 = 13.43, df = 6 (P = 0.04); I2 =55%
Test for overall effect: Z = 0.53 (P = 0.60)
Test for subgroup differences: Chi2 = 0.34, df = 1 (P = 0.56), I2 =0.0%
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Analysis 4.2. Comparison 4 Oxytocin versus ergot alkaloids--subgroup analyses, Outcome 2 Blood loss 500
mL or more after delivery; IM v. IV oxytocin.
Review: Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage
Comparison: 4 Oxytocin versus ergot alkaloids–subgroup analyses
Outcome: 2 Blood loss 500 mL or more after delivery; IM v. IV oxytocin
Study or subgroup Oxytocin Ergot Alkaloids Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 IM oxytocin
Boopathi 2014 10/150 4/150 8.7 % 2.50 [ 0.80, 7.80 ]
De Groot 1996 12/39 54/146 19.5 % 0.83 [ 0.50, 1.39 ]
Dhananjaya 2014 1/50 6/50 3.3 % 0.17 [ 0.02, 1.33 ]
Ezeama 2014 12/151 3/149 7.6 % 3.95 [ 1.14, 13.70 ]
Modi 2014 0/25 0/25 Not estimable
Saito 2007 17/156 38/187 19.1 % 0.54 [ 0.32, 0.91 ]
Subtotal (95% CI) 571 707 58.2 % 1.01 [ 0.48, 2.16 ]
Total events: 52 (Oxytocin), 105 (Ergot Alkaloids)
Heterogeneity: Tau2 = 0.47; Chi2 = 14.58, df = 4 (P = 0.01); I2 =73%
Test for overall effect: Z = 0.04 (P = 0.97)
2 IV oxytocin
Ilancheran 1990 0/5 1/5 1.7 % 0.33 [ 0.02, 6.65 ]
Orji 2008 12/297 18/303 15.1 % 0.68 [ 0.33, 1.39 ]
Singh 2009 0/75 2/75 1.7 % 0.20 [ 0.01, 4.10 ]
Sorbe 1978 48/506 63/543 23.4 % 0.82 [ 0.57, 1.17 ]
Subtotal (95% CI) 883 926 41.8 % 0.77 [ 0.56, 1.05 ]
Total events: 60 (Oxytocin), 84 (Ergot Alkaloids)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.30, df = 3 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 1.63 (P = 0.10)
Total (95% CI) 1454 1633 100.0 % 0.84 [ 0.56, 1.25 ]
Total events: 112 (Oxytocin), 189 (Ergot Alkaloids)
Heterogeneity: Tau2 = 0.15; Chi2 = 15.92, df = 8 (P = 0.04); I2 =50%
Test for overall effect: Z = 0.88 (P = 0.38)
Test for subgroup differences: Chi2 = 0.44, df = 1 (P = 0.51), I2 =0.0%
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Analysis 4.3. Comparison 4 Oxytocin versus ergot alkaloids--subgroup analyses, Outcome 3 Blood loss 500
mL or more after delivery; oxytocin dose < 10 IU v. 10 IU.
Review: Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage
Comparison: 4 Oxytocin versus ergot alkaloids–subgroup analyses
Outcome: 3 Blood loss 500 mL or more after delivery; oxytocin dose < 10 IU v. 10 IU
Study or subgroup Oxytocin Ergot Alkaloids Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Oxytocin dose < 10 IU
De Groot 1996 12/39 54/146 19.6 % 0.83 [ 0.50, 1.39 ]
Saito 2007 17/156 38/187 19.3 % 0.54 [ 0.32, 0.91 ]
Singh 2009 0/75 2/75 1.8 % 0.20 [ 0.01, 4.10 ]
Subtotal (95% CI) 270 408 40.7 % 0.66 [ 0.46, 0.95 ]
Total events: 29 (Oxytocin), 94 (Ergot Alkaloids)
Heterogeneity: Tau2 = 0.00; Chi2 = 2.00, df = 2 (P = 0.37); I2 =0%
Test for overall effect: Z = 2.21 (P = 0.027)
2 Oxytocin dose 10 IU
Boopathi 2014 10/150 4/150 9.1 % 2.50 [ 0.80, 7.80 ]
Dhananjaya 2014 1/50 6/50 3.5 % 0.17 [ 0.02, 1.33 ]
Ezeama 2014 12/151 3/149 8.0 % 3.95 [ 1.14, 13.70 ]
Modi 2014 0/25 0/25 Not estimable
Orji 2008 12/297 18/303 15.4 % 0.68 [ 0.33, 1.39 ]
Sorbe 1978 48/506 63/543 23.3 % 0.82 [ 0.57, 1.17 ]
Subtotal (95% CI) 1179 1220 59.3 % 1.08 [ 0.54, 2.17 ]
Total events: 83 (Oxytocin), 94 (Ergot Alkaloids)
Heterogeneity: Tau2 = 0.36; Chi2 = 11.94, df = 4 (P = 0.02); I2 =67%
Test for overall effect: Z = 0.22 (P = 0.83)
Total (95% CI) 1449 1628 100.0 % 0.85 [ 0.56, 1.29 ]
Total events: 112 (Oxytocin), 188 (Ergot Alkaloids)
Heterogeneity: Tau2 = 0.16; Chi2 = 15.60, df = 7 (P = 0.03); I2 =55%
Test for overall effect: Z = 0.76 (P = 0.45)
Test for subgroup differences: Chi2 = 1.50, df = 1 (P = 0.22), I2 =33%
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Analysis 4.4. Comparison 4 Oxytocin versus ergot alkaloids--subgroup analyses, Outcome 4 Need for
additional uterotonics; active v. expectant management.
Review: Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage
Comparison: 4 Oxytocin versus ergot alkaloids–subgroup analyses
Outcome: 4 Need for additional uterotonics; active v. expectant management
Study or subgroup Oxytocin Ergot Alkaloids Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Active management
Adhikari 2007 5/100 4/100 12.0 % 1.25 [ 0.35, 4.52 ]
Boopathi 2014 11/150 3/150 12.2 % 3.67 [ 1.04, 12.88 ]
Ezeama 2014 35/151 11/149 16.6 % 3.14 [ 1.66, 5.95 ]
Orji 2008 18/297 30/303 17.1 % 0.61 [ 0.35, 1.07 ]
Saito 2007 8/156 23/187 15.7 % 0.42 [ 0.19, 0.91 ]
Singh 2009 2/75 11/75 10.7 % 0.18 [ 0.04, 0.79 ]
Subtotal (95% CI) 929 964 84.3 % 0.96 [ 0.40, 2.32 ]
Total events: 79 (Oxytocin), 82 (Ergot Alkaloids)
Heterogeneity: Tau2 = 0.94; Chi2 = 29.52, df = 5 (P = 0.00002); I2 =83%
Test for overall effect: Z = 0.09 (P = 0.93)
2 Expectant management
De Groot 1996 7/39 21/146 15.7 % 1.25 [ 0.57, 2.72 ]
Subtotal (95% CI) 39 146 15.7 % 1.25 [ 0.57, 2.72 ]
Total events: 7 (Oxytocin), 21 (Ergot Alkaloids)
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.58)
Total (95% CI) 968 1110 100.0 % 1.01 [ 0.48, 2.09 ]
Total events: 86 (Oxytocin), 103 (Ergot Alkaloids)
Heterogeneity: Tau2 = 0.73; Chi2 = 29.79, df = 6 (P = 0.00004); I2 =80%
Test for overall effect: Z = 0.02 (P = 0.99)
Test for subgroup differences: Chi2 = 0.19, df = 1 (P = 0.66), I2 =0.0%
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Analysis 4.5. Comparison 4 Oxytocin versus ergot alkaloids--subgroup analyses, Outcome 5 Need for
additional uterotonics; IM v. IV oxytocin.
Review: Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage
Comparison: 4 Oxytocin versus ergot alkaloids–subgroup analyses
Outcome: 5 Need for additional uterotonics; IM v. IV oxytocin
Study or subgroup Oxytocin Ergot Alkaloids Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 IM oxytocin
Adhikari 2007 5/100 4/100 11.6 % 1.25 [ 0.35, 4.52 ]
Boopathi 2014 11/150 3/150 11.7 % 3.67 [ 1.04, 12.88 ]
De Groot 1996 7/39 21/146 14.8 % 1.25 [ 0.57, 2.72 ]
Dhananjaya 2014 0/50 9/50 5.0 % 0.05 [ 0.00, 0.88 ]
Ezeama 2014 35/151 11/149 15.6 % 3.14 [ 1.66, 5.95 ]
Saito 2007 8/156 23/187 14.8 % 0.42 [ 0.19, 0.91 ]
Subtotal (95% CI) 646 782 73.5 % 1.16 [ 0.47, 2.83 ]
Total events: 66 (Oxytocin), 71 (Ergot Alkaloids)
Heterogeneity: Tau2 = 0.89; Chi2 = 23.41, df = 5 (P = 0.00028); I2 =79%
Test for overall effect: Z = 0.32 (P = 0.75)
2 IV oxytocin
Orji 2008 18/297 30/303 16.0 % 0.61 [ 0.35, 1.07 ]
Singh 2009 2/75 11/75 10.4 % 0.18 [ 0.04, 0.79 ]
Subtotal (95% CI) 372 378 26.5 % 0.41 [ 0.13, 1.26 ]
Total events: 20 (Oxytocin), 41 (Ergot Alkaloids)
Heterogeneity: Tau2 = 0.43; Chi2 = 2.32, df = 1 (P = 0.13); I2 =57%
Test for overall effect: Z = 1.56 (P = 0.12)
Total (95% CI) 1018 1160 100.0 % 0.87 [ 0.41, 1.82 ]
Total events: 86 (Oxytocin), 112 (Ergot Alkaloids)
Heterogeneity: Tau2 = 0.82; Chi2 = 34.22, df = 7 (P = 0.00002); I2 =80%
Test for overall effect: Z = 0.38 (P = 0.71)
Test for subgroup differences: Chi2 = 2.02, df = 1 (P = 0.16), I2 =50%
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Analysis 4.6. Comparison 4 Oxytocin versus ergot alkaloids--subgroup analyses, Outcome 6 Need for
additional uterotonics; oxytocin dose < 10 IU v. 10 IU.
Review: Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage
Comparison: 4 Oxytocin versus ergot alkaloids–subgroup analyses
Outcome: 6 Need for additional uterotonics; oxytocin dose < 10 IU v. 10 IU
Study or subgroup Oxytocin Ergot Alkaloids Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Oxytocin dose < 10 IU
De Groot 1996 7/39 21/146 14.8 % 1.25 [ 0.57, 2.72 ]
Saito 2007 8/156 23/187 14.8 % 0.42 [ 0.19, 0.91 ]
Singh 2009 2/75 11/75 10.5 % 0.18 [ 0.04, 0.79 ]
Subtotal (95% CI) 270 408 40.0 % 0.52 [ 0.18, 1.45 ]
Total events: 17 (Oxytocin), 55 (Ergot Alkaloids)
Heterogeneity: Tau2 = 0.58; Chi2 = 7.01, df = 2 (P = 0.03); I2 =71%
Test for overall effect: Z = 1.26 (P = 0.21)
2 Oxytocin dose 10 IU
Adhikari 2007 5/100 4/100 11.6 % 1.25 [ 0.35, 4.52 ]
Boopathi 2014 11/150 3/150 11.8 % 3.67 [ 1.04, 12.88 ]
Dhananjaya 2014 0/50 9/50 5.0 % 0.05 [ 0.00, 0.88 ]
Ezeama 2014 35/151 11/151 15.6 % 3.18 [ 1.68, 6.03 ]
Orji 2008 18/297 30/303 16.0 % 0.61 [ 0.35, 1.07 ]
Subtotal (95% CI) 748 754 60.0 % 1.22 [ 0.42, 3.48 ]
Total events: 69 (Oxytocin), 57 (Ergot Alkaloids)
Heterogeneity: Tau2 = 1.03; Chi2 = 22.17, df = 4 (P = 0.00019); I2 =82%
Test for overall effect: Z = 0.36 (P = 0.72)
Total (95% CI) 1018 1162 100.0 % 0.87 [ 0.41, 1.83 ]
Total events: 86 (Oxytocin), 112 (Ergot Alkaloids)
Heterogeneity: Tau2 = 0.83; Chi2 = 34.50, df = 7 (P = 0.00001); I2 =80%
Test for overall effect: Z = 0.37 (P = 0.71)
Test for subgroup differences: Chi2 = 1.30, df = 1 (P = 0.25), I2 =23%
0.01 0.1 1 10 100
Favours Oxytocin Favours Ergots
105Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 5.1. Comparison 5 Oxytocin + ergometrine versus ergot alkaloids, Outcome 1 Blood loss 500 mL
or more after delivery.
Review: Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage
Comparison: 5 Oxytocin + ergometrine versus ergot alkaloids
Outcome: 1 Blood loss 500 mL or more after delivery
Study or subgroup Syntometrine Ergot Alkaloids Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bonham 1963 5/391 13/416 59.2 % 0.41 [ 0.15, 1.14 ]
Francis 1965 4/171 9/183 40.8 % 0.48 [ 0.15, 1.52 ]
Ilancheran 1990 0/5 0/2 Not estimable
Total (95% CI) 567 601 100.0 % 0.44 [ 0.20, 0.94 ]
Total events: 9 (Syntometrine), 22 (Ergot Alkaloids)
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 2.12 (P = 0.034)
Test for subgroup differences: Not applicable
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Analysis 5.2. Comparison 5 Oxytocin + ergometrine versus ergot alkaloids, Outcome 2 Manual removal of
the placenta.
Review: Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage
Comparison: 5 Oxytocin + ergometrine versus ergot alkaloids
Outcome: 2 Manual removal of the placenta
Study or subgroup Syntometrine Ergot Alkaloids Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bonham 1963 5/391 5/416 100.0 % 1.06 [ 0.31, 3.65 ]
Total (95% CI) 391 416 100.0 % 1.06 [ 0.31, 3.65 ]
Total events: 5 (Syntometrine), 5 (Ergot Alkaloids)
Heterogeneity: not applicable
Test for overall effect: Z = 0.10 (P = 0.92)
Test for subgroup differences: Not applicable
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Analysis 5.3. Comparison 5 Oxytocin + ergometrine versus ergot alkaloids, Outcome 3 Mean blood loss
(mL).
Review: Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage
Comparison: 5 Oxytocin + ergometrine versus ergot alkaloids
Outcome: 3 Mean blood loss (mL)
Study or subgroup Synometrine Ergot alkaloids
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Vaughan Williams 1974 19 185 (102) 8 124 (60) 100.0 % 61.00 [ -0.90, 122.90 ]
Total (95% CI) 19 8 100.0 % 61.00 [ -0.90, 122.90 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.93 (P = 0.053)
Test for subgroup differences: Not applicable
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Analysis 5.4. Comparison 5 Oxytocin + ergometrine versus ergot alkaloids, Outcome 4 Maternal all-cause
mortality.
Review: Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage
Comparison: 5 Oxytocin + ergometrine versus ergot alkaloids
Outcome: 4 Maternal all-cause mortality
Study or subgroup Syntometrine Ergot alkaloids Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bonham 1963 0/391 0/416 Not estimable
Total (95% CI) 391 416 Not estimable
Total events: 0 (Syntometrine), 0 (Ergot alkaloids)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 6.1. Comparison 6 Oxytocin + ergometrine versus ergot alkaloids--subgroup analyses, Outcome 1
Blood loss 500 mL or more after delivery; active v. expectant management.
Review: Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage
Comparison: 6 Oxytocin + ergometrine versus ergot alkaloids–subgroup analyses
Outcome: 1 Blood loss 500 mL or more after delivery; active v. expectant management
Study or subgroup Syntometrine Ergot Alkaloids Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Active management
Francis 1965 4/171 9/183 100.0 % 0.48 [ 0.15, 1.52 ]
Subtotal (95% CI) 171 183 100.0 % 0.48 [ 0.15, 1.52 ]
Total events: 4 (Syntometrine), 9 (Ergot Alkaloids)
Heterogeneity: not applicable
Test for overall effect: Z = 1.26 (P = 0.21)
2 Expectant management
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Syntometrine), 0 (Ergot Alkaloids)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 171 183 100.0 % 0.48 [ 0.15, 1.52 ]
Total events: 4 (Syntometrine), 9 (Ergot Alkaloids)
Heterogeneity: not applicable
Test for overall effect: Z = 1.26 (P = 0.21)
Test for subgroup differences: Not applicable
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Analysis 6.2. Comparison 6 Oxytocin + ergometrine versus ergot alkaloids--subgroup analyses, Outcome 2
Blood loss 500 mL or more after delivery; IM v. IV oxytocin.
Review: Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage
Comparison: 6 Oxytocin + ergometrine versus ergot alkaloids–subgroup analyses
Outcome: 2 Blood loss 500 mL or more after delivery; IM v. IV oxytocin
Study or subgroup Syntometrine Ergot Alkaloids Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 IM oxytocin
Bonham 1963 5/391 13/416 59.2 % 0.41 [ 0.15, 1.14 ]
Francis 1965 4/171 9/183 40.8 % 0.48 [ 0.15, 1.52 ]
Subtotal (95% CI) 562 599 100.0 % 0.44 [ 0.20, 0.94 ]
Total events: 9 (Syntometrine), 22 (Ergot Alkaloids)
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 2.12 (P = 0.034)
2 IV oxytocin
Ilancheran 1990 0/5 0/2 Not estimable
Subtotal (95% CI) 5 2 Not estimable
Total events: 0 (Syntometrine), 0 (Ergot Alkaloids)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 567 601 100.0 % 0.44 [ 0.20, 0.94 ]
Total events: 9 (Syntometrine), 22 (Ergot Alkaloids)
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 2.12 (P = 0.034)
Test for subgroup differences: Not applicable
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Analysis 7.1. Comparison 7 Oxytocin versus no uterotonics or placebo--subgroup analyses, Outcome 1
Blood loss 500 mL or more after delivery; active v. expectant management.
Review: Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage
Comparison: 7 Oxytocin versus no uterotonics or placebo–subgroup analyses
Outcome: 1 Blood loss 500 mL or more after delivery; active v. expectant management
Study or subgroup Oxytocin Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Active management
Abdel-Aleem 2010 68/1291 65/659 22.7 % 0.53 [ 0.39, 0.74 ]
Pierre 1992 37/488 126/482 22.2 % 0.29 [ 0.21, 0.41 ]
Subtotal (95% CI) 1779 1141 45.0 % 0.39 [ 0.22, 0.72 ]
Total events: 105 (Oxytocin), 191 (Control)
Heterogeneity: Tau2 = 0.16; Chi2 = 6.41, df = 1 (P = 0.01); I2 =84%
Test for overall effect: Z = 3.03 (P = 0.0024)
2 Expectant management
De Groot 1996 13/39 55/143 17.9 % 0.87 [ 0.53, 1.41 ]
Nordstrom 1997 104/513 175/487 26.1 % 0.56 [ 0.46, 0.70 ]
Poeschmann 1991 7/28 10/24 11.0 % 0.60 [ 0.27, 1.33 ]
Subtotal (95% CI) 580 654 55.0 % 0.62 [ 0.48, 0.81 ]
Total events: 124 (Oxytocin), 240 (Control)
Heterogeneity: Tau2 = 0.01; Chi2 = 2.50, df = 2 (P = 0.29); I2 =20%
Test for overall effect: Z = 3.62 (P = 0.00030)
Total (95% CI) 2359 1795 100.0 % 0.52 [ 0.37, 0.73 ]
Total events: 229 (Oxytocin), 431 (Control)
Heterogeneity: Tau2 = 0.10; Chi2 = 16.25, df = 4 (P = 0.003); I2 =75%
Test for overall effect: Z = 3.78 (P = 0.00016)
Test for subgroup differences: Chi2 = 1.90, df = 1 (P = 0.17), I2 =47%
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Analysis 7.2. Comparison 7 Oxytocin versus no uterotonics or placebo--subgroup analyses, Outcome 2
Blood loss 500 mL or more after delivery; IM v. IV oxytocin.
Review: Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage
Comparison: 7 Oxytocin versus no uterotonics or placebo–subgroup analyses
Outcome: 2 Blood loss 500 mL or more after delivery; IM v. IV oxytocin
Study or subgroup Oxytocin Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 IV oxytocin
Ilancheran 1990 0/3 0/5 Not estimable
Nordstrom 1997 104/513 175/487 26.1 % 0.56 [ 0.46, 0.70 ]
Pierre 1992 37/488 126/482 22.2 % 0.29 [ 0.21, 0.41 ]
Subtotal (95% CI) 1004 974 48.3 % 0.41 [ 0.21, 0.79 ]
Total events: 141 (Oxytocin), 301 (Control)
Heterogeneity: Tau2 = 0.21; Chi2 = 10.75, df = 1 (P = 0.001); I2 =91%
Test for overall effect: Z = 2.65 (P = 0.0081)
2 IM oxytocin
Abdel-Aleem 2010 68/1291 65/659 22.7 % 0.53 [ 0.39, 0.74 ]
De Groot 1996 13/39 55/143 17.9 % 0.87 [ 0.53, 1.41 ]
Poeschmann 1991 7/28 10/24 11.0 % 0.60 [ 0.27, 1.33 ]
Subtotal (95% CI) 1358 826 51.7 % 0.63 [ 0.46, 0.87 ]
Total events: 88 (Oxytocin), 130 (Control)
Heterogeneity: Tau2 = 0.02; Chi2 = 2.63, df = 2 (P = 0.27); I2 =24%
Test for overall effect: Z = 2.83 (P = 0.0047)
Total (95% CI) 2362 1800 100.0 % 0.52 [ 0.37, 0.73 ]
Total events: 229 (Oxytocin), 431 (Control)
Heterogeneity: Tau2 = 0.10; Chi2 = 16.25, df = 4 (P = 0.003); I2 =75%
Test for overall effect: Z = 3.78 (P = 0.00016)
Test for subgroup differences: Chi2 = 1.34, df = 1 (P = 0.25), I2 =26%
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Analysis 7.3. Comparison 7 Oxytocin versus no uterotonics or placebo--subgroup analyses, Outcome 3
Blood loss 500 mL or more after delivery; oxytocin dose < 10 IU v. 10 IU.
Review: Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage
Comparison: 7 Oxytocin versus no uterotonics or placebo–subgroup analyses
Outcome: 3 Blood loss 500 mL or more after delivery; oxytocin dose < 10 IU v. 10 IU
Study or subgroup Oxytocin Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Oxytocin dose < 10 IU
De Groot 1996 13/39 55/143 17.9 % 0.87 [ 0.53, 1.41 ]
Pierre 1992 37/488 126/482 22.2 % 0.29 [ 0.21, 0.41 ]
Poeschmann 1991 7/28 10/24 11.0 % 0.60 [ 0.27, 1.33 ]
Subtotal (95% CI) 555 649 51.2 % 0.52 [ 0.24, 1.14 ]
Total events: 57 (Oxytocin), 191 (Control)
Heterogeneity: Tau2 = 0.40; Chi2 = 14.03, df = 2 (P = 0.00090); I2 =86%
Test for overall effect: Z = 1.63 (P = 0.10)
2 Oxytocin dose 10 IU
Abdel-Aleem 2010 68/1291 65/659 22.7 % 0.53 [ 0.39, 0.74 ]
Nordstrom 1997 104/513 175/487 26.1 % 0.56 [ 0.46, 0.70 ]
Subtotal (95% CI) 1804 1146 48.8 % 0.56 [ 0.47, 0.66 ]
Total events: 172 (Oxytocin), 240 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.08, df = 1 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 6.56 (P < 0.00001)
Total (95% CI) 2359 1795 100.0 % 0.52 [ 0.37, 0.73 ]
Total events: 229 (Oxytocin), 431 (Control)
Heterogeneity: Tau2 = 0.10; Chi2 = 16.25, df = 4 (P = 0.003); I2 =75%
Test for overall effect: Z = 3.78 (P = 0.00016)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.87), I2 =0.0%
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Analysis 7.4. Comparison 7 Oxytocin versus no uterotonics or placebo--subgroup analyses, Outcome 4
Need for additional uterotonics; active v. expectant management.
Review: Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage
Comparison: 7 Oxytocin versus no uterotonics or placebo–subgroup analyses
Outcome: 4 Need for additional uterotonics; active v. expectant management
Study or subgroup Oxytocin Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Active management
Abdel-Aleem 2010 41/1260 53/641 38.5 % 0.39 [ 0.26, 0.58 ]
Subtotal (95% CI) 1260 641 38.5 % 0.39 [ 0.26, 0.58 ]
Total events: 41 (Oxytocin), 53 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 4.61 (P < 0.00001)
2 Expectant management
De Groot 1996 7/39 26/143 19.3 % 0.99 [ 0.46, 2.10 ]
Nordstrom 1997 40/513 67/487 40.4 % 0.57 [ 0.39, 0.82 ]
Poeschmann 1991 0/28 2/24 1.7 % 0.17 [ 0.01, 3.42 ]
Subtotal (95% CI) 580 654 61.5 % 0.64 [ 0.42, 0.99 ]
Total events: 47 (Oxytocin), 95 (Control)
Heterogeneity: Tau2 = 0.03; Chi2 = 2.39, df = 2 (P = 0.30); I2 =16%
Test for overall effect: Z = 1.99 (P = 0.047)
Total (95% CI) 1840 1295 100.0 % 0.54 [ 0.36, 0.80 ]
Total events: 88 (Oxytocin), 148 (Control)
Heterogeneity: Tau2 = 0.07; Chi2 = 5.39, df = 3 (P = 0.15); I2 =44%
Test for overall effect: Z = 3.05 (P = 0.0023)
Test for subgroup differences: Chi2 = 2.66, df = 1 (P = 0.10), I2 =62%
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Analysis 7.5. Comparison 7 Oxytocin versus no uterotonics or placebo--subgroup analyses, Outcome 5
Need for additional uterotonics; IM v. IV oxytocin.
Review: Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage
Comparison: 7 Oxytocin versus no uterotonics or placebo–subgroup analyses
Outcome: 5 Need for additional uterotonics; IM v. IV oxytocin
Study or subgroup Oxytocin Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 IV oxytocin
Nordstrom 1997 40/513 67/487 40.4 % 0.57 [ 0.39, 0.82 ]
Subtotal (95% CI) 513 487 40.4 % 0.57 [ 0.39, 0.82 ]
Total events: 40 (Oxytocin), 67 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.00 (P = 0.0027)
2 IM oxytocin
Abdel-Aleem 2010 41/1260 53/641 38.5 % 0.39 [ 0.26, 0.58 ]
De Groot 1996 7/39 26/143 19.3 % 0.99 [ 0.46, 2.10 ]
Poeschmann 1991 0/28 2/24 1.7 % 0.17 [ 0.01, 3.42 ]
Subtotal (95% CI) 1327 808 59.6 % 0.54 [ 0.24, 1.19 ]
Total events: 48 (Oxytocin), 81 (Control)
Heterogeneity: Tau2 = 0.26; Chi2 = 4.92, df = 2 (P = 0.09); I2 =59%
Test for overall effect: Z = 1.54 (P = 0.12)
Total (95% CI) 1840 1295 100.0 % 0.54 [ 0.36, 0.80 ]
Total events: 88 (Oxytocin), 148 (Control)
Heterogeneity: Tau2 = 0.07; Chi2 = 5.39, df = 3 (P = 0.15); I2 =44%
Test for overall effect: Z = 3.05 (P = 0.0023)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.91), I2 =0.0%
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Analysis 7.6. Comparison 7 Oxytocin versus no uterotonics or placebo--subgroup analyses, Outcome 6
Need for additional uterotonics; oxytocin dose < 10 IU v. 10 IU.
Review: Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage
Comparison: 7 Oxytocin versus no uterotonics or placebo–subgroup analyses
Outcome: 6 Need for additional uterotonics; oxytocin dose < 10 IU v. 10 IU
Study or subgroup Oxytocin Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Oxytocin dose < 10 IU
De Groot 1996 7/39 26/143 19.3 % 0.99 [ 0.46, 2.10 ]
Poeschmann 1991 0/28 2/24 1.7 % 0.17 [ 0.01, 3.42 ]
Subtotal (95% CI) 67 167 21.0 % 0.76 [ 0.22, 2.63 ]
Total events: 7 (Oxytocin), 28 (Control)
Heterogeneity: Tau2 = 0.33; Chi2 = 1.27, df = 1 (P = 0.26); I2 =21%
Test for overall effect: Z = 0.44 (P = 0.66)
2 Oxytocin dose 10 IU
Abdel-Aleem 2010 41/1260 53/641 38.5 % 0.39 [ 0.26, 0.58 ]
Nordstrom 1997 40/513 67/487 40.4 % 0.57 [ 0.39, 0.82 ]
Subtotal (95% CI) 1773 1128 79.0 % 0.48 [ 0.33, 0.68 ]
Total events: 81 (Oxytocin), 120 (Control)
Heterogeneity: Tau2 = 0.03; Chi2 = 1.73, df = 1 (P = 0.19); I2 =42%
Test for overall effect: Z = 4.08 (P = 0.000045)
Total (95% CI) 1840 1295 100.0 % 0.54 [ 0.36, 0.80 ]
Total events: 88 (Oxytocin), 148 (Control)
Heterogeneity: Tau2 = 0.07; Chi2 = 5.39, df = 3 (P = 0.15); I2 =44%
Test for overall effect: Z = 3.05 (P = 0.0023)
Test for subgroup differences: Chi2 = 0.49, df = 1 (P = 0.48), I2 =0.0%
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A P P E N D I C E S
Appendix 1. ICTRP and ClinicalTrials.gov - search methods
ICTRP
oxytocin AND hemorrhage
oxytocin AND third stage
oxytocin AND labor AND bleeding
oxytocin AND labour AND bleeding
ClinicalTrials.gov
Advanced search
oxytocin | postpartum hemorrhage
oxytocin | third stage
F E E D B A C K
Pastrana, March 2007
Summary
It is important to take care that the conclusions are based on pre-specified objectives, as sometimes the study is done and then the
objectives decided afterwards.
In this review, there is no discussion of the way different studies determined blood loss, and the limitations of these methods. This
is especially true for Pierre 1992. Also, the results should take into account Hoffman 2004, comparing oxytocin with expectant
management. In this study, although the mean change in hematocrit was significantly less in the oxytocin group, there was no difference
in the incidence of postpartum haemorrhage.
(Summary of comment from Jose Luis Pastrana, March 2007)
Reply
6 July 2011
We agree that there are a lot of limitations to this review, specifically that in the studies included there are differences in the method of
delivery of pitocin, definition of the active management of the third stage, and determining accurate blood loss after delivery. However,
this review incorporates the only randomised controlled trials that attempt to address this important topic. We agree that a formalized
method for determining blood loss is needed as that will further advance our ability to perform useful research in this field.
Please see our conclusion section for a more thorough discussion of these topics.
Contributors
Feedback: Jose Luis Pastrana
Response: Gina Westhoff
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WH A T ’ S N E W
Date Event Description
6 March 2019 New search has been performed Search updated. Six new trials have been included
(Adhikari 2007; Boopathi 2014; Dhananjaya 2014;
Ezeama2014;Modi 2014; Singh 2009) and 10 new stud-
ies were excluded (Jans 2017;Neri-Mejia 2016;Nuamsiri
2016; Oguz Orhan 2014; Quibel 2016; Rouse 2011;
Sharma 2014; Stanton 2010; Stanton 2013; Suhrabi
2013). Two studies that were included in the previous
version of this review were excluded in this version as we
felt that they could not be classified as either randomised
or quasi-randomised studies (Barbaro 1961; Soiva 1964)
.
6 March 2019 New citation required but conclusions have not changed The overall conclusions remain unchanged. Incorpora-
tion of new evidence suggests that any benefit of oxy-
tocin over ergot alkaloids is now uncertain with regard
to blood loss, and that oxytocin may be associated with
an increased risk of a prolonged second stage, with an
uncertain effect on manual placental removal. Addition-
ally, there may be a slight reduction in blood loss with
oxytocin-ergometrine compared to ergot alkaloids
H I S T O R Y
Protocol first published: Issue 4, 1999
Review first published: Issue 4, 2001
Date Event Description
24 June 2013 New citation required and conclusions have changed There is now evidence to show that prophylactic oxy-
tocin is associated with fewer side effects than ergot
alkaloids
A new author has joined the review team and is now
the guarantor for the review
31 May 2013 New search has been performed Search updated. Six new trials have been included
(Abdel-Aleem 2010; Jago 2007; Jerbi 2007; Moodie
1976; Orji 2008; Saito 2007) and eight trials ex-
cluded (Dickinson 2009; Dommisse 1980; Rouse
2011; Sariganont 1999; Stanton 2012; Tita 2012;
Wetta 2011; Vasegh 2005). We also identified one ad-
ditional report identified for an already excluded trial
(Hoffman 2006a).
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(Continued)
This updated reviews is now comprised of 20 included
studies (involving 10,806 women)
6 July 2011 Feedback has been incorporated The authors have responded to feedback fromPastrana
(March 2007) - see Feedback 1.
1 October 2009 Amended Search updated. Ten reports added to Studies awaiting
classification.
20 September 2008 Amended Converted to new review format.
1 March 2007 Feedback has been incorporated Feedback added from Pastrana, March 2007.
1 December 2004 New search has been performed Search updated. We identified 16 new studies; how-
ever, none fulfilled the inclusion criteria
C O N T R I B U T I O N S O F A U T H O R S
For this 2018 update, Jennifer Salati and Sebastian Leathersich independently assessed new trials for inclusion, extracted data and
performed risk of bias assessments for the included studies. MyfanwyWilliams and Anna Cuthbert assisted in review and data extraction
from previously included studies. Jennifer Salati and Myfanwy Williams performed GRADE assessments. Jennifer Salati edited the
results and main text of the review based on the updated analysis.
D E C L A R A T I O N S O F I N T E R E S T
Jennifer Salati: none known.
Sebastian Leathersich: none known.
Myfanwy Williams: is employed by the University of Liverpool as a Research Associate for Cochrane Pregnancy and Childbirth. Her
role is supported by the World Health Organization.
Anna Cuthbert: is employed by the University of Liverpool as a Research Associate for Cochrane Pregnancy and Childbirth. Her role
was supported by the World Health Organization.
Jorge Tolosa: none known.
S O U R C E S O F S U P P O R T
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Internal sources
• The University of Liverpool, UK.
External sources
• Human Reproduction Programme. World Health Organization. Geneva, Switzerland.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In this updated version of the review, we have added several new outcomes to reflect those recommended as part of a core outcome set
for reporting in postpartum haemorrhage prevention studies (Meher 2018). We have added maternal mortality to the list of primary
outcomes. We also changed the previously included secondary outcome of maternal Hb < 9 g/dL to a maternal Hb < 7 g/dL as we felt
this was a more specific outcome for significant blood loss. We removed the subgroup analysis examining the effect of quasi-randomised
versus randomised trials, as this was accounted for in our GRADE assessments.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Ergonovine [administration & dosage]; Ergot Alkaloids [administration & dosage]; Labor Stage, Third [∗drug effects]; Maternal Mor-
tality; Oxytocics [∗administration & dosage]; Oxytocin [∗administration & dosage]; Postpartum Hemorrhage [mortality; ∗prevention
& control]; Randomized Controlled Trials as Topic
MeSH check words
Female; Humans; Pregnancy
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